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CHAPTER 1  
1.1 General introduction
Mast cells
Mast cells are pluripotent, long-lived leukocytes that reside in connective tis-
sue and mucosa 1. It is assumed that mast cells originate from CD34+ mye-
loid progenitors cells, although a recent publication hypothesized that the 
hematopoietic progenitor cells might be more flexible than was previously 
thought and that mast cells can also be phylogenetically related to cells of the 
lymphoid lineage 2. Mast cell progenitors leave the bone marrow and mature 
in other tissues such as skin and mucosa, were they will remain for the rest of 
their lifespan. Roughly, two subtypes of mast cells are recognized: MCTC who 
produce the enzymes tryptase and chymase, and MCT who produce tryptase 
but not chymase 3. MCTC are typically found in the mucosa of the gastrointes-
tinal tract, whereas MCT are more prominent in connective tissue. Mast cells 
retain a certain level of plasticity after they have matured, and their pheno-
type can be influenced by their environment to an important extent 3. They 
are one of a few cell types which express the KIT-receptor: A single chain 
transmembrane receptor with intrinsic tyrosine kinase activity that is essen-
tial to cell proliferation and survival and is activated by its ligand stem cell 
factor (SCF) 4. 
Mast cells are part of the innate immune system and play a role in the first 
line of defense against pathogens from outside, matching their location in 
barrier sites of the body 5. It is therefore important that they can react to 
many different stimuli, including pathogen related molecules, venoms and 
drugs, as well as signaling substances produced by other human cells such 
as interleukins and hormones (figure 1) 3. Physical triggers such as abrupt 
temperature shifts and mechanical stress can also induce mast cell activa-
tion 6. To enable the mast cell to respond to so many different triggers, it can 
express many different receptors, each with their own intracellular pathway 
and subsequent action of the cell 7. The most well-known route of mast cell 
activation is through the cross-linking of IgE that is bound to the high-affinity 
IgE receptor FcεR1 8. This route of activation is pivotal in allergy, and it has 
been researched extensively since the discovery of IgE in the ‘60s 9. Anoth-
9
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er activating receptor that has gained more interest in the last decade is the 
Mas-related G-protein coupled receptor 2 (MRGPRX2), which is rather specif-
ic to mast cells although it can be found on eosinophils and basophils as well 
10. MRGPRX2 responds to a remarkable amount of possible ligands including 
small molecule drugs, venoms, certain hormones and neuropeptides such 
as substance P 11. The MRGPRX2 receptor has been linked to non-IgE me-
diated drug and venom hypersensitivity, and is also upregulated in patients 
with chronic spontaneous urticaria 12. The fact that activation of MRGPRX2 
can lead to symptoms that are very similar to allergic reactions, but without 
involvement of IgE, has made it a topic of interest for mast cell researchers 
in recent years 13. The role of the MRGPRX2 receptor in mastocytosis is still 
unknown. 
Upon activation, mast cells immediately expel preformed mediators by de-
granulation (figure 1). The type of mediators that are released is dependent 
on the route of activation 8. Well-known mast cell mediators that are involved 
in anaphylaxis are histamine, leukotrienes and prostaglandins 7 but many 
more mediators can be released upon degranulation. Furthermore, different 
types of proteases are released that are involved in wound healing but also 
in the defense to toxic venoms 14. Of these proteases, tryptase is the most 
well-known in clinical practice because it can be measured relatively easily 
in blood and is often used as a biomarker for mast cell activation. In masto-
cytosis, serum tryptase levels are correlated to the mast cell load in the body, 
arguing for a basic level of mast cell activity at all times 15. Shortly after de-
granulation, the production of pro-inflammatory cytokines is started, which 
is a slower process that takes up to 24 hours 16. 
10
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released	that	are	involved	in	wound	healing	but	also	in	the	defense	to	toxic	venoms	14.	Of	these	
proteases,	tryptase	is	the	most	well-known	in	clinical	practice	because	it	can	be	measured	relatively	
easily	in	blood	and	is	often	used	as	a	biomarker	for	mast	cell	activation.	In	mastocytosis,	serum	tryptase	
levels	are	correlated	to	the	mast	cell	load	in	the	body,	arguing	for	a	basic	level	of	mast	cell	activity	at	all	
times	15.	Shortly	after	degranulation,	the	production	of	pro-inflammatory	cytokines	is	started,	which	is	a	
slower	process	that	takes	up	to	24	hours	16.		
	
Downstream	of	every	receptor	is	an	intracellular	cascade	of	activating	and	inhibiting	molecules	that	
together	orchestrate	a	tailored	response.	Although	papers	and	books	typically	depict	one	pathway	
downstream	of	one	receptor,	in	real	life,	different	pathways	communicate	with	each	other,	and	
different	stimuli	will	approach	a	mast	cell	simultaneously.	This	makes	it	difficult	to	reliably	study	mast	
cell	biology,	or	any	other	immune	cell	for	that	matter,	in	vitro.	One	of	the	signaling	cascades	that	has		
multiple	functions	in	mast	cells	is	the	Janus-Kinase-2	(JAK2)	and	Signal	Transducer	and	Activator	of	
Transcription	5	(STAT5)	route.	The	JAK-STAT	routes	are	relatively	uncomplicated:	Upon	activation	of	a	
receptor,	JAK2	that	is	docked	to	the	intracellular	domain	of	the	receptor	is	phosphorylated	by	kinases	of	
the	receptor	itself.	Phosphorylated	JAK2	forms	a	dimer	and	subsequently	phosphorylates	other	
molecules	present	in	the	cytosol,	including	STAT5.	Phosphorylated	STAT5	then	translocates	to	the	cell	
nucleus,	as	monomer	or	dimer,	and	functions	as	a	transcription	factor	17.	It	is	well	known	that	STAT5	is	
often	constitutively	activated	in	myeloid	malignancies,	and	this	has	also	been	demonstrated	in	
mastocytosis,	where	it	is	one	of	the	main	effectors	downstream	of	the	KIT	receptor	18.	To	illustrate	its	
importance,	it	was	demonstrated	that	STAT5	deficient	murine	mast	cells	cannot	survive	17.	However,	
STAT5	appears	to	be	important	for	IgE	mediated	mast	cell	activation	as	well	19.	Interestingly,	STAT5	
interacts	with	another	pluripotent	intracellular	signalling	molecule,	termed	phosphoinositide	3-kinase	
(PI3K)	20.	PI3K	is	one	of	the	most	important	molecules	to	be	activated	by	G-protein	coupled	receptors	
such	as	the	MRGPRX2	receptor,	but	is	actually	involved	in	many	other	intracellular	processes	to	some	
Figure	1.	Schematic	overview	of	mast	cell	
degranulation.	A)	activators	of	MCs	are	
listed,	that	can	cause	mast	cell	activation.	
The	release	of	these	mediators	will	result	in	
modulation	of	biological	processes.	Cartoon	
is	constructed	from	microscopic	toluidine	
blue	staining	of	human	mast	cells.	B)	MC	
degranulation	results	in	mediator	release,	
among	them	β-hexosaminidase.	Also,	as	
depicted	in	the	doted	square,	CD63	is	
expressed	on	the	extracellular	membrane.	
Both	β-hexosaminidase	release	and	CD63	
expression	are	read-out	systems	for	MC	
activation.	C)	Another	reaction	upon	
activation	of	MCs,	is	the	release	of	
mediators	such	as	cytokines,	chemokines	
and	lipid	mediators.	
Credits:	master	thesis	A.C.	van	Stigt	2019. 
Downstream of every receptor is an intracellular cascade of activating and 
inhibi ing molecules that together orchestrate a tailored response. Although 
papers and books typically depict one pathway downstream of one receptor, 
in real life, differen  pathways communic e with each other, and d fferent 
stimuli will approach a mast cell simultaneously. This makes it difficult to 
reliably study mast cell biology, or any t e  immune c ll for that matter, in 
vitro. One of the signaling cascades that has  multiple functions in mast cells 
is the Janus-Kina e-2 (JAK2) and Signal Transduc r and Activator of Tran-
scription 5 (STAT5) route. The JAK-STAT routes are relatively uncomplicated: 
Upon activ tion of a receptor, JAK2 th t is d cked o the intracellular domain 
of the receptor is phosphorylated by kinases of the receptor itself. Phosphor-
ylated JAK2 forms a dimer and subsequently phosphorylates other molecules 
present in the cytosol, including STAT5. Phosphorylated STAT5 then translo-
cates to the cell nucleus, as monomer or dimer, and functions as a transcrip-
tion factor 17. It is well known that STAT5 is often constitutively activated in 
myeloid malignancies, and this has also been demonstrated in mastocytosis, 
where it is one of the main effectors downstream of the KIT receptor 18. To 
illustrate its importance, it was demonstrated that STAT5 deficient murine 
mast cells cannot survive 17. However, STAT5 appears to be important for IgE 
mediated mast cell activation as well 19. Interestingly, STAT5 interacts with 
another pluripotent intracellular signalling molecule, termed phosphoinos-
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itide 3-kinase (PI3K) 20. PI3K is one of the most important molecules to be 
activated by G-protein coupled receptors such as the MRGPRX2 receptor, but 
is actually involved in many other intracellular processes to some extent 21. 
These mechanisms have not yet been a target for treatment in mastocytosis, 
possibly because they have not been fully elucidated.
	
	
extent	21.	These	mechanisms	have	not	yet	been	a	target	for	treatment	in	mastocytosis,	possibly	because	
they	have	not	been	fully	elucidated.		
	
In	vitro	research	with	mast	cells	is	hampered	by	the	slow	proliferation	rate	of	wild-type	mast	cells	and	
the	delicate	nature	of	these	cells.	The	isolation	of	mast	cells	from	the	human	body	is	also	difficult	
because	they	are	tissue	resident	and	not	present	in	peripheral	blood	of	healthy	humans.	Murine	mast	
cells	are	often	used,	but	have	essential	biological	differences	compared	to	human	mast	cells.	Several	
human	mast	cell	lines	are	available	for	researchers	of	mast	cell	biology	(figure	2).	LAD2	cells	(Laboratory	
of	Allergic	Diseases	type	2)	are	moderately	resembling	wild-type	mast	cells	regarding	their	expression	of	
the	IgE	receptor,	their	dependence	on	SCF	for	survival,	and	their	slow	doubling	time	of	2-3	weeks	22.	
Human	Mast	Cell	1	(HMC1)	was	derived	from	a	patient	with	mast	cell	leukemia	and	harbors	1	or	2	
activating	mutations	in	KIT,	making	them	independent	of	SCF	for	survival	23.	These	cells	have	a	much	
more	convenient	doubling	time	of	a	few	days,	but	have	less	similarities	to	wild-type	mature	human	mast	
cells.	For	instance,	they	do	not	express	the	IgE	receptor	and	release	less	histamine,	tryptase	and	other	
typical	mast	cell	mediators	upon	degranulation	23,24.	Lastly,	HuMCs	(human	mast	cells)	are	grown	from	
CD34+	progenitors	cells	from	peripheral	blood	or	bone	marrow	25.	These	cells	most	closely	resemble	
‘real-life’	mast	cells,	but	since	it	takes	6-8	weeks	to	grow	them	into	mature	mast	cells,	it	is	a	time	
consuming	and	costly	option.		
	
Mast	cells	as	immune	regulators	
As	stated	previously,	mast	cells	are	pluripotent	cells	and	their	functional	variety	enables	them	to	
communicate	with	many	other	cells	via	soluble	mediators	or	direct	(co-)stimulation	26.	As	such,	they	are	
involved	in	various	homeostatic	processes	and	are	considered	important	immune	regulators.	Depending	
on	the	route	of	activation,	mast	cells	will	produce	pro-inflammatory	cytokines	and	chemokines	that	can	
enhance	both	a	type	1	as	a	type	2	immunological	reaction	3,8.	Mast	cells	can	also	communicate	with	for	
instance	dendritic	cells	and	T-cells	via	extracellular	vesicles	as	well	as	through	direct	cell-to-cell	contact	
Figure	2 
A)	HuMC,	16	weeks	 B)	LAD2 C)	HMC1 
Figure	2.	Toluidine	blue	staining.	Shown	are	HuMC	(A),	LAD2	(B)	and	HMC1	(C)	cells,	 100x.	HuMC	
and	LAD2	show	a	typical	granular	pattern,	whereas	HMC1	cells	are	hypogranular.	 
In vitro research with mast cells is hampered by the slow proliferation rate 
of wild-type mast cells and the delicate nature of these cells. The isolation of 
mast cells from the uman body is also difficult b cause th y are tissue res-
ident and not present in peripheral blood of healthy humans. Murine mast 
cells are often used, but have essential biological differences compared to hu-
man mast cells. Several human mast cell lines are available for researchers of 
mast cell biol gy (figure 2). LAD2 cells (Laboratory o  Allergic Diseases type 
2) are moderately resembling wild-type mast cells regarding their expression 
of the IgE receptor, their dependence on SCF for survival, and their slow dou-
bling time of 2-3 weeks 22. Human Mast Cell 1 (HMC1) was derived from a 
p tient with mast cell l ukemia and harb rs 1 or 2 activating mutation  in 
KIT, making them independent of SCF for survival 23. These cells have a much 
more convenient doubling time of a few days, but have less similarities to 
wild-type mature human mast cells. For instance, they do not express the IgE 
receptor and release less histamine, tryptase and other typical mast cell me-
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diators upon degranulation 23,24. Lastly, HuMCs (human mast cells) are grown 
from CD34+ progenitors cells from peripheral blood or bone marrow 25. These 
cells most closely resemble ‘real-life’ mast cells, but since it takes 12-16 weeks 
to grow them into mature mast cells, it is a time consuming and costly option. 
Mast cells as immune regulators
As stated previously, mast cells are pluripotent cells and their functional vari-
ety enables them to communicate with many other cells via soluble mediators 
or direct (co-)stimulation 26. As such, they are involved in various homeostatic 
processes and are considered important immune regulators. Depending on 
the route of activation, mast cells will produce pro-inflammatory cytokines 
and chemokines that can enhance both a type 1 as a type 2 immunological 
reaction 3,8. Mast cells can also communicate with for instance dendritic cells 
and T-cells via extracellular vesicles as well as through direct cell-to-cell con-
tact 27,28. Non-immune cells that typically lie in proximity to mast cells such 
as keratinocytes, endothelial cells, nerve fibers and fibroblasts, can in their 
turn activate mast cells through the production of various soluble or cell-ex-
pressed signals 29,30. An interesting cell type with regard to mast cell-immune 
interaction is the group 2 innate lymphoid cell (ILC2). Innate lymphoid cells 
are leukocytes that arise from lymphoid precursors and that lack classical T- 
or B-cell markers 31. ILC2s are mostly present in skin, airway epithelium and 
mucosa. They can be found in peripheral blood but only in very low numbers. 
They are considered to be the native counterpart of T helper 2 cells, since 
they produce type 2 cytokines including IL-4, IL-5 and IL-13. Not surprisingly, 
ILC2s are implicated in allergic diseases such as asthma and atopic dermatitis 
31. An important route of activation occurs upon epithelial cell damage via 
thymic stromal lymphoprotein and IL-33, but also by lipid mediators that are 
produced by activated mast cells 31,32. Considering these properties, the inter-
action between mast cells and ILC2s forms an interesting topic for research.
13
CHAPTER 1
Mastocytosis
Mastocytosis is a rare hematological disease which is characterized by the ac-
cumulation of aberrant mast cells 33. The World Health Organization recogniz-
es different subtypes of mastocytosis. In cutaneous mastocytosis (CM), only 
the skin is involved 33. This subtype is most common among children, and of-
ten spontaneously resolves in puberty 34. It is yet unknown whether children 
who have persistent CM throughout adulthood have a similar prognosis as 
patients with systemic mastocytosis, and whether they have the same risk on 
developing complications such as anaphylaxis or osteoporosis. From one co-
hort study, it appeared that patients with CM did not have an increased risk of 
osteoporosis after correction for conventional risk factors for osteoporosis 35. 
Among adults, the most common form of mastocytosis in the skin is urticaria 
pigmentosa, now called maculopapular cutaneous mastocytosis (MPCM) 36. 
Adult-onset MPCM causes monomorphic livid-to-brown colored maculae, as 
depicted in figure 3. The aesthetic aspects of this, sometimes extensive, rash 
can be rather debilitating for patients. When MPCM originates after puberty, 
the chance of systemic involvement of mastocytosis is very high, even bor-
dering on 100% in some studies 35,37. When an adult patient with MPCM is not 
yet evaluated for systemic involvement, they are termed as having mastocy-
tosis in the skin (MIS) and should be evaluated for the presence of systemic 
mastocytosis.
Systemic mastocytosis (SM) is defined by the World Health Organization 
(WHO) as the accumulation of neoplastic mast cells in at least one extra-cuta-
neous organ, most often the bone marrow (table 1) 33. A bone marrow biopsy 
is thus virtually always necessary to confirm a clinical suspicion for SM. The 
most common form of SM is indolent systemic mastocytosis (ISM). This is 
a benign condition which has an excellent prognosis with regard to surviv-
al, but can be accompanied by a wide variety of bothersome symptoms. The 
prevalence of ISM in The Netherlands is approximately 13 in 100.000 resi-
dents 38.
14
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In	smoldering	systemic	mastocytosis	(SSM),	the	patient	has	signs	of	a	high	mast	cell	load,	defined	as	two	
or	more	B-findings	(table	1)	33.	Although	there	is	no	organ	failure	in	SSM,	its	survival	is	decreased	
compared	to	ISM,	but	this	could	partly	be	attributed	to	factors	unrelated	to	mastocytosis	such	as	age	at	
diagnosis	39.	The	term	advanced	systemic	mastocytosis	(AdvSM)	describes	the	three	most	aggressive	
forms	of	mastocytosis:	Aggressive	systemic	mastocytosis	(ASM),	systemic	mastocytosis	with	an	
associated	hematological	neoplasm	(SM-AHN),	and	mast	cell	leukemia	(MCL).	These	subtypes	have	an	
unfavorable	prognosis,	although	the	perspectives	for	patients	with	ASM	and	MCL	have	been	improved	
significantly	since	the	advent	of	selective	tyrosine	kinase	inhibitors	such	as	midostaurin	40,41.	The	
prognosis	of	SM-AHN	is	largely	defined	by	the	associated	hematological	neoplasm.		
The	rest	of	this	introduction	only	involves	adult	patients	and	systemic	mastocytosis.	
	
	
Pathophysiology	of	mastocytosis		
SM	is	associated	with	an	acquired	mutation	in	the	gene	encoding	for	KIT,	leading	to	uncontrolled	
proliferation	and	reduced	apoptosis	through	autonomous	stimulation	of	KIT,	even	in	the	absence	of	
stem	cell	factor	42.	The	D816V	mutation	is	found	in	the	majority	of	SM	patients	(80-90%),	but	other	
mutations	in	KIT	have	been	described	as	well,	mostly	in	children.	This	mutation	is	often	limited	to	mast	
cells	but	can	be	found	in	other	leukocytes	too,	mostly	of	the	myeloid	lineage	43.	The	development	of	a	
highly	sensitive	method	to	detect	low	levels	of	mutated	KIT	DNA	by	real	time-quantitative	polymerase-
chain-reaction	(RQ-PCR)	has	been	a	useful	addition	to	the	diagnostic	arsenal	for	patients	in	whom	SM	is	
suspected.	Although	mast	cells	do	not	circulate	in	peripheral	blood,	a	low	level	of	D816V	mutated	KIT	
can	be	detected	in	most	patients	with	SM.	Probably,	this	reflects	mast	cell	precursors	that	have	left	the	
bone	marrow	and	are	on	their	way	to	their	place	of	homing.	RQ-PCR	also	provides	an	quantitative	allelic	
burden	which	has	proven	to	be	a	measure	for	the	total	mast	cell	burden	and	can	be	used	as	a	tool	in	the	
follow-up	of	patients	with	AdvSM	in	particular	43,44.	An	allelic	burden	of	over	~2%	is	considered	to	be	an	
adverse	prognostic	sign,	although	this	has	not	been	confirmed	prospectively	45.		
Figure	3.		
A	case	of	extensive	
maculopapular	cutaneous	
mastocytosis.	
Picture	shown	with	consent	
from	the	patient.	
 smoldering systemic mastocytosis (SSM), the patient has signs of a high 
mast cell load, defined as two or more B-findings (table 1) 33. Although there 
is no organ failure in SSM, its survival is decreas d compared to ISM, but this 
could partly be attributed to factors unrelated to mastocytosis such as age at 
diagnosis 39. The term advanced systemic ma tocytosis (AdvSM) d scribes the 
three most aggressive forms of mastocytosis: Aggressive systemic mastocyto-
sis (ASM), systemic mastocytosis with an ssociated hematological neoplasm 
(SM-AHN), and mast cell leukemia (MCL). These subtypes have an unfavora-
ble prognosis, although the perspectives for patients with ASM and MCL have 
been improved significantly si ce the advent of selective tyrosine kinase in-
hibitors such as midostaurin 40,41. The prognosis of SM-AHN is largely defined 
by the associat d hematological ne p asm. 
The rest of this introduction only involves adult patients and systemic mas-
tocytosis.
Pathophysiology of mastocytosis 
SM is associated with an acquired mutation in the gene encoding for KIT, 
leading to uncontrolled proliferation and reduced apoptosis through autono-
mous stimulation of KIT, even in the absence of stem cell factor 42. The D816V 
mutation is found in the majority of SM patients (80-90%), but other muta-
tions in KIT have been described as well, mostly in children. This mutation 
is often limited to mast cells but can be found in other leukocytes too, most-
ly of the myeloid lineage 43. The development of a highly sensitive method 
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to detect low levels of mutated KIT DNA by real time-quantitative polymer-
ase-chain-reaction (RQ-PCR) has been a useful addition to the diagnostic ar-
senal for patients in whom SM is suspected. Although mast cells do not circu-
late in peripheral blood, a low level of D816V mutated KIT can be detected in 
most patients with SM. Probably, this reflects mast cell precursors that have 
left the bone marrow and are on their way to their place of homing. RQ-PCR 
also provides an quantitative allelic burden which has proven to be a measure 
for the total mast cell burden and can be used as a tool in the follow-up of pa-
tients with AdvSM in particular 43,44. An allelic burden of over ~2% is consid-
ered to be an adverse prognostic sign, although this has not been confirmed 
prospectively 45.
	
	
Table	1.	Diagnostic	criteria	for	systemic	mastocytosis	as	defined	by	the	WHO	33	
Systemic	mastocytosis	
Presence	of	1	major	and	1	minor	criterium	or	3	minor	criteria.	
Major	criterion:	
• Multifocal,	dense	MC	infiltrate	(with	>15	MC	per	infiltrate)	in	bone	marrow	and/or	extracutaneous	organ.	
Minor	criteria:	
• Presence	of	D816V	KIT	mutation	in	bone	marrow,	peripheral	blood	or	extracutaneous	tissue.	
• Expression	of	CD117	+	either	CD2	or	CD25	in	MC	in	bone	marrow.	
• >25%	atypical	or	spindle	shaped	MC.	
• Serum	tryptase	>20	μg/mL.	*	
ISM	 SSM	 SM-AHN	 ASM	
Fulfills	criteria	
for	SM,	without	
the	presence	of	
B-	or	C-findings	
	
Fulfills	criteria	for	SM	+	
	>	2	B-findings:	
• Hepato-	and/or	
splenomegaly	without	
organ	dysfunction	
and/or	
lymphadenopathy	
• >30%	MC	infiltration	in	
bone	marrow	and/or	
serum	tryptase	>	200	
μg/mL	
• Signs	of	dysplasia	or	
myeloproliferative	
disease	without	fulfilling	
criteria	for	SM-AHN	
Fulfills	criteria	for	SM	+	
a	non-mast	cell	lineage	
clonal	hematological	
disease	
Fulfills	critera	for	SM	+		
>1	C-finding:	
• Anemia,	neutropenia	of	
thrombocytopenia†	
• Hepatomegaly,	ascites,	
hepatic	dysfunction	and/or	
portal	hypertension	
• Malabsorption	
• Bone	involvement	with	
pathological	fracture	and/or	
osteolytical	bone	lesions	
• Splenomegaly	with	
hypersplenism	
ISMs-	
ISM	without	
skin	lesions	
ISMs+	
ISM	with	skin	
lesions	
MC:	mast	cells.	SM:	systemic	mastocytosis.	ISM:	indolent	systemic	mastocytosis.	SSM:	smouldering	systemic	
mastocytosis.	ASM:	aggressive	systemic	mastocytosis.	SM-AHN:	systemic	mastocytosis	with	associated	
hematological	non-mast	cell	lineage	disease.	
*Not	valid	in	presence	of	an	associated	clonal	hematological	disease.	
†Anemia	Hb<10g/dL,	neutropenia	absolute	neutrophil	count	<50x106,	thrombopenia	<1,500	x106.	
	
	
Symptoms	of	mastocytosis	and	uncertainties	in	the	clinical	care	
Considering	the	wide	armory	of	mast	cells,	it	is	not	surprising	that	a	surplus	of	these	cells	can	also	
present	with	a	diverse	variety	of	signs	and	symptoms	46.	Symptoms	of	mastocytosis	are	either	caused	by	
the	high	levels	of	mast	cell	mediators,	or	by	direct	consequences	of	mast	cell	infiltration.	Examples	of	
mast	cell	mediator-related	symptoms	are	itch,	flushing,	pyrosis,	diarrhea,	and	osteoporosis.	Moreover,	
between	30-49%	of	patients	experience	at	least	one	episode	of	anaphylaxis	in	their	life	47,48.	Anaphylaxis	
is	defined	as	an	acute,	systemic	and	severe	reaction	secondary	to	mast	cell	activation.	It	can	be	life-
threatening	and	logically	causes	substantial	anxiety	among	patients	49.	Typically,	anaphylaxis	in	patients	
with	mastocytosis	is	not	accompanied	by	urticaria	or	angioedema,	and	patients	can	experience	a	rapid	
decrease	of	blood	pressure	50.	This	rapid	and	profound	circulatory	shock	might	lead	to	life-threatening	
situations	and	several	(near-)fatal	cases	of	mastocytosis-related	anaphylaxis	have	been	described,	
fueling	the	fear	of	both	patients	and	physicians	51.	The	unpredictability	of	these	symptoms	are	often	
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Symptoms of mastocytosis and uncertainties in the clin ical care
Considering the wide armory of mast cells, it is not surprising that a surplus 
of these cells can also present with a diverse variety of signs and symptoms 
46. Symptoms of mastocytosis are either caused by the high levels of mast cell 
mediators, or by direct consequences of mast cell infiltration. Examples of 
mast cell mediator-related symptoms are itch, flushing, pyrosis, diarrhea, 
and osteoporosis. Moreover, between 30-49% of patients experience at least 
one episode of anaphylaxis in their life 47,48. Anaphylaxis is defined as an 
acute, systemic and severe reaction secondary to mast cell activation. It can 
be life-threatening and logically causes substantial anxiety among patients 
49. Typically, anaphylaxis in patients with mastocytosis is not accompanied 
by urticaria or angioedema, and patients can experience a rapid decrease of 
blood pressure 50. This rapid and profound circulatory shock might lead to 
life-threatening situations and several (near-)fatal cases of mastocytosis-re-
lated anaphylaxis have been described, fueling the fear of both patients and 
physicians 51. The unpredictability of these symptoms are often labelled as 
one of the main factors that negatively influence the quality of life of patients 
with mastocytosis 52-54.
The most common trigger for anaphylaxis in mastocytosis is venom from Hy-
menoptera (mostly wasps) 47. Conventional allergy tests such as intradermal 
tests or measurement of specific IgE to the culprit insect is frequently neg-
ative, which can complicate the management of these patients and makes 
it an unusable tool to predict future reactions to insect stings 55. Next to Hy-
menoptera venom, patients with mastocytosis can have anaphylaxis to other 
venoms, for instance of the fire ant or jellyfish 56. Other possible triggers for 
anaphylaxis are food, medications or physical stimuli such as temperature 
change, exercise or heat. Furthermore, an often feared elicitor is medication, 
with anesthetic agents, opiates, and radiocontrast media as the main culprit 
drugs 57. This fear is based on pathophysiologic hypotheses and in vitro stud-
ies that showed mast cell activation upon opiates and radiocontrast media 
58,59. Several subsequently published case reports have caused the now com-
mon idea that these drugs pose a serious threat for patients with mastocyto-
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sis. However, patients with mastocytosis relatively often need analgesic drugs 
because of nonspecific myalgia or pain due to osteoporotic fractures 60. More-
over, the risk of cardiovascular morbidity is increased, rendering a frequent 
need for acetylsalicylic acid 61, and acetylsalicylic acid is a potent treatment 
for flushing related to mastocytosis. Lastly, prophylactic therapy with corti-
costeroids can cause side effects that are maybe unnecessary. It would thus 
be of great value to be able to predict whom is at risk for anaphylaxis and to 
which triggers. 
A large amount of anaphylactic episodes actually remains idiopathic, even 
after evaluation by an allergist. As mentioned before, conventional allergy 
tests are unreliable in mastocytosis, possibly  because in these patients an-
aphylaxis is often caused by direct mast cell activation for instance via the 
MRGPRX2 receptor, rather than activation via FcεR1. It is therefore very dif-
ficult to adequately consult a patient on their individual risk of anaphylax-
is 50. The uncertain risk of possible anaphylaxis has a negative influence on 
the quality of life of many patients 52,62. Other factors that influence the dis-
ease-related quality of life are the cosmetic aspects of skin mastocytosis, cog-
nitive problems, and bone pain 52,62. Furthermore, at least half of the patients 
suffer from chronic fatigue 63. The pathophysiological mechanisms that cause 
these symptoms have not been elucidated yet, but it is assumed that they are 
caused by the increased levels of pro-inflammatory cytokines 8,64. Indeed, 
cohort studies in France showed an increased prevalence of depression and 
cognitive dysfunction among adults with mastocytosis 65,66. However, they did 
not compare these data to adequate control groups. It thus remains unclear to 
what extent neuropsychiatric morbidity is specific to mastocytosis, or rather 
a consequence of having a chronic disease in general. 
Management and follow-up
The treatment of mastocytosis depends on the subtype. Since patients with 
ISM have a normal life expectancy, cytoreductive treatment is often withheld 
because of concerns for disproportionate toxicity. However, ISM can be very 
18
CHAPTER 1
debilitating due to the aforementioned symptoms 52. The goal of treatment 
in ISM is therefore symptom reduction, for which a cocktail of histamine re-
ceptor antagonists, leukotriene antagonists, and so-called mast cells stabiliz-
ers (e.g. cromoglycate) is often used 67. High doses of these drugs are usually 
necessary to achieve adequate control of symptoms. As outlined before, the 
clinical picture of patients with mastocytosis is very heterogeneous. Because 
it is still not possible to predict the risk of anaphylaxis on an individual basis, 
it is recommended to distribute one or two adrenalin auto-injectors to each 
patient. If a patient has experienced prior Hymenoptera-associated anaphy-
laxis, venom subcutaneous immunotherapy might be indicated 68. Of note, 
venom immunotherapy is not 100% effective in patients with mastocytosis, 
and needs to be continued lifelong 69.
A certain part of the patients with ISM has deblitating mast cell-mediator re-
lated symptoms that are refractory to high doses of anti-mediator medica-
tion. We currently cannot offer these patients much with regard to pharma-
cological therapy. Two studies have been published in which the efficacy of 
midostaurin and masitinib in ISM was investigated. For masitinib, only 18% 
of patients reached the primary endpoint of experiencing symptom relief in 
four domains 70. Midostaurin was studied in a small non-controlled trial with 
highly symptomatic ISM patients and proved to have some degree of symp-
tom relief in 75% 71. Studies with other tyrosine kinase inhibitors that inhib-
it the function of KIT are currently running in patients with ISM, of which 
avapritinib seems to be quite promising based on the first results of phase 2 
studies 72.
In advanced forms of SM, cytoreductive therapy might be indicated when or-
gan failure is present or imminent 67. Up to a few years ago, the treatment 
options for AdvSM were limited to corticosteroids, interferon-α, cladribin, or 
imatinib. These therapies were complicated by serious side effects and often 
not very effective 73. Allogenic hematopoietic stem cell transplantation has 
had varying results and considerable mortality and is mainly advised for SM-
AHN or acute MCL 74. Since 2017, the tyrosine kinase inhibitor midostaurin 
was approved for the treatment of AdvSM in both the USA and Europe. This 
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has led to an improvement in survival rates of particularly MCL. However, 
midostaurin has considerable side effects, with over 80% of patients experi-
encing moderate to severe nausea 75. Furthermore, the neoplastic cells can 
become resistant to its effects over time. Although promising new tyrosine 
kinase inhibitors are currently studied, there is still a need to broaden the 
therapeutic arsenal for the treatment of all subtypes of mastocytosis.
1.2 Aims of this thesis
The aim of this thesis was to address clinical questions on mastocytosis from 
a practice-based perspective. The first project was a cohort study of all adult 
patients in the Erasmus MC up to that time. The findings of this study led to 
a series of research questions and hypotheses that were studied in the rest of 
this thesis. Since it is a rare and miscellaneous disease, a substantial part of 
daily clinical practice is based on expert opinion and theoretical hypotheses 
instead of on scientific evidence. This thesis was aimed at finding scientific 
grounds for some of those “myths”. 
Firstly, several studies have previously demonstrated an increased preva-
lence of depression and anxiety among patients with mastocytosis, but none 
of these studies made a comparison with healthy controls or people with 
other chronic diseases. We hypothesized that the increased prevalence of 
psychological symptoms in mastocytosis could at least partially be explained 
by the impact of having a chronic disease in general. We therefore conduct-
ed a cross-sectional study using questionnaires for psychological symptoms 
and health-related quality of life and compared these results to several norm 
groups. 
Furthermore, several diagnostic issues were investigated. Serum tryptase is 
used as a screening tool for SM and the WHO criterion of >20 μg/L is often 
seen as the cut-off value for that purpose. However, we suspected that this 
seemingly arbitrary cut-off level of 20 μg/L has a low sensitivity. We performed 
a retrospective study that described the serum tryptase levels of patients with 
SM at the moment of diagnosis. Also, we studied whether ultrasonography of 
the abdomen is useful in the management and follow-up of patients with SM. 
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This study also provided information on the prognosis of ISM in general. 
Lastly, we tried to find a method to predict Hymenoptera-related anaphylaxis 
in patients with mastocytosis, by using the basophil activation test. 
Another part of this thesis involves iatrogenic anaphylaxis in patient with 
mastocytosis. The main aim here was to find scientific rationale to generate 
advices on the administration of medication to patients with mastocytosis. In 
daily practice, we found that most patients could tolerate NSAIDs and other 
drugs that are deemed dangerous for patients with mastocytosis. To scientifi-
cally corroborate this, we performed a randomized controlled trial in which 
patients with SM were challenged with acetylsalicylic acid. Furthermore, we 
reviewed the current literature on perioperative management and formulat-
ed practical recommendations for prophylaxis prior to the administration of 
radiocontrast media and anesthesia. 
The last chapter in this thesis contains translational research. There is still a 
lack of effective pharmacological therapies available to treat mast cell media-
tor related symptoms. Based on the effects on itch in patients with myelopro-
liferative neoplasms, we postulated that inhibitors of the JAK-STAT pathway 
would probably be effective to inhibit mast cell activation. This was studied 
in vitro. 
Lastly, although mastocytosis is a disease of mast cells primarily, those ab-
errant mast cells might theoretically influence other immune cells in many 
ways. Since ILC2s are one of a few human cell types that can express KIT in 
their mature form, we were interested in the ILC2 numbers and phenotype 
in patients with systemic mastocytosis. This was investigated in the last part 
of this thesis. 
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Chapter 2 
Mastocytosis is a 
multifaceted disease
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2.1 Systemic mastocytosis: a cohort study on clinical charac-
teristics of 136 patients in a large tertiary centre. 
M.A.W. Hermans, M.J.A. Rietveld, J.A.M. van Laar, V.A.S.H. Dalm, M. Ver-
burg, S.G.M.A. Pasmans, R. Gerth van Wijk, P.M. van Hagen, P.L.A. van Daele
European Journal of Internal Medicine 2016 May;30:25-30
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Abstract
Background: Systemic Mastocytosis (SM) is a rare heterogeneous disease 
which is characterized by the aberrant proliferation of mast cells. It can be 
divided in various subtypes with different phenotypes and prognosis. Here, 
we report on the clinical characteristics of 136 SM patients.
Methods: A retrospective cohort study was conducted from January 2009 to 
September 2014 in a large tertiary center in the Netherlands. We included all 
patients who fulfilled WHO criteria for SM. Data were collected from elec-
tronic patient files. 
Results: 124 patients had indolent SM (ISM) (91.2%), 7 had aggressive SM 
(ASM) (5.1%) and 5 had SM with associated haematological non-mast cell 
lineage disease (SM-AHNMD) (3.7%). There was no progression from ISM to 
advanced SM subtypes, but 1 patient with ASM developed chronic myelocyt-
ic leukemia, 2 years after diagnosis. The average time to diagnosis for the 
whole population was 8,1 years (range 0-49 years). The most frequent triggers 
for work-up- skin involvement, anaphylaxis and osteoporosis- were charac-
terized by an interval to diagnosis of 10.9, 2.9 and 7.5 years, respectively. 32 
patients (23.5%) had a serum tryptase level below the cut-off value of 20 ng/
ml at the time of diagnosis, but these patients did not have significant differ-
ences in clinical phenotype. 
Conclusions: SM comprises a wide spectrum of signs and symptoms and its 
often atypical presentation can delay the establishment of the diagnosis 
substantially. Skin involvement, anaphylaxis and unexplained osteoporosis 
should trigger analysis for mastocytosis. A normal serum tryptase does not 
exclude the diagnosis of SM.
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Introduction
Mastocytosis is a rare systemic disease which is characterized by uncontrolled 
proliferation of aberrant mast cells.1 According to the definition of the World 
Health Organization (WHO) it is a myeloproliferative disease with different 
subtypes.76 In systemic mastocytosis (SM), at least one extracutaneous organ is 
affected.  Systemic mastocytosis is divided in various subtypes (table 1). Most 
patients have indolent SM (ISM), which generally has a mild course and does 
not affect overall survival. It is increasingly recognized that ISM patients with or 
without skin lesions (ISMs+ or ISMs-, respectively) have clinically distinct phe-
notypes.77 Smouldering SM (SSM) is a relatively new subtype of ISM and is de-
fined by the presence of organ involvement without organ dysfunction. In SM 
with associated hematological non-mast cell lineage disease (SM-AHNMD), the 
prognosis is determined by the associated condition. Furthermore, aggressive 
SM (ASM) is characterized by organ dysfunction due to infiltration of mast cells. 
This subtype often needs more intensive treatment with cytoreductive therapy. 
	
	
Introduction	
Mastocytosis	is	a	rare	systemic	disease	which	is	characterized	by	uncontrolled	proliferation	of	aberrant	
mast	cells.1	According	to	the	definition	of	the	World	Health	Organization	(WHO)	it	is	a	myeloproliferative	
disease	with	different	subtypes.76	In	systemic	mastocytosis	(SM),	at	least	one	extracutaneous	organ	is	
affected.		Systemic	mastocytosis	is	divided	in	various	subtypes	(table	1).	Most	patients	have	indolent	SM	
(ISM),	which	generally	has	a	mild	course	and	does	not	affect	overall	survival.	It	is	increasingly	recognized	
that	ISM	patients	with	or	without	skin	lesions	(ISMs+	or	ISMs-,	respectively)	have	clinically	distinct	
phenotypes.77	Smouldering	SM	(SSM)	is	a	relatively	new	subtype	of	ISM	and	is	d fined	by	the	presence	
of	organ	involvement	without	organ	dysfunction.	In	SM	with	associated	hematological	non-mast	cell	
lineage	disease	(SM-AHNMD),	the	prognosis	is	determined	by	the	associated	condition.	Furthermore,	
aggressive	SM	(ASM)	is	characterized	by	organ	dysfunction	due	to	infiltration	of	mast	cells.	This	subtype	
often	needs	more	intensive	treatment	with	cytoreductive	therapy.		
	
	
Table	1.	Diagnostic	criteria	for	systemic	mastocytosis	
Systemic	mastocytosis	
Presence	of	1	major	and	1	minor	criterium	or	3	minor	criteria.	
Major	criterium:	
• Multifocal,	dense	MC	infiltrate	(with	>15	MC	per	infiltrate)	in	bone	marrow	and/or	extracutaneous	organ.	
Minor	criteria:	
• Presence	of	D816V	KIT	mutation	in	bone	marrow,	peripheral	blood	or	extracutaneous	tissue.	
• Serum	tryptase	>20	μg/mL.	
• Expression	of	CD117	+	either	CD2	or	CD25	in	MC	in	bone	marrow.	
• >25%	atypical	or	spindle	shaped	MC.	
ISM	 SSM	 SM-AHNMD	 ASM	
Fulfills	criteria	
for	SM,	without	
the	presence	of	
B-	or	C-findings	
	
Fulfills	criteria	for	SM	+	
	>	2	B-findings:	
• Hepato-	or	
splenomegaly	without	
organ	dysfuntion.	
• Lymphadenopathy.	
• >30%	MC	infiltration	
in	bone	marrow.	
• Serum	tryptase	>	200	
ng/mL.	
• Signs	of	dysplasia	or	
myeloproliferative	
disease	without	
fulfilling	criteria	for	
SM-AHNMD.	
Fulfills	criteria	for	SM	+	
a	non-mast	cell	lineage	clonal	
hematological	disease	
(myelodysplastic	syndrome,	
acute	myeloid	leukemia,	non-
Hodgkin	lymphoma	or	
myeloproliferative	neoplasm).	
Fulfills	critera	for	SM	+		
>1	“C-findings”:	
• Anemia,	neutropenia	of	
thrombocytopenia*	
• Hepatomegaly,	ascites,	
hepatic	dysfunction	and/or	
portal	hypertension.	
• Malabsorption.	
• Bone	involvement	with	
pathological	fracture	and/or	
osteolytical	bone	lesions.	
• Splenomegaly	with	
hypersplenism.	
ISMs-	
ISM	without	
skin	lesions	
ISMs+	
ISM	with	skin	
lesions	
MC:	mast	cells.	SM:	systemic	mastocytosis.	ISM:	indolent	systemic	mastocytosis.	SSM:	smouldering	systemic	
mastocytosis.	ASM:	aggressive	systemic	mastocytosis.	SM-AHNMD:	systemic	mastocytosis	with	associated	
hematological	non-mast	cell	lineage	disease.	
*Anemia	Hb<10g/dL,	neutropenia	absolute	neutrophile	count	<50x106,	thrombopenia	<1,500	x106	
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The prevalence of SM in The Netherlands is approximately 13 in 100.000 res-
idents, which appears to be in accordance with other European countries. 
38 In 80-90% of patients, the D816V mutation is found in the gene encoding 
for c-KIT, a tyrosine kinase that functions as stem cell factor (SCF) receptor. 
A small proportion of patients has other mutations in c-KIT. This mutation 
leads to uncontrolled proliferation and inhibition of apoptosis through con-
tinuous stimulation of c-KIT, even in the absence of SCF. 42 However, not every 
SM patient has the D816V mutation, and conversely, not all patients with the 
D816V mutation express the same phenotype. Therefore, other unknown fac-
tors also have to play a role in the pathogenesis of SM.4
SM is known to cause a wide diversity of symptoms. These can vary from the 
typical urticaria pigmentosa or flushing and itching, to less specific symp-
toms like osteoporosis, diarrhea or unexplained syncope. Most symptoms are 
caused by high levels of mast cell mediators, mainly histamine and proin-
flammatory cytokines. 78 Due to this heterogeneous presentation, diagnosing 
this disease, particularly ISM, can be a true challenge which requires high 
clinical suspicion. It does not need further explanation that delay in the di-
agnostic process can lead to several undesired consequences like organ dys-
function, life threatening anaphylaxis or severe osteoporosis. 52,79
The objective of this study is to describe the clinical characteristics of all pa-
tients with SM who were referred to the Erasmus University Medical Centre 
in the last 5 years. Hereby, we hope to create a better understanding of the 
way patients present to us and hopefully improve the diagnostic process.
Methods
Patient selection and follow-up
We selected all patients who visited the Erasmus MC University Medical Centre 
from January 2009 to September 2014 and fulfilled the WHO criteria for system-
ic mastocytosis.76 Recently, the NFU (Dutch federation of academic medical 
centres) classified the Erasmus MC Mastocytosis Centre as a centre of excel-
lence. Included patients could have visited either the outpatient clinic of clini-
cal immunology, hematology or allergology. Therefore, no uniform diagnostic 
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work-up was performed. Also, guidelines on the work-up of SM have changed 
in the studied period. However, general laboratory tests including serum 
tryptase and bone marrow examination was performed in most patients. Pa-
tients were routinely seen once yearly for follow-up purposes in the outpatient 
clinic. Yearly, data on clinical symptoms, laboratory markers (including serum 
tryptase) and an abdominal ultrasound were performed to screen for progres-
sion. Once in every 2 years, bone densitometry was performed for follow-up 
on osteoporosis. By retrospectively studying the patient files, we collected a 
wide array of data: the symptom that triggered referral and analysis, the time 
of diagnosis, other mastocytosis related symptoms, various laboratory results 
and organ involvement. Most patient were followed-up in our centre. For the 
patients who were not followed-up in our centre, we only retrieved information 
on their visits in our centre and on their survival until September 2014.
Definitions
For the different subtypes of SM, we used the WHO classification.76 For skin 
involvement, both urticaria pigmentosa and teleangiëctasia macularis erup-
tiva perstans were accounted for. Neuropsychiatric symptoms were defined 
as every psychiatric diagnosis in the patient’s medical history or the current 
use of psychiatric medication. Cytopenia involved anemia (Hb <10 g/dL), 
leukopenia (<400x 106) and/or thrombocytopenia (<1,500x 106). Osteoporosis 
was classified according to T-scores: osteoporosis = T-score < - 2.5; osteope-
nia = T-score -1 to -2.5; osteosclerosis = T-score > + 2.5. A pathological frac-
ture was defined as a spontaneous fracture directly linked to SM. Osteoporo-
tic vertebral fractures were not included in this definition. 
Statistical analysis
We used IBM Statistics SPSS 21 for all analyses. Frequencies, percentages with 
range or standard deviation were calculated for all variables. The subtypes 
of SM were compared with a one-way ANOVA test for continuous variables 
and with a chi-square test for dichotomous variables. Correlation coefficients 
were calculated with Spearman’s rho.
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Mutational analysis
In brief, 400 μL of EDTA-preserved bone marrow was used to isolate DNA 
with the MagNApure (Roche Molecular Systems, Mannheim, Germany) 
according to the manufacturer’s instructions. Subsequently, a standard solu-
tion of 50 ng/µL was prepared using the Nandrop (Shimadzu Corporation, 
Kyoto, Japan) of which 3 µL was used for each analysis. Detection of D816V 
KIT mutation was performed by two independent methods in all samples: 
the LightCycler System (Roche Molecular Systems, Mannheim, Germany) 
for the primary result and the Taqman System (Fisher Scientific, Amster-
dam, The Netherlands) for confirmation. In the LightCycler assay, the am-
plification rate of mutated DNA over wildtype DNA was improved by adding 
Locked Nucleic Acid (LNA, Tib Molbiol, Berlin, Germany). The mutation 
was detected by melting point analysis. In the Taqman assay, a mismatched 
positive primer with a much higher affinity for the mutant DNA compared 
to wildtype DNA was used. A cycle time (CT) value <40 was considered as 
positive for the presence of D816V. In both assays the detection limit is 0.1% 
mutated copies. Two negative controls (a blanc without DNA and one with 
wildtype DNA) and two positive controls (one with diluted plasmid DNA of 
the mutation to assess the detection limit and one with the D816V mutation) 
were used. The wildtype and mutated controls were left-over samples of 
which the genotype was established in a previous run.
Results
The total patient population consisted of 136 persons of whom 58 (42.6%) 
were female. The mean age at diagnosis was 48.5 years (range 14-80). The 
mean total duration of illness from the start of symptoms until the moment 
of inclusion was 15.9 years (range 0-71). At inclusion in September 2014, 4 pa-
tients had died (2.9%), of whom 3 patients had SM-AHNMD and one had ASM. 
Unfortunately, the cause of death was only available of 1 patient:, she died 
due to substantial organ infiltration by ASM. The mean duration of illness 
of the deceased patients was 14.3 years (range 6-25). The most common pre-
senting symptoms were skin involvement and anaphylaxis (table 2). The aver-
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age time from the start of symptoms to diagnosis was 8.1 years (range 0-49). 
When divided by symptom, the mean time to diagnosis was longest for skin 
involvement (10.9 years) and shortest for flushing (1.3 years). 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Vitamin	B12	
For	the	whole	population,	vitamin	B12	levels	tended	to	correlate	with	serum	tryptase	levels	(rho	=	
0.427;	p=0.060)	and	were	significantly	correlated	with	eosinophilia	(rho=	0.491,	p=0.028).	Of	all	10	
patients	in	whom	eosinophilia	was	present,	it	was	always	mild	to	moderate	with	a	mean	absolute	
eosinophil	count	of	750x106	(range	400	–	1.730).	Hypereosinophilic	syndrome	and	chronic	eosinophilic	
leukemia	were	ruled	out	in	these	patients	by	bone	marrow	biopsy	and	molecular	studies.	
	
Anaphylaxis	
When	taking	the	whole	population	into	account,	42	patients	experienced	at	least	one	anaphylactic	
reaction.	24	cases	were	triggered	by	insect	venom	of	which	21	were	Hymenoptera	(87.5%).	In	3	patients,	
anaphylaxis	was	caused	by	medication:	NSAID	or	radiocontrast	media.	Another	4	reactions	were	related	
to	food	(peanut	or	shrimp)	and	in	11	patients	no	trigger	could	be	identified.	A	specific	IgE	level	was	
determined	in	31	patients	and	was	detectable	in	12	patients	(38.7%)	from	which	11	cases	were	IgE	
against	Hymenoptera	venom.		
	
Serum	tryptase	levels	
Interestingly,	32	patients	(23.5%	of	the	total	population)	had	a	serum	tryptase	level	<20	μg/l	at	diagnosis	
and	9	of	these	even	had	a	serum	tryptase	level	<11.4	μg/l.	22	of	the	32	patients	never	reached	elevated	
tryptase	levels	during	follow-up.	When	dividing	the	study	population	according	to	serum	tryptase	level	
in	three	groups:	<11.4	μg/l;	11.4-20	μg/l;	>20	μg/l,	there	was	no	significant	difference	in	age,	D816V	
status,	nor	in	their	clinical	phenotype	(data	not	shown).	One	exception	was	bone	disease:		although	not	
reaching	statistical	significance,	patients	with	a	serum	tryptase	level	>20	μg/l	showed	a	trend	towards	
having	more	osteoporosis	(35.4%	vs	60.8%	respectively;	p	0.091)	and	more	often	had	pathological	
fractures	(0%	vs	4.9%;	p	0.026)	than	patients	with	a	serum	tryptase	level	<20	μg/l.	
	
Neuropsychiatric	symptoms	
In	our	population,	17	patients	(12.5%)	had	neuropsychiatric	symptoms.	7	of	those	suffered	from	
depression,	5	had	cognitive	problems,	3	patients	had	an	anxiety	disorder.	Furthermore,	1	person	had	
schizophrenia	and	1	had	Attention	Deficit	Hyperactivity	Disorder.	The	cognitive	problems	mainly	
consisted	of	lack	of	concentration	and	decreased	short-term	memory.	
Table	2.	Symptom	that	triggered	diagnostic	work-up.	
Presenting	symptom	 N=136	
n	(%)	
Time	to	diagnosis		
mean	(SD)	
Skin	involvement	 68	(50)	 10,9	(10,1)	
Anaphylaxis/angioedema	 34	(25)	 2,9	(6,2)	
Osteoporosis/bone	pain	 10	(7,4)	 7,5	(6,3)	
Fatigue	 8	(5,9)	 6	(8,8)	
Diarrhea	 4	(2,9)	 12	(9,4)	
Syncope	 4	(2,9)	 8,3	(8,5)	
Flushing	 4	(2,9)	 1,3	(1,9)	
Miscellaneous*	 4	(2,9)	 	
*Miscellaneous:	leukopenia	(1),	accidental	finding	with	biopsy	(2),	itching	(1).	
Vitamin B12
For the whole population, vitamin B12 levels tended to correlate with serum 
tryptase levels (rho = 0.427; p=0.060) and were significantly correlated with 
eosinophilia (rho= 0.491, p=0.028). Of all 10 patients in whom eosinophilia 
was present, it was always mild to moderate with a mean absolute eosinophil 
count of 750x106 (range 400 – 1.730). Hypereosin philic syndrome and chron-
ic eosinophilic leukemia were ruled out in these patients by bone marrow 
biopsy and molecular studies.
Anaphylaxis
When taking the whole population into account, 42 patients experienced at 
least one anaphylactic reaction. 24 cases were triggered by insect venom of 
which 21 were Hymenoptera (87.5%). In 3 patients, anaphylaxis was caused 
by medication: NSAID or radiocontrast media. Another 4 reactions were re-
lated to food (peanut or shrimp) and in 11 patients no trigger could be iden-
tified. A specific IgE l vel was determined in 31 atients and wa  detec able 
in 12 patients (38.7%) from which 11 cases w re IgE a ainst Hym noptera 
venom. 
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Serum tryptase levels
Interestingly, 32 patients (23.5% of the total population) had a serum tryptase 
level <20 μg/l at diagnosis and 9 of these even had a serum tryptase level 
<11.4 μg/l. 22 of the 32 patients never reached elevated tryptase levels during 
follow-up. When dividing the study population according to serum tryptase 
level in three groups: <11.4 μg/l; 11.4-20 μg/l; >20 μg/l, there was no signifi-
cant difference in age, D816V status, nor in their clinical phenotype (data not 
shown). One exception was bone disease:  although not reaching statistical 
significance, patients with a serum tryptase level >20 μg/l showed a trend to-
wards having more osteoporosis (35.4% vs 60.8% respectively; p 0.091) and 
more often had pathological fractures (0% vs 4.9%; p 0.026) than patients 
with a serum tryptase level <20 μg/l.
Neuropsychiatric symptoms
In our population, 17 patients (12.5%) had neuropsychiatric symptoms. 7 of 
those suffered from depression, 5 had cognitive problems, 3 patients had an 
anxiety disorder. Furthermore, 1 person had schizophrenia and 1 had Atten-
tion Deficit Hyperactivity Disorder. The cognitive problems mainly consisted 
of lack of concentration and decreased short-term memory.
Bone density abnormalities
We had access to bone density measurements of 129 patients. Of those, 29 
(22.4%) had osteoporosis and 41 (31.8%) had osteopenia. The average age of 
the patients with abnormal bone density was 52 years (range 23-72) and al-
most half of them was male (48%). Osteosclerosis was only found in 3 per-
sons. Bone pain was reported by 46 patients (33.8% of the total population) 
but in 6 of 7 ASM patients (85.7%).
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Bone	density	abnormalities	
We	had	access	to	bone	density	measurements	of	129	patients.	Of	those,	29	(22.4%)	had	osteoporosis	
and	41	(31.8%)	had	osteopenia.	The	average	age	of	the	patients	with	abnormal	bone	density	was	52	
years	(range	23-72)	and	almost	half	of	them	was	male	(48%).	Osteosclerosis	was	only	found	in	3	
persons.	Bone	pain	was	reported	by	46	patients	(33.8%	of	the	total	population)	but	in	6	of	7	ASM	
patients	(85.7%).	
	
	
	
	
Classification	
According	to	WHO	criteria,	124	of	136	patients	had	ISM	(91.2%),	7	had	ASM	(5.1%)	and	5	had	SM-
AHNMD	(3.7%).	Of	all	patients	with	SM-AHNMD,	3	had	chronic	myelomonocytic	leukemia,	1	had	acute	
myeloid	leukemia	AML-M5	and	1	had	myelodysplastic	syndrome.		
C-findings	that	classified	the	7	patients	as	ASM	were	mostly	bone-related;	5	patients	had	pathological	
fractures,	1	of	whom	also	had	osteolytical	lesions.	The	other	2	ASM	patients	had	malabsorption,	and	
hepatosplenomegaly	with	portal	hypertension	and	ascites,	respectively.	We	did	not	record	any	
progression	from	ISM	to	another	subtype	during	follow-up,	however,	1	patient	with	ASM	developed	
chronic	myelocytic	leukemia	(and	thus	SM-AHNMD)	2	years	after	diagnosis.	
In	patients	with	ISM,	skin	involvement	was	the	most	common	symptom,	most	often	urticaria	
pigmentosa.	Furthermore,	they	mainly	suffered	from	classical	mast	cell-mediator	related	symptoms	like	
itching,	flushing	and	diarrhea	(figure	1).	The	differences	between	ISMs-	and	ISMs+	patients	are	outlined	
elsewhere	in	this	article.	Of	all	patients	with	ASM,	6	out	of	7	had	osteoporosis	and	5	patients	had	at	least	
once	suffered	a	pathological	fracture.	Fatigue	and	bone	pain	also	were	significantly	more	prevalent	in	
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Figure	1.	Symptoms	associated	with	ISM,	ASM	and	SM-AHN	
Classification
According to WHO criteri , 124 of 136 patients h d ISM (91.2%), 7 
had ASM (5.1%) and 5 had SM-AHNMD (3.7%). Of all patients with 
SM-AHNMD, 3 had chronic myel monocytic leuk mia, 1 had acute 
myeloid leukemia AML-M5 and 1 had myelodysplastic syndrome. 
C-fi dings at classified the 7 patients s ASM w re mostly bone-related; 5 
patients had pathological fractures, 1 of whom also had osteolytical lesions. 
The other 2 ASM p tients had malabs rption, and hepatosplenomeg y with 
portal hypertension and ascites, respectively. We did not record any progres-
sion from ISM to another subtype during follow-up, however, 1 patient with 
ASM developed chronic myelocytic leukemia (and thus SM-AHNMD) 2 years 
after diagnosis.
In patients with ISM, skin involvement was the most common symptom, most 
often urticaria pigmentosa. Furthermore, they mainly suffered from classical 
mast cell-mediator related symptoms like itching, flushing and diarrhea (fig-
ure 1). The differences between ISMs- and ISMs+ patients are outlined else-
where in this article. Of all patients with ASM, 6 out of 7 had osteoporosis and 
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5 patients had at least once suffered a pathological fracture. Fatigue and bone 
pain also were significantly more prevalent in this group when compared to 
ISM (table 3). For SM-AHNMD, all patients had cytopenias and constitutional 
symptoms at diagnosis. Moreover, erythrocyte sedimentation rate and vita-
min B12 levels were significantly higher than in other groups. 
Indolent systemic mastocytosis without skin lesions
Patients with ISM were further divided into patients with and without skin 
involvement (ISMs- or ISMs+, respectively). Of ISMs- patients, 57% was male 
versus 34% of ISMs+ patients. ISMs- patients more often had anaphylaxis but 
less often experienced mast cell mediator related symptoms (table 3). In fact, 
anaphylaxis was the presenting symptom for 60% of ISMs- patients, com-
pared with 14% of ISMs+ patients. For the latter, skin lesions were the most 
common presenting symptom (72%). The trigger for anaphylaxis in ISMs- pa-
tients was Hymenoptera venom in 64%, food in 14% and was unknown in 
23%. For ISMs+ patients, anaphylaxis was triggered by Hymenoptera venom 
in 39%, food or NSAID in 17% and the trigger was unknown in 44%. Serum 
tryptase at baseline was lower in ISMs- patients compared with ISMs+ pa-
tients (mean 34.5 vs. 65.6 μg/l, p 0.037). However, the number of patients with 
a serum tryptase level <20 μg/l was similar in ISMs- and ISMs+ patients (27% 
vs. 25%, p 0.723) and the same accounted for serum tryptase levels below the 
’normal’ cut-off value of <11.4 μg/l (5% vs. 8%, p 0.617).
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Table	3.	Clinical	and	laboratory	characteristics.	
Characteristic*	 All	patients	 ISMs-	
(n=37)	
ISMs+	
(n=87)	
ASM	(n=7)	 SM-AHNMD	
(n=5)	
p†	
Age	at	diagnosis	in	years	
	
48.5		
(14-80)	
51.8	
(30-76)	
46.1		
(14-75)	
52.6		
(32-68)	
60.4		
(43-80)	
0.010	
Total	duration	of	illness	in	
years	
15.9	(0-71)	 13.0	(0-31)	 17.1	(2-71)	 17.8	(4-46)	 13.4	(6-25)	 NS	
Time	to	diagnosis	in	years	 8.1	(0-49)	 5.7	(0-24)	 9.5	(0-49)	 7.5	(1-28)	 1.6	(0-5)	 NS	
ESR	(mm/hour)‡		 11.2	(1-105)	 10.4	(2-32)	 8.4	(1-33)	 10	(2-29)	 64	(25-105)	 0.000	
Vitamin	B12	(ng/l)	‡	
	
535.7		
(118-1475)	
353.7		
(148-622)	
458		
(212-1061)	
312.5	
(118-507)	
1210.7	
(826-1475)	
0.002	
WHO	criteria§	 	 	 	 	 	 	
MC	infiltrates	in	bone	marrow	
on	histologic	evaluation	
124/126	
(98.4)	
22/25	(88)	 67/73	(91.8)	 7/7	(100)	 4/5	(80)	 NS	
Flow	cytometry	positive	 84/89	(94.4)	 26/27	(96.3)	 52/55	(94.5)	 3/4	(75)	 3/3	(100)	 NS	
D816V	mutation	 63/78	(80.8)	 14/23	(60.9)	 44/49	(89.8)	 2/3	(66.7)	 3/3	(100)	 0.023	
Tryptase	(μg/l)*	 61		
(4.2-457)	
34.5	(8-103)	 65.6	(4.2-
457)	
61.5		
(21.2-99.3)	
206		
(72.8-280)	
0.000	
Aberrant	MC	morphology	in	
bone	marrow	smear	
110/120	
(91.7)	
32/35	(91.4)	 67/73	(91.8)	 7/7	(100)	 4/5	(80)	 NS	
Symptoms	 All	patients	 ISMs-	
(n=37)	
ISMs+	
(n=87)	
ASM	(n=7)	 SM-AHNMD	
(n=5)	
p†	
Skin	involvement	 95/136	(69.9)	 0/37	(0)	 87/87	(100)	 4/7	(57.1)	 4/5	(80)	 0.000	
Fatigue	 59/136	(43.4)	 13/37	(35.1)	 36/87	(41.4)	 5/7	(71.4)	 5/5	(100)	 0.019	
Itching	 58/136	(42.6)	 5/37	(13.5)	 48/87	(55.2)	 2/7	(28.6)	 3/5	(60)	 0.000	
Flushing	 57/136	(41.9)	 9/37	(24.3)	 44/87	(50.6)	 4/7	(57.1)	 0/5	(0)	 0.009	
Diarrhea	 50/136	(36.8)	 3/37	(8.1)	 43/87	(49.4)	 2/7	(28.6)	 2/5	(40)	 0.000	
Anaphylaxis	 42/136	(30.9)	 22/37	(59.5)	 18/87	(20.7)	 1/7	(14.3)	 1/5	(20)	 0.000	
Dyspepsia		 40/136	(29.4)	 7/37	(18.9)	 28/87	(32.2)	 4/7	(57.1)	 1/5	(20)	 NS	
Alcohol	intolerance		 18/105(13.2)	 4/37	(10.8)	 14/68	(20.5)	 0/3	(0)	 0/4	(0)	 NS	
Syncope	 18/136	(13.2)	 8/37	(21.6)	 10/87	(11.5)	 0/7	(0)	 0/5	(0)	 NS	
Neuropsychiatric	 17/136	(12.5)	 4/37	(10.8)	 12/87	(13.8)	 1/7	(14.3)	 0/5	(0)	 NS	
Constitutional	symptoms	 13/136	(9.6)	 2/37	(5.4)	 5/87	(5.7)	 1/7	(14.3)	 5/5	(100)	 0.000	
Eosinophilia		 10/135	(7.4)	 1/37	(2.7)	 7/87	(8)	 0/7	(0)	 2/5	(40)	 0.023	
Cytopenia	 7/135	(5.2)	 2/37	(5.4)	 1/87	(1)	 0/7	(0)	 5/5	(100)	 0.000	
B-findings	 	 	 	 	 	 	
Hepatomegaly	 18/135	(13.2)	 1/37	(2.7)	 11/87	(12.6)	 2/7	(28.6)	 4/5	(80)	 0.000	
Splenomegaly	 16/134	(11.9)	 1/37	(2.7)	 3/87	(3.4)	 1/7	(14.3)	 4/5	(80)	 0.000	
Serum	tryptase	>200	ng/mL	 9/136	(6.6)	 0/37	(0)	 6/87	(6.9)	 0/7	(0)	 3/5	(60)	 0.000	
>30%	MC	in	bone	marrow		 2/33	(6.1)	 0/31	(0)	 1/21	(4.8)	 1/3	(33.3)	 0/3	(0)	 NS	
Lymphadenopathy	 7/136	(5.1)	 1/37	(2.7)	 3/87	(3.4)	 0/7	(0)	 3/5	(60)	 0.000	
Abbrevations:	ISMs-:	Indolent	systemic	mastocytosis	without	skin	lesions,	ISMs+:	Indolent	systemic	mastocytosis	with	
skin	lesions,	ASM:	aggressive	systemic	mastocytosis,	SM-AHNMD:	systemic	mastocytosis	with	associated	hematologic	
non-mastcell	disease,	NS:	not	significant,	ESR:	erythrocyte	sedimentation	rate,	MC:	mast	cells.	
*Values	as	mean	+	range.	
†	p	value	for	the	4	subtypes	compared.	
‡	ESR	was	tested	in	103	patients,	vitamin	B12	level	was	tested	in	20	patients.	
§	Each	patient	could	have	more	than	one	symptom.	Values	as	n(%)	except	for	mean	tryptase	levels.	
Treatment
The majority of patients was treated symptomatically with histamine antag-
onists and cromoglycate; respectively 93 (70%) and 17 (12.7%). Furthermore, 
10 patients received glucocorticoids, but mostly as an adjunct to cytoreduc-
tive therapy. When cytoreductive therapy was indicated, imatinib was most 
often used.  This is partly due to the fact that a study on imatinib was conduct-
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ed during part of the studied period.80 Imatinib was prescribed to 9 patients 
with ISM, 1 with ASM and 3 patients with SM-AHNMD. Of the ISM patients 
who were treated with imatinib, indication for treatment was disabling itch-
ing, splenomegaly, or gastrointestinal complaints. It was effective in 5 pa-
tients in total and mainly seemed to improve fatigue, skin lesions and serum 
tryptase levels. For further information on imatinib treatment, we refer to 
the article of Droogendijk et al., which included our patients.80 The second 
most used cytoreductive agent was cladribin in 4 patients, of whom 3 suffered 
from SM-AHNMD and 1 had ISM. Cladribin was effective in 1 patient who 
had SM-AHNMD; it mainly improved gastrointestinal symptoms and reduced 
pancytopenia. Interferon was applied in 1 patient, but was discontinued early 
because of adverse effects. A last notable fact is that only 62 patients (46.3%) 
were equipped with an epinephrine autoinjector. Of all patients who initially 
presented with anaphylaxis, 31 (73.8%) had an epinephrine autoinjector. 
Discussion
In this study, we describe a relatively large population of SM patients in a ter-
tiary center. The clinical presentation of our patients was rather diverse and 
mainly included skin involvement and mast cell mediator-related symptoms. 
We found a considerable diagnostic delay. The mean time to diagnosis was 
8.1 years.  Until now, only one other study investigated the time to diagno-
sis and found a median of 33 months (range 0-516 months). 40 The diagnostic 
process was more delayed when patients had atypical symptoms. However, 
even when anaphylaxis was the first symptom, the mean time to diagnosis 
was still 2.9 years. This substantial delay might have various reasons, but an 
important explanation might be the lack of clinical suspicion with many phy-
sicians. Moreover, there could have been patient delay because patients with 
(asymptomatic) skin involvement often postpone seeking medical advice. 
Our study encompasses the care of SM patients from 2009 to 2014. During this 
period, a lot was learned on this disease and our study shows the evolution 
of care for SM patients in the last years. For instance, standard mutational 
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analysis only included D816V c-KIT mutation, which might have led to mis-
diagnosing of a few patients who did not have the D816V mutation, but an-
other mutation in the gene encoding for c-KIT. Our data again underline the 
need for standardized algorithms for work-up and treatment, which has been 
demonstrated before in work from the Spanish and European Networks on 
Mastocytosis.81,82 Fortunately, since recent years, we are following a standard-
ized diagnostic workflow for SM patients in our center.
Another important finding of our study is the high rate of osteoporosis and 
osteopenia. These figures are comparable to other Western European liter-
ature on SM. 77,83,84 Pathological fractures were rare. However, we did not ac-
count for so-called fragility fractures like vertebral fractures because they 
are not included in the diagnostic criteria for Systemic Mastocytosis. Obvi-
ously, vertebral fractures can also cause significant disability. The patients 
with osteoporosis in our population were not the typical elderly lady, on the 
contrary: half of them was middle-aged and/or male. This is in line with oth-
er literature on this topic and leads to the recommendation that SM needs 
to be considered in (male) patients without conventional risk factors for os-
teoporosis.85
In 17 patients (12.5%), neuropsychiatric morbidity was reported. When eval-
uating neuropsychiatric symptoms in SM patients, data strongly vary. The 
prevalence seems to be around 21-24% in other general population studies 
48,83,86 However, when neuropsychiatric symptoms are specifically studied 
with validated questionnaires, much more impressive results are shown: 74% 
of SM patients reports subjective cognitive problems 65 and 56% fulfills the 
criteria for depression. 66 We therefore suspect that neuropsychiatric symp-
toms are not sufficiently recognized. In line with our previous remark on the 
importance of standardized work-up methods, implementing a standardized 
questionnaire in routine outpatient visits might improve the recognition and 
treatment of these symptoms as well. 
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Similar to other studies 40,83, there were clear differences in clinical symptoms 
between the subtypes in our population. Most differences are inherent to the 
diagnostic criteria. Remarkably, patients with SM-AHNMD had significantly 
higher serum tryptase and vitamin B12 levels compared with the other two 
subtypes. A spontaneously elevated vitamin B12 level has mainly been de-
scribed with hematological malignancies and hypereosinophilic syndrome, 
where it is caused by a raised serum haptocorrin level, which is a transporta-
tion protein for vitamin B12. 87 In hypereosinophilic syndrome, vitamin B12 
and serum tryptase levels seem to be positively correlated to each other. 88 We 
were able to confirm this correlation in our patients. Unfortunately, data on 
vitamin B12 levels were available in a limited number of patients which only 
leaves us to speculate on the clinical significance of this association.
A relatively new subdivision of ISM patients in those with and without skin 
lesions was also made in our cohort. ISMs- patients were more often male, 
more often had anaphylaxis of which wasp venom the most common trigger, 
and reported less mast cell mediator related symptoms. These characteristics 
are in accordance with other cohort studies on this topic.77 Data on serum 
tryptase levels in ISMs- patients are contradictory. One Dutch study postu-
lated that in patients without skin lesions/UP, a normal serum tryptase level 
sufficiently excluded SM.15 However, in our cohort, a considerable number of 
ISMs- patients had serum tryptase levels below the normal cut-off value and 
over a quarter of ISMs- patients had a baseline serum tryptase of <20 μg/l. 
A notable difference to other studies is the favorable prognosis in our cohort. 
In another large cohort studies of SM, the median survival was 41 months for 
ASM patients and 24 months for SM-AHNMD patients.40 Of course, we had 
small numbers of patients with ASM or SM-AHNMD. Also, most patients with 
ASM classified for this subtype due to bone lesions which generally do not 
influence one’s survival. Moreover, in recent years, the treatment for non-
mast cell hematological diseases in general has greatly improved which could 
explain part of the survival of our SM-AHNMD patients. 
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Several limitations of this study should be addressed. Firstly, the retrospec-
tive design could lead to incomplete data, which for instance explains the rel-
atively low prevalence of neuropsychiatric symptoms in our population. Sec-
ondly, we searched for eligible patients via diagnostic codes in the electronic 
patient file. This method inevitably excludes patients who have received an 
inaccurate diagnostic code. Lastly, we did not differentiate smouldering SM 
(SSM) from ISM. This is due to the fact that we did not work with the separate 
diagnosis of SSM in our daily practice at that time. However, we provided in-
formation on B-findings in table 3 to give an impression of how many patients 
actually had SSM.
Conclusion
Here, we present a relatively large population of 136 SM patients who visited 
a tertiary center over a period of 15 years. This study shows the considerable 
diagnostic delay that is partly due to the heterogeneous nature of this dis-
ease. Symptoms are often present for years before the diagnosis is made. The 
diagnostic delay is generally shorter in patients with more classical or more 
severe symptoms. A high clinical suspicion is needed for prompt diagnosis. 
Moreover, our retrospective study underlines the importance of standardized 
methods for work-up and treatment. 
Importantly, not all patients with SM have raised serum tryptase levels at di-
agnosis and clinicians sometimes need to be triggered by other small clues 
like spontaneously raised vitamin B12 levels or unexplained osteoporosis. 
However, SM also needs to be included in the differential diagnosis for pa-
tients with (recurrent) anaphylaxis or long-lasting abdominal complaints. 
Finally, points of interest in the care for SM patients are the prescription of 
epinephrine autoinjectors and recognition of neuropsychiatric symptoms. 
CHAPTER 2
37
2.2 Psychological functioning and quality of life in patients 
with mastocytosis: a cross-sectional study.
M.R. Vermeiren, L.W. Kranenburg, P.L.A. van Daele, R. Gerth van Wijk, 
M.A.W. Hermans
Annals of Allergy, Asthma and Immunology 2020 Apr;124(4):373-37
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Abstract
Background: Psychological symptoms appear to be frequent among patients 
with mastocytosis and can significantly affect their quality of life. Yet, it re-
mains unclear whether and to which extent this may be the case. We aimed to 
investigate both the presence and type of psychological symptoms and quali-
ty of life in patients with mastocytosis.  
Methods: A cross-sectional cohort study in adult patients with mastocytosis. 
All patients completed the 36-item Short Form health survey (SF-36) and the 
90-item Symptom Checklist (SCL-90). Results were compared to established 
norm groups of patients with other diseases (chronic pain and cancer) and 
healthy populations.
Results: Fifty patients were included. Seventy percent had indolent systemic 
mastocytosis. Patients with mastocytosis scored significantly worse than a 
healthy norm group on the total SCL-90 and more specifically on the dimen-
sions of depression, somatization, sleeping problems and inadequacy of acting and 
thinking. Strikingly, patients with mastocytosis scored similar to cancer pa-
tients on the SF-36 subdomains of general health perception and vitality. There 
was however no significant difference in the mental health subdomain of the 
SF-36 when compared with a healthy norm group. 
Conclusion:  In addition to the presence of psychological symptoms, the phys-
ical symptoms that are associated with mastocytosis also have a significant 
impact on the quality of life of patients with this disease. Therefore, correct 
treatment through symptom control and psychological counselling is neces-
sary. 
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Introduction 
Mastocytosis is a chronic hematological disease that is characterized by an 
accumulation of aberrant mast cells in one or several organs. Symptoms can 
be caused by tissue infiltration of mast cells or by the excessive release of 
mast cell mediators such as histamine, eicosanoids, heparin and many differ-
ent cytokines.89 In cutaneous mastocytosis, only the skin is involved, whereas 
systemic mastocytosis is characterized by the involvement of at least one ex-
tracutaneous organ, most often the bone marrow.33 The WHO has formulat-
ed several subtypes of systemic mastocytosis (SM), ranging from indolent to 
more aggressive forms. When a patient has cutaneous signs of mastocytosis 
but a bone marrow examination has not been performed, they are termed to 
have  mastocytosis in the skin (MIS).90 Indolent systemic mastocytosis (ISM) 
is the most common subtype of SM and has virtually no influence on life ex-
pectancy.40 Nevertheless, it is associated with significant disability – mean-
ing: one or more symptom(s) that prevent the patient from continuing their 
everyday life. The clinical presentation is very heterogenous and there are 
various symptoms that negatively impact the quality of life of these patients. 
From a survey among patients in the USA, the symptoms that were perceived 
as most debilitating were flushing, diarrhea, fatigue and the everyday risk of 
anaphylaxis.52,91 
Next to these physical symptoms, previous studies have consistently shown 
an increased prevalence of psychiatric morbidity in patients with mastocyto-
sis.65,92  This might be caused by the effect of various mast cell mediators to 
the brain function.92  However, it is still unclear whether psychological mor-
bidity is a specific feature of mastocytosis, or whether it is a more general 
consequence of having a chronic disease with debilitating physical symp-
toms. In order to understand the type and extent of psychological symptoms 
in patients with mastocytosis, it appears useful to make comparisons with 
emotional and physical distress levels in patients with other diseases. In this 
study, we therefore aimed to investigate the presence of various psychologi-
cal symptoms and quality of life in a representative cohort of patients with 
mastocytosis and compared these outcomes to already established reference 
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values for patients with chronic pain or cancer and healthy norm groups. Sec-
ondly, we analyzed the correlation between psychological symptoms, quality 
of life and mastocytosis-related characteristics. 
Methods
Patients and procedures
A cross-sectional study was performed in 50 adult patients diagnosed with 
mastocytosis. This study was performed as an addition to a trial that in-
vestigated the prevalence and severity of acetylsalicylic acid among adult 
patients with mastocytosis.93M. A. W.</author><author>van der Vet, S. 
Q. A.</author><author>van Hagen, P. M.</author><author>van Wijk, R. 
G.</author><author>van Daele, P. L. A.</author></authors></contribu-
tors><auth-address>Department of internal medicine, section of Clinical 
Immunology, Erasmus University Medical Center, Rotterdam, The Neth-
erlands.&#xD;Department of internal medicine, section of Allergy, Eras-
mus MC, Rotterdam, The Netherlands.</auth-address><titles><title>Low 
frequency of acetyl salicylic acid hypersensitivity in mastocytosis: the re-
sults of a double-blind, placebo-controlled challenge study</title><second-
ary-title>Allergy</secondary-title></titles><periodical><full-title>Allergy</
full-title></periodical><edition>2018/03/24</edition><dates><year>2018</
year><pub-dates><date>Mar 22</date></pub-dates></dates><isbn>1398-9995 
(Electronic Therefore, the inclusion and exclusion criteria were based on that 
trial. Patients were recruited from the outpatient clinic of a tertiary university 
medical center, which is a national reference center for mastocytosis.. All 
patients under current treatment in the fall of 2016 received an invitation to 
participate by mail and were subsequently contacted by telephone. Adult pa-
tients with biopsy-proven cutaneous or systemic mastocytosis were eligible. 
All participants were asked to complete three questionnaires on psychologi-
cal symptoms, health-related quality of life and general mastocytosis-related 
symptoms. The study was approved by the local medical ethics committee. 
All participants provided written informed consent. 
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Measures
Basic demographic characteristics and mastocytosis related characteristics 
such as subtype, presence of skin involvement and anaphylaxis, were record-
ed. 
The participants completed the 90-item Symptom Checklist and the 36-item 
Short Form health survey. These questionnaires were used to screen for psy-
chological symptoms and health-related quality of life from a patients’ per-
spective. They are not intended to diagnose patients with specific psychiatric 
diseases.
The Symptom Checklist 90 (SCL-90) is a multidimensional psychopatholo-
gy-indicator, that assesses to which extent patients were bothered by each 
item in the last week, including the day of the questionnaire.94 The question-
naire consists of 90 items (symptoms) with scores ranging from 1 (not at all) 
to 5 (very). There are eight subscales: anxiety, agoraphobia, depression, soma-
tization, distrust and interpersonal sensitivity, hostility, sleeping problems and 
inadequacy of thinking and acting. All items contribute to a total SCL-90 score 
of psychoneuroticism. Lower scores indicate a better state of recent mental 
health. Mean test scores of the study cohort were compared to scores of a 
healthy Dutch norm group and a norm group of patients with chronic pain, 
described by Arrindell and Ettema.94 The internal consistency of the ques-
tionnaire is above 0.70, and most coefficient alpha’s range from 0.80 to 1.00.94 
The Short Form 36 (SF-36) is a multidimensional measuring instrument that 
captures the general state of health and functioning, physically as well as 
emotionally and socially.95 Item scores are summoned and transformed into 
eight scale scores: physical functioning, role limitations due to physical health, 
role limitations due to emotional problems, vitality, mental health, social role func-
tioning, bodily pain and general health perception. Overall, a physical health 
component and mental health component can be discerned. SF-36 outcomes 
are presented on a hundred-points scale. Higher scores indicate a better state 
of health. Mean test scores of the study cohort were compared to scores of 
a healthy Dutch norm group and a norm group of patients with cancer, de-
scribed by Aaronson et al.96 For all test scores the Dutch reference for women 
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was used. The mean coefficient alpha across scales and samples was 0.84.96 
Lastly, we asked patients to rate 18 mastocytosis-related symptoms in a 
self-developed questionnaire. These included pruritus, flushing, bone pain, 
myalgia, dyspepsia, diarrhea, collapse, dizziness, dyspnea, rhinitis, head-
ache, insomnia, fever, night sweats, fatigue, brain fog, subjective cognitive 
problems, anddifficulties with memory. Symptoms were scored from 0 to 3 
with 0 meaning ‘never present’, 1 meaning ‘present < three days a week’, 2 
meaning ‘present > three days a week’, 3 meaning ‘present every day’. 
Analysis
IBM SPSS 25 was used for all analyses. Patient characteristics are given as 
mean with standard deviation (SD) for continuous variables and as the abso-
lute number with percentage for dichotomous variables. The unequal vari-
ances 2-sided t-test was used to compare the mean test scores of the study 
cohort to norm scores of other populations.(11, 13) The 2-tailed Pearson cor-
relation coefficient was calculated to investigate a correlation between test 
scores and continuous variables, and the independent samples t-test was used 
for dichotomous variables. For all tests α was set at 0.05. A few mastocytosis 
characteristics that were expected to be correlated to psychological disabili-
ty, were compared to the main outcomes. These mastocytosis characteristics 
are tryptase levels, the presence of urticaria pigmentosa and symptoms of 
fatigue, diarrhea and anaphylaxis. The choice for these characteristics was 
based on previous literature 52,97 and our own experience from working with 
these patients. Test outcomes used for this analysis were: total SCL-90 score 
and SF-36 mental- and physical health components. By restricting the com-
parison analyses, a bias due to multiple testing was avoided. Procedures on 
missing items, provided by Arrindel and Ettema for the SCL-90, and by van 
der Zee and Sanderman for the SF-36, were followed.(11, 12) If, according to 
these guide lines, not enough items were answered, the patient was excluded 
from the analysis of the relevant questionnaire. 
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Results
Patient characteristics
Fifty patients were includ-
ed. The mean age was 54.3 
years (range 19-74 years), the 
majority of participants was 
female (68%) and most had 
indolent systemic mastocy-
tosis (70%). Nine patients 
(18%) who were under the 
age of 65 years were not able 
to work due to health issues. 
The mean serum tryptase lev-
el was 42.5 μg/l, however with 
a wide range between 6.4 and 
221.0 μg/l. The mean duration 
of disease was 19.2 years, 
also with a wide range of 
74-2 years. Two patients used 
psychiatric medication, both 
a selective serotonin reuptake 
inhibitor. See Table 1 for all 
patient characteristics.
SCL-90
The study cohort scored significantly higher than the healthy norm group on 
the total SCL-90 score (p = 0.02), but lower than the norm group of chronic 
pain patients (p = 0.003). For the subscales of depression, somatization, inade-
quacy of thinking and acting and sleeping problems, the study population scored 
significantly worse than the healthy norm group (p = 0.04, 0.00002, 0.002, 
0.001, respectively), but again lower than the patients with chronic pain (p = 
0.007, 0.01, 0.0006, 0.006, respectively). There was no significant difference on 
CHAPTER 2
	
	
outcomes	used	for	this	analysis	were:	total	SCL-90	score	and	SF-36	mental-	and	physical	health	
components.	By	restricting	the	
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multiple	testing	was	avoided.		
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provided	by	Arrindel	and	Ettema	for	
the	SCL-90,	and	by	van	der	Zee	and	
Sanderman	for	the	SF-36,	were	
followed.(11,	12)	If,	according	to	
these	guide	lines,	not	enough	items	
were	answered,	the	patient	was	
excluded	from	the	analysis	of	the	
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mean	age	was	54.3	years	(range	19-74	
years),	the	majority	of	participants	
was	female	(68%)	and	most	had	
indolent	systemic	mastocytosis	(70%).	
Nine	patients	(18%)	who	were	under	
the	age	of	65	years	were	not	able	to	
work	due	to	health	issues.	The	mean	
serum	tryptase	level	was	42.5	μg/l,	
however	with	a	wide	range	between	
6.4	and	221.0	μg/l.	The	mean	duration	
of	disease	was	19.2	years,	also	with	a	
wide	range	of	2-74	years.	Two	
patients	used	psychiatric	medication,	
both	a	selective	serotonin	reuptake	
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SCL-90	
The	study	cohort	scored	significantly	higher	than	the	healthy	norm	group	on	the	total	SCL-90	score	(p	=	
0.02),	but	lower	than	the	norm	group	of	chronic	pain	patients	(p	=	0.003).	For	the	subscales	of	
depression,	somatization,	inadequacy	of	thinking	and	acting	and	sleeping	problems,	the	study	
population	scored	significantly	worse	than	the	healthy	norm	group	(p	=	0.04,	0. 0 02,	0.002,	0.001,	
respectively),	but	again	lower	than	the	patients	with	chronic	pain	(p	=	0.007,	0.01,	0.0006,	0.006,	
respectively).	There	was	no	significant	difference	on	the	subscales	of	anxiety,	agoraphobia	and	
Table	1.	Baseline	characteristics	study	population	(n=50).	
Age	in	years,	mean	(SD)	 54.3	(12.8)	
Male,	n	(%)	 16	(32)	
Educational	level,	n	(%)	 	
• High	school	 2	(4)	
• Secondary	vocational	education	 27	(54)	
• Higher	professional	education	 16	(32)	
• University	education	 5	(10)	
Currently	working‡,	n	(%)	 28	(56)	
• Not	working	due	to	health	issues	 9	(18)	
• Retired	 12	(24)	
Subtype	according	to	WHO	criteria33,98,	n	(%)	 	
• MIS	 9	(18)§	
• ISM	 	
with	skin	lesions	 26	(52)	
without	skin	lesions	 9	(18)	
• SSM	 3	(6)	
• SM-AHN	 2	(4)	
• ASM	 1	(2)	
Duration	of	disease	in	years,	mean	(SD)	 19.2	(14.4)	
Serum	tryptase	level	at	diagnosis	in	μg/l,	mean	(SD)	 42.5	(47.8)	
Daily	mast	cell	mediator-related	symptoms,	n	(%)	 	
• Pruritus	 36	(72)	
• Flushing	 35	(70)	
• Diarrhea	 36	(72)	
• Fatigue	 43	(86)	
• Anaphylaxis	 22	(44)	
• Osteoporosis†	 8	(16)	
§One	patient	underwent	incomplete	bone	marrow	investigation,	8	
patients	declined	bone	marrow	punction.	
†Osteoporosis	was	defined	as	a	T-score	<	2.5	SD	for	bone	
densitometry	of	the	lumbar	spine	and/or	left	femur.	
‡One	person	is	a	housewife.	
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the subscales of anxiety, agoraphobia and interpersonal sensitivity. See figure 1 
for a graphic summary. The exact mean subscale values with standard devia-
tion are summarized in Online Supplementary eTable 1. 
SF-36
Figure 1. Mean SCL-90 subscale scores of the study cohort compared to norm 
scores of healthy persons and patients with chronic pain. A higher score means more 
symptoms. The y-axis depicts the absolute mean score value. On the x-axis, the subscales of 
the Dutch SCL-90 subscales are shown. Anx = anxiety; Ago = agoraphobic symptoms; Dep = 
depression; Som = somatization; In = inadequacy of thinking and acting; Sen = interpersonal 
sensitivity; Hos = hostility; Sle = sleeping problems. *p <0.05 for comparison of the subscale 
value of the study population versus the other norm groups (t-test)
The study cohort scored significantly worse than the healthy norm group on 
the subscales of bodily pain, physical role functioning, social role functioning, vi-
tality and general health perception (p = 0.006, 0.001, 0.03, 0.0002, 0.00001, respec-
tively). There was no difference in the subscales of mental health, emotional role 
functioning and physical functioning between the study cohort and the healthy 
norm group. The study cohort scored significantly worse than the norm group 
of cancer patients on bodily pain and similarly on vitality and general health 
perception (p = 0.03, 0.12, 0.64, respectively). However, cancer patients had sig-
nificantly lower scores on mental health, emotional role functioning and physical 
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role functioning than our study cohort (p = 0.0004, 0.008, 0.04, respectively). See 
figure 2 for a graphic summary. The exact mean subscale values with standard 
deviation are summarized in Online Supplementary eTable 2. 
Figure 2. Mean SF-36 subscale values of the study cohort compared to SF-36 norm 
score of the Dutch population and cancer patients. A lower score means lower quality 
of life on that area. The y-axis depicts the absolute score value. The subscales on the x-axis are 
shown as abbreviations of the SF-36 subscales. BP = bodily pain; PF = physical functioning; 
RP = physical role functioning; RE = emotional role functioning; VT = vitality; MH = mental 
health; SF = social role functioning; GH = general health perception. *p<0.05 for comparison 
of the subscale value of the study population versus the other norm groups (t-test)
Correlation between psychological symptoms and mastocytosis-related 
characteristics
There was no significant correlation between the serum tryptase levels and 
the absolute scores of the total SCL-90 and the mental and physical compo-
nent of the SF-36 (Pearson correlation coefficients 0.128, -0.021, -0.299 with 
p = 0.40, 0.90, 0.05, respectively). Graphical illustrations are given as Online 
Supplementary eFigure 1.
The presence of fatigue was significantly correlated with worse scores on the 
total SCL-90 as well as on the SF-36 mental component and physical com-
ponent (Pearson correlation coefficients 0.461, -0.380, -0.328 with p = 0.001, 
0.01, 0.03, respectively). Patients with diarrhea had significantly higher total 
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SCL-90 scores (Pearson correlation coefficient 0.342, p = 0.02). Diarrhea was 
not significantly correlated with worse absolute scores of the SF-36 mental 
and physical component (Pearson correlation coefficients -0.132, -0.088 with 
p = 0.40, 0.56, respectively). Furthermore, there was no significant correlation 
between urticaria pigmentosa and the absolute scores of the total SCL-90 and 
the mental and physical component of the SF-36 (p = 0.15, 0.52, 0.26, respective-
ly). Finally, symptoms of anaphylaxis were not found to be significantly corre-
lated to total SCL-90 scores and the mental and physical component of the SF-
36 (p = 0.08, 0.36, 0.09, respectively). A graphical illustration of the correlations 
between these characteristics and the total SCL-90 is given in figure 3.
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Discussion
In this cross-sectional cohort study we investigated the presence and type of 
psychological symptoms of 50 adults with mastocytosis and their health-re-
lated quality of life. Secondly, we aimed to identify correlations with masto-
cytosis-related characteristics. This is the first study to compare psycholog-
ical symptoms of patients with mastocytosis to historical norm groups of a 
healthy population and of patients with other illnesses that may greatly im-
pact one’s health-related quality of life, i.e. chronic pain or cancer. Patients 
with mastocytosis scored worse than the healthy norm group on the total 
SCL-90 scale as well as on its subscales of depression, somatization, sleeping 
problems and inadequacy of acting and thinking. The study cohort scored simi-
lar to a healthy norm group on the SF-36 subscales of mental health and emo-
tional role functioning and similar to a norm group of patients with cancer on 
the SF-36 subscales of general health perception and vitality and even worse on 
the subscale of bodily pain. 
Previous studies show that 30-64% of patients with ISM had symptoms of de-
pression66,99, and 38.6% had some degree of cognitive impairment.65 In a ques-
tionnaire-based cohort study in the USA, 49.3% of patients reported some 
degree of depression, and 28.8% reported moderate to severe depression.52 
A similar prevalence of self-reported depression was found in a Dutch and 
another French cohort.53,91 Since the designs of these studies differ from each 
other and from our study, it is difficult to directly compare the results. Howev-
er, the rates of depression were considerable in every single study. Our study 
investigated mental and physical burden rather than the presence of specific 
psychiatric disorders in patients with mastocytosis. For example, the SCL-
90 subscale of depression is not synonymous to the diagnosis of depression 
by a psychiatrist. We have used questionnaires that investigate psychological 
symptoms as well as the health-related quality of life of patients. . By compar-
ing our cohort to scores of standard norm groups for the used questionnaires, 
we can confirm that patients with mastocytosis more often have psycholog-
ical symptoms than healthy controls. However, our study cohort scored bet-
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ter on most subscales of the SCL-90 than an established norm group with 
chronic pain. This may not be so surprising, as it is well known that chron-
ic pain is strongly related to psychological functioning.100 It must be noted 
that although the use of historical norm groups is in our opinion better than 
making no comparison at all, it is not certain that these groups are similar to 
the studied cohort regarding age, sex and other demographic characteristics. 
Moreover, the norm groups were obtained in the 90’s and early 00’s, and the 
general perception of health might have changed with time. 
In general, our study population is a representative cohort of adults with 
mastocytosis, except for a relatively low number of male participants. Only 
two patients in our cohort were using antidepressants at the moment of ob-
taining the questionnaires, therefore this is probably not a significant factor 
in interpreting the results, but on the other hand emphasizing the underes-
timation of psychological burden in this patient category. Since we are an 
allergology-oriented clinic, relatively few patients with advanced subtypes 
of SM were included. Although the numbers were too small to perform sta-
tistical subgroup analyses, the patients with advanced SM did not seem to 
score worse on the different questionnaires than patients with MIS or ISM. 
This might be resultant of the fact that patients with advanced SM usually 
have less mast cell mediator-related symptoms.101 Furthermore, only a few 
study patients had osteoporosis, which can cause chronic pain. The absence 
of chronic pain due to osteoporosis therefore might have influenced the SF-36 
scores in a positive sense. A last possible limitation of our study is the use of 
self-report questionnaires. This could lead to both under- as overestimation, 
depending on the coping style of the included patients. 
Strikingly, patients with mastocytosis have a similar perception of their gen-
eral health to patients with cancer, while many physicians probably perceive 
mastocytosis as a benign and mild disease. The fact that 18% of the studied 
patients were not able to work due to their mastocytosis-related health issues 
stresses the debilitating nature of this disease in everyday life. Other studies 
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that investigated the quality of life of patients with mastocytosis reported that 
both fatigue as well as the unpredictability of symptoms such as anaphylaxis, 
diarrhea and flushing have a large influence on their quality of life.97,102 Our 
results indeed showed positive correlations between fatigue, the total SCL-
90 and the mental and physical component of the SF-36. Furthermore, the 
presence of diarrhea was significantly correlated to the total SCL-90 score. 
Correlations with serum tryptase levels, anaphylaxis and urticaria pigmento-
sa did not prove significant.
It appears logical that experiencing these debilitating symptoms on a daily 
basis has a negative influence on one’s perception of overall health and can 
result in a depressed mood. Accordingly, other studies found a high prev-
alence of clinically significant fatigue among patients with mastocytosis, 
ranging from 43.4% to 62.4%.52,63,103 Several phenomena could contribute 
to the increased perception of fatigue in patients with mastocytosis. First-
ly, depressive symptoms often coincide with a feeling of fatigue.104 Second-
ly, fatigue in the presence of chronic disease could also be explained in the 
context of the sickness behavior response. This is an automated response, 
triggered by innate immunity activation, to increase the survival of an an-
imal by decreasing their activity.105 However, as mastocytosis patients con-
tinuously have high levels of various mast cell mediators, this might exert 
direct effects on the brain. Recent research indeed showed an impaired 
tryptophan metabolism in patients with mastocytosis.92 A small cohort study 
also showed a high prevalence of atypical white matter lesions in patients 
with mastocytosis (49%) and an increased perfusion of the putamen region 
compared with healthy controls.99 The fact that treatment with the tyrosine 
kinase inhibitor masitinib has a positive effect on psychological symptoms 
suggests that depression may indeed be an endogenous manifestation of 
mastocytosis, rather than a sole secondary consequence of physical illness.66 
However, this study was not designed to identify biological pathophysiologi-
cal processes that cause psychological symptoms in mastocytosis. For future 
CHAPTER 2
50
studies, it would be interesting to combine all aspects mentioned above: neu-
robiological processes, the patient’s own perspective, and the evaluation by 
an expert mental health professional.
Conclusion
Patients with mastocytosis score higher on psychological symptoms when 
compared to healthy controls, but lower than patients with chronic pain or 
cancer. More specifically, patients with mastocytosis significantly more often 
have depressive symptoms, sleeping problems, somatic complaints and in-
adequacy of acting and thinking, compared to healthy controls. Strikingly, 
patients with mastocytosis score similar to cancer patients on the SF-36 sub-
scale of general health perception. These findings stress the importance of 
correct treatment of physical mastocytosis-related symptoms, as well as ade-
quate psychological counselling for patients with mastocytosis. 
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Supplementary	Material	belonging	to:	
Psychological	functioning	and	quality	of	life	in	patients	with	mastocytosis:	a	cross-sectional	study.	
	
Table	1.	Comparison	of	mean	SCL-90	subscale	values	for	the	study	cohort,	a	healthy	
Dutch	norm	group	and	a	norm	group	of	patients	with	chronic	pain.	
	 Study	cohort	
(N=49†)	
Healthy	Dutch	
population	
(N=2368)	
Patients	with	
chronic	pain	
(N=2458)	
Anxiety	
Mean	(SD)	
13.98	(4.86)	
	
12.76	(4.41)	 15.36	(6.29)	
Agoraphobia		
Mean	(SD)	
8.34	(2.94)	 7.86	(2.34)	 9.06	(3.95)	
Depression	
Mean	(SD)	
24.51	(9.66)	 21.58	(7.56)*	 28.43	(11.36)*	
Somatization	
Mean	(SD)	
21.97	(7.86)	 16.68	(5.34)*	 24.88	(7.93)*	
Inadequacy	of	
thinking	and	acting	
Mean	(SD)	
15.10	(5.20)	 12.63	(4.25)*	 17.86	(6.40)*	
Interpersonal	
sensitivity	
Mean	(SD)	
23.48	(7.18)	 24.05	(7.64)	 25.15	(9.13)	
Hostility	
Mean	(SD)	
7.34	(2.09)	 7.22	(2.10)	 8.15	(3.11)*	
Sleeping	problems	
Mean	(SD)	
6.07	(3.27)	 4.46	(2.20)*	 7.42	(3.67)*	
Total	SCL-90	
Mean	(SD)	
131.74	(36.95)	 118,28	(32.38)*	 148.57	(45.51)*	
SCL-90:	90-item	Symptom	Checklist	
†	One	participant	was	excluded	because	of	too	many	missing	values	
*p	<0.05	for	comparison	of	the	subscale	value	of	the	study	population	versus	the	other	
norm	groups	(t-test)	
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Table	2.	Comparison	of	mean	SF-36	subscale	values	for	the	study	cohort,	a	healthy	Dutch	
norm	group	and	a	norm	group	of	patients	with	cancer.	
	 Study	cohort†		 Dutch	population	
	
Patients	with	cancer	
	
Bodily	pain	
n	
Mean	(SD)	
	
46	
63.78	(26.46)	
	
1729	
75.1	(24.95)*	
	
481	
73.0	(21.93)*	
Physical	functioning	
n	
Mean	(SD)	
	
46	
77.91	(23.22)	
	
1718	
83.9	(20.72)	
	
478	
70.8	(21.86)	
Physical	role	functioning	
n	
Mean	(SD)	
	
46	
55.43	(42.79)	
	
1693	
77.0	(37.03)*	
	
473	
41.4	(34.8)*	
Emotional	role	
functioning	
n	
Mean	(SD)	
	
	
46	
76.09	(38.27)	
	
	
1686	
82.2	(36.95)	
	
	
474	
60.0	(32.66)*	
Vitality	
n	
Mean	(SD)	
	
46	
57.03	(18.72)	
	
1715	
68.2	(20.71)*	
	
479	
61.6	(19.7)	
Mental	health	
n	
Mean	(SD)	
	
46	
78.74	(17.18)	
	
1714	
76.5	(16.56)	
	
479	
68.7	(17.51)*	
Social	role	functioning	
n	
Mean	(SD)	
	
46	
75.27	(26.55)	
	
1729	
84.2	(20.79)*	
	
481	
76.3	(21.93)	
General	health	
perception	
n	
Mean	(SD)	
	
	
46	
55.54	(21.61)	
	
	
1705	
71.4	(20.65)*	
	
	
479	
57.1	(19.70)	
SF-36;	SD:	standard	deviation.	
†	Four	participants	were	excluded	because	of	too	many	missing	values	
*p<0.05	for	comparison	of	the	subscale	value	of	the	study	population	versus	the	other	norm	
groups	(t-test)	
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Figure	S1.	Graphical	illustration	of	the	association	between	serum	tryptase	and	A)	the	total	SCL-90	scale	
(p	0.396),	B)	the	mental	component	of	the	SF-36	(p	0.894)	and	C)	the	physical	component	of	the	SF-36	(p	
0.052).		
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CHAPTER 3
3.1 Systemic mastocytosis with normal serum tryptase: rule 
or exception? 
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CHAPTER 3
Systemic mastocytosis (SM) is a rare disease which is characterized by the 
accumulation of mast cells in >1 extra-cutaneous organ, most often the bone 
marrow.33 In the majority of patients, the activating D816V mutation in KIT 
induces increased proliferation and survival in the neoplastic mast cells. The 
WHO has formulated criteria for the diagnosis of SM: Most criteria can usu-
ally only be obtained by bone marrow (BM) aspiration and biopsy.33 Due to 
the heterogeneous clinical picture of SM, it can be challenging to determine 
when BM examination is indicated. Serum tryptase is often used as a screen-
ing tool for SM.106 However, it is unclear at what value SM can be ruled out. 
The general international cut-off value is 11.4 ng/mL, whereas the WHO has 
established a level of > 20 ng/mL as minor criterion for mastocytosis. Fur-
thermore, an ECNM consensus paper included a tryptase level of 15 ng/mL in 
their diagnostic algorithm.90 
We investigated whether a serum tryptase level <11.4 ng/mL sufficiently rules 
out SM in adults by retrospectively reviewing the files of all adults who vis-
ited the mastocytosis centre in the Erasmus MC from January 2009 to April 
2019. Patients who fulfilled the WHO criteria for SM were included. All diag-
nostic procedures were performed according to the international consensus. 
Serum tryptase was analysed by FEIA technology on the Phadia250 system 
(Thermo Fisher Scientific, Uppsala, Sweden). Patients were divided into three 
categories according to 
tryptase levels: < 11.4 
ng/mL; 11.5 – 19.9 ng/
mL; and > 20 ng/mL.
Of the 238 patients who 
were evaluated, 198 pa-
tients had SM (figure 
1). Thirty-six patients 
had probable SM but 
declined BM investiga-
tion. Four patients had 
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Of	the	238	patients	who	were	evaluated,	198	patients	had	SM	(figure	1).	Thirty-six	patients	had	
probable	SM	but	declined	BM	
investigation.	Four	patients	had	
CM,	among	whom	the	highest	
baseline	tryptase	level	was	12.7	
ng/mL.	Three	patients	had	
onset	of	MPCM	in	infancy	and	
one	had	a	solitary	skin	lesion	
compatible	with	the	now	
outdated	diagnosis	
teleangiectasia	macularis	
eruptiva	perstans.	
Table	1	summarises	the	
characteristics	of	the	198	
patients	with	SM.	The	median	
follow-up	from	the	onset	of	
symptoms	was	16	years	(IQR	15,	
range	1-58	years).	The	majority	
(46.4%)	presented	with	MPCM.	
Anaphylaxis	was	the	second	
most	prevalent	reason	for	further	investigation	(23.7%)	and	7.2%	presented	with	osteoporosis.	Twenty	
patients	(10.1%)	had	a	tryptase	level		<11.4	ng/ml	at	diagnosis.	Fifteen	of	them	(75%)	presented	with	
MPCM,	one	patient	presented	with	anaphylaxis,	one	with	fatigue,	one	with	hypereosinophilia,	one	with	
	
Figure	1:	Flowchart	of	inclusion	process.		
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CM, among whom the highest baseline tryptase level was 12.7 ng/mL. Three 
patients had onset of MPCM in infancy and one had a solitary skin lesion 
compatible with the now outdated diagnosis teleangiectasia macularis erup-
tiva perstans.
Table 1 summarises the characteristics of the 198 patients with SM. The me-
dian follow-up from the onset of symptoms was 16 years (IQR 15, range 1-58 
years). The majority (46.4%) presented with MPCM. Anaphylaxis was the sec-
ond most prevalent reason for further investigation (23.7%) and 7.2% pre-
sented with osteoporosis. Twenty patients (10.1%) had a tryptase level  <11.4 
ng/ml at diagnosis. Fifteen of them (75%) presented with MPCM, one patient 
presented with anaphylaxis, one with fatigue, one with hypereosinophilia, 
one with angioedema, and one with flushing. In the patients without MPCM, 
BM investigation was performed because D816V mutated cells were demon-
strated in peripheral blood (n=2) or because of very high clinical suspicion of 
SM (n=3). All patients with advanced forms of SM had a tryptase level  >11.4 
ng/mL. There was a trend towards more skin involvement and less anaphylax-
is in the group with a serum tryptase < 11.4 ng/mL, but statistical significance 
was not reached. In eight patients (33.3%) with a tryptase level <11.4 ng/mL 
at diagnosis, a tryptase level >11.4 ng/mL was measured some time during 
follow-up. Of the 142 patients with a tryptase level >20 ng/mL at diagnosis, 
seven had a tryptase level <11.4 ng/mL somewhere during follow-up without 
mast cell reductive pharmacotherapy. Thus, tryptase levels can significantly 
fluctuate over time.  
Here, we show that 10.1% of patients with SM have a baseline tryptase level 
<11.4 ng/mL. There were no significant differences in clinical characteristics 
between the three categories of serum basal tryptase levels, but this could be 
due to the small group numbers. Few studies have yet investigated the diag-
nostic accuracy of serum tryptase measurement. Two papers that described 
the prevalence of SM among adults with MPCM found that 39% and 24.2% 
of patients with SM had a serum tryptase level <20 ng/mL.35,37 This is very 
comparable to our results. In another cohort of ISM patients without skin 
involvement, the lowest tryptase level found was 16.7 ng/mL.15 This might 
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represent a diagnostic bias, if patients with a tryptase level < 11.4 ng/mL were 
excluded of further screening.  In recent years, peripheral blood D816V PCR 
was developed as an additional means to  sensitively screen for mastocytosis 
and it is rapidly finding its way into daily practice.43 Studies investigating the 
sensitivity of this PCR confirm that a normal tryptase level does not rule out 
SM in individuals with adult-onset MPCM or Hymenoptera venom-related an-
aphylaxis.107,108 
In conclusion, 28.3% of adults with SM had a serum tryptase level below 20 
ng/mL at diagnosis. It can be questioned whether the current WHO minor 
criterion of a tryptase level >20 ng/mL should be adjusted. We advocate com-
plete BM examination in every patient with a tryptase level >11.4 ng/mL. Fur-
ther investigation should also be considered in patients with a tryptase level 
<11.4 ng/mL with clinical symptoms that are suggestive of mastocytosis, es-
pecially adult-onset MPCM or Hymenoptera venom-related anaphylaxis.
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Table	1.	Patient	characteristics	according	to	serum	tryptase	levels	at	diagnosis.	
	 Tryptase	<	11.4	
ng/mL	
N=20	
Tryptase		11.5	–	
19.9	ng/mL	
N=36	
Tryptase	>	20	
ng/mL	
N=142	
p	
Age	at	diagnosis	in	years,	
median	(IQR)	
44	(17)	 50	(19)	 51	(15)	 0.067	
Male,	n	(%)	 6	(30)	 12	(33.3)	 64	(45)	 0.244	
Years	to	diagnosis,	median	
(IQR)	
10	(9)	 4.5	(10.5)	 4	(11)	 0.357	
BMI,	median	(IQR)	 23.8	(5.5)	 27.2	(6.3)	 28.4	(7.0)	 0.219	
Diagnostic	results	positive,	n	
(%)*	
- BM	biopsy	
- BM	aspirate	
- Flowcytometry†	
- D816V	KIT	detectable	
	
	
16/17	(94.1)	
16/19	(84.2)	
17/18	(94.4)	
14/17	(82.4)	
	
	
19/21	(90.5)	
30/32	(93.8)	
24/28	(85.7)	
22/27	(81.5)	
	
	
102/111	(91.9)	
126/134	(94.0)	
101/104	(97.1)	
79/92	(85.9)	
	
Not	
calculated	
Mastocytosis	subtype,	n(%)	
- ISM	
- SSM	
- SM-AHN	
- ASM	
- MCL	
	
20	(100)	
0	
0	
0	
0	
	
32	(88.8)	
0	
3	(8.3)	
1	(2.8)	
0	
	
118	(83.1)	
5	(3.5)	
9	(6.4)	
7	(4.9)	
2	(1.4)	
Not	
calculated	
Skin	involvement,	n	(%)	 16	(80)	 24	(66.7)	 96	(68.1)	 0.488	
Anaphylaxis,	n	(%)	 4	(20)	 17	(47.2)	 51	(35.9)	 0.125	
Flushing,	n	(%)	 13	(65)	 18	(50)	 63	(44.4)	 0.147	
Dyspepsia	,	n	(%)	 8	(40)	 11	(30.6)	 57	(40.1)	 0.707	
Diarrhoea,	n	(%)	 9	(45)	 13	(36.1)	 51	(36)	 0.733	
Fatigue,	n	(%)	 11	(55)	 18	(50)	 75	(45.1)	 0.746	
Atopy,	n	(%)	 3	(15)	 2	(5.6)	 10	(7)	 0.720	
Hepatosplenomegaly,	n	(%)¶	 2	(10)	 2	(5.6)	 19	(13.4)	 0.396	
Osteoporosis,	n	(%)	 3/20	(15.0)	 5	(13.9)	 36/134	(26.9)	 0.189	
Bone	marrow	density	femur,	
median	(IQR)	
-0.55	(1.0)	 -0.50	(1.8)	 -0.60	(1.30)	 0.904	
ASM	=	aggressive	systemic	mastocytosis,	BM=bone	marrow,	CM=cutaneous	mastocytosis,		ISM=	indolent	
systemic	mastocytosis,	IQR=interquartile	range,	MCL=mast	cell	leukemia,	SM-AHN=systemic	mastocytosis	
with	associated	haematological	neoplasm,	SSM=smouldering	systemic	mastocytosis.	
*Bone	marrow	investigation	was	not	always	completely	performed,	as	patients	were	often	referred	from	
other	clinics	after	the	diagnosis	of	mastocytosis	was	made.	
†Flowcytometry	is	considered	positive	when	CD2	and/or	CD25	expression	was	proven	on	mast	cells.	
¶As	determined	by	ultrasonography	at	diagnosis.	
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3.2 The basophil activation test is not a useful screening tool 
for Hymenoptera venom-related anaphylaxis in patients with 
systemic mastocytosis.
M.J.A. Rietveld, M.W.J. Schreurs, R. Gerth van Wijk, P.L.A. van Daele, M.A.W. 
Hermans
International Archives of Allergy and Immunology 2016 Apr;169:125-129
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Abstract
Background: Systemic mastocytosis (SM) patients are at high risk of anaphy-
laxis, with Hymenoptera as main culprit. A screening instrument to identify 
which patients are sensitized to Hymenoptera, before they experience an-
aphylaxis, would therefore be of great value. Basophil Activation Test (BAT) 
is proposed as a possible tool for diagnosing Hymenoptera venom-related 
allergy (HVA), especially in patients in whom conventional allergy tests give 
contradictory results. 
Methods: We included outpatients with SM, according to the WHO criteria, in 
a period of September 2011 to January 2012. Next to obtaining various clini-
cal data including intradermal test results, sIgE measurement and BAT were 
performed.
Results: We included 29 patients, of whom 9 had a history of HVA and 4 had 
experienced anaphylaxis due to other triggers. 16 patients had no history of 
anaphylaxis. sIgE was detected in 6 patients with HVA and in 2 patients with 
anaphylaxis due to other triggers. BAT was positive in only 1 patient, in whom 
the skin test and sIgE were also positive. Compared with patients with skin 
lesions, those without skin lesions had significantly more anaphylaxis and 
sIgE to Hymenoptera. During three year follow-up, no-one experienced new 
anaphylactic episodes.
Conclusion: BAT is not a reliable tool for randomly screening SM patients for 
HVA.
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Introduction 
Systemic mastocytosis (SM) is a rare disease which is characterized by pro-
liferation of aberrant mast cells in which at least one extracutaneous organ 
is affected. 109 Since mast cells are the culprit cells of type I hypersensitivity 
reactions, SM patients are at a high risk of anaphylaxis with a cumulative inci-
dence ranging between 20 and 49%. 47,48,110 Another study showed that 12% of 
patients of a cohort had life-threatening anaphylaxis, sometimes with serious 
cerebral hypoxic damage.51 Patients with skin lesions have a lower lifetime 
risk of anaphylaxis than patients without skin lesions.77 Many triggers can 
cause anaphylactic reactions, but in SM patients most are Hymenoptera-ven-
om related .51 This can obviously lead to life threatening situations. There-
fore, it would be of great value to determine those patients that are sensitized 
to Hymenoptera venom before they experience anaphylaxis, and maybe even 
preemptively treat them with immunotherapy. Conventional tests including 
intradermal tests and measurement of specific IgE (sIgE) in serum are feasi-
ble to confirm sensitization after a patient has experienced an anaphylactic 
reaction, but are not currently deemed useful for screening purposes. In par-
ticular, the presence of sIgE does not always predict  Hymenoptera-related 
anaphylaxis (HVA). The basophil activation test (BAT) has been proposed as a 
useful adjunct in the diagnosis of allergic disease, especially in patients with 
negative or contradictory conventional tests. 111-114 In BAT, basophils are used 
as an in vitro model for mast cells, despite their slightly different character-
istics regarding appearance and function. Both however contain granules of 
preformed molecules that can cause anaphylactic reaction after degranula-
tion. Degranulation occurs after a wide range of stimuli, for instance acti-
vation by IgE, complement mediators or bacterial-derived peptides.81 Using 
BAT, both IgE-mediated as well as IgE-independent type-1-hypersensitivity 
can be measured in vitro. 115-117. In previous studies, BAT has varying diagnos-
tic characteristics when compared with intradermal tests and sIgE measure-
ment in populations with, as well as without, mastocytosis. 118,119 
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Materials and methods
The objective of this study was to determine whether BAT is also applicable 
for screening SM patients for Hymenoptera venom sensitization, and there-
by, their risk for anaphylaxis due to a wasp sting. We used sIgE as a control 
measurement to determine who was sensitized to Hymenoptera venom.
Subjects
In the period of September 2011 to January 2012, we prospectively included 
patients who visited the outpatient clinic for routine visits and who fulfilled 
the WHO criteria for systemic mastocytosis.15 We collected both demographic 
and disease related data including personal characteristics, subtype of sys-
temic mastocytosis, and a detailed history regarding anaphylaxis. All patients 
gave informed consent. We retrospectively checked all patient files until Sep-
tember 2015 (3 years) for new episodes of anaphylaxis.
Basophil Activation Test (BAT)
Venom-activated basophils were identified by flow cytometry using the Flow2 
CAST system (BÜHLMANN Laboratories AG, Schönenbuch, Switzerland), ac-
cording to the manufacturer’s instructions. Briefly, 50 µL  EDTA anticoagulat-
ed whole blood of the patient was incubated for 25 minutes at 37°C with 50 
µL venom extract diluted to 100 ng/mL, in the presence of 100 µL  stimulation 
buffer containing calcium and IL-3. We used Hymenoptera venom included 
in the Flow2 CAST kit. Subsequently, 20 µL fluorochrome-labeled monoclonal 
anti-CD63 antibodies and anti-CCR3 antibodies (staining reagent) was add-
ed (Bühlmann Laboratories, Schönenbuch, Switzerland). After washing the 
samples, flow cytometry was performed using a FACSCalibur (BD BioScience, 
New Jersey, USA) to detect degranulated CCR3 positive basophils based on 
the amount of CD63 expression. We used stimulation buffer as negative con-
trol and the positive control consisted of anti-FcεRI antibodies.(all Bühlmann 
Laboratories, Schönenbuch, Switzerland). A <15% increase in CD63 positive 
basophils, compared with the negative control was considered negative. A 
>15% increase in CD63 positive basophils was considered a positive result. 
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Results were only considered suitable for analysis when of the negative and 
the the positive controls gave the expected results. Figure 1a shows a flow cy-
tometry plot of patient-derived leukocytes indicating CCR3 positive basophils 
(selected), either <15% degranulated (1b) or >15% degranulated (1c), based 
on CD63 expression.
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Specific	IgE	measurement	
Specific	IgE	(sIgE)	antibodies	against	bee	venom	(i1)	and	wasp	venom	(i3)	were	determined	using	the	
Phadia	250	system	(Thermo	Fisher	Scientific/Phadia	B.V.	,	Freiburg,	Germany).	Values	of	sIgE	below	0.35	
kU/L	were	considered	negative.	All	analyses	were	performed	according	to	manufacturer’s	instructions.	
	
Statistical	analysis	
SPSS	21	(IBM	SPSS	Inc,	IL,	USA)	was	used	for	all	statistical	analyses.	Values	are	reported	as	median	with	
range,	or	median	with	standard	deviation.	We	used	chi-square	and	the	t-test	to	compare	different	
subgroups.	However,	because	of	the	small	population,	we	only	performed	statistical	analysis	on	relevant	
characteristics.		
	
Results	
Figure	1.	Flow	cytometry	plots	of	a	negative	BAT	(A)	and	a	positive	BAT	(B),	according	to	the	
surface	CD63	expression	on	basophils.	
A	 B	
Spec fic IgE measu ement
Specific IgE (sIgE) antibodies against bee venom (i1) and wasp venom (i3) 
were determined using the Phadia 250 system (Thermo Fisher Scientific/
Phadia B.V. , Freiburg, Germany). Values of sIgE below 0.35 kU/L were con-
sidered negative. All analyses were performed according to manufacturer’s 
instruction .
Statistical analysis
SPSS 21 (IBM SPSS Inc, IL, USA) was used for all statistical analyses. Values 
are reported as median with range, or median with standard deviation. We 
used chi-square and the t-test to compare different subgroups. However, be-
cause of the small population, we only performed statistical analysis on rele-
vant characteristics. 
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Results
We included 29 patients (Table 1). The median age was 48 years (range 25-72) 
and 17 patients were female (59%). None of the patients used systemic corti-
costeroids at the time of our study. Patients with a history of anaphylaxis had 
a lower median serum tryptase level (p 0.438) than patients without anaphy-
laxis, not reaching statistical significance. Of the 13 patients who had experi-
enced at least one anaphylactic reaction, 9 patients reported a wasp sting as 
the trigger. 3 patients had food-related anaphylaxis, after ingestion of prawn, 
hazelnut or peanut respectively. In 1 patient, the trigger for anaphylaxis was 
unidentified. 
Appropriate skin tests were performed in all patients with reported anaphy-
laxis after a wasp sting. In 2 of these 9 patients, skin tests were negative. These 
patients also had undetectable sIgE for either wasp or bee venom.
Of all 9 patients who reported Hymenoptera-related anaphylaxis, 5 had de-
tectable sIgE levels for Hymenoptera venom. One of these patients had de-
tectable sIgE for bee venom, without a clinical history of bee-venom related 
anaphylaxis. Skin testing in this patient was positive for wasp, but negative 
for bee venom, thus the sIgE for bee venom probably represents irrelevant 
cross-reactivity with sIgE for wasp venom. Interestingly, 1 patient who re-
ported anaphylaxis due to medication or prawn, also had detectable sIgE for 
Hymenoptera venom. 
All BATs were considered suitable for analysis. Of all 29 patients, the BAT was 
positive in only one patient. This patient had ISMs-, and had experienced 
wasp-related anaphylaxis 2 years before inclusion in our study. Of note, she 
also had the highest level of sIgE to Hymenoptera venom of our population 
(4.61 kU/l) and positive intradermal test for wasp venom. sIgE for bee venom 
was not detectable in this patient. In the 3 year follow-up period, 1 patient 
was lost to follow-up. From the other 28 patients, no-one reported another 
wasp sting, nor did they experience new anaphylaxis. 
Lastly, data were viewed in a different perspective for additional information. 
Irrespective of their clinical history of anaphylaxis, patients with ISM were 
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further divided in patients with or without skin lesions (ISMs+ vs. ISMs-, re-
spectively). Anaphylaxis was significantly more frequent in ISMs- vs. ISMs+ 
patients (6/7 vs. 7/20, p 0.021). In accordance with this, sIgE to Hymenoptera 
venom also was significantly more often detectable in ISMs- vs. ISMs+ pa-
tients (5/7 vs. 2/20, p 0.001).
	
	
Table	1.	Patient	characteristics.	 	 	 	
	 No	history	of	
anaphylaxis	(n=16)	
History	of	anaphylaxis	not	
Hymenoptera-related	(n=4)	
Hymenoptera-related	
anaphylaxis	(n=9)	
Age	at	diagnosis	in	years*	 44	(25	–	56)	 50	(38	–	63)	 52.5	(36	–	72)	
Female	gender	(n)	 9/16	 4/4	 4/9	
Time	anaphylaxis	to	BAT	in	years*	 N/A	 2	(0.5	–	6)	 3	(2	–	10)	
Wasp	sting	after	diagnosis	 0/14	 0/4	 0/8	
Wasp	immunotherapy	before	BAT	 N/A	 0/4	 1/9	
Subtype	systemic	mastocytosis	(n)	†	
ISM	 14/16	 4/4	 9/9	
		ISMs+	 12/14	 2/2	 5/9	
		ISMs-	 2/14	 2/2	 4/9	
ASM	 2/2	 0/0	 0/0	
WHO	criteria	13‡	 	 	 	
Skin	lesions	(n)	 14/16	 2/4	 5/9	
Bone	marrow	histology	positive	(n)	 5/6¶	 1/1	 3/3	
Bone	marrow	morphology	positive	(n)	 10/10	 2/2	 8/8	
Tryptase	at	diagnosis	in	ng/L*	 38,7	(9,8	–	324,0)	 31	(22.6	–	44.1)	 23.7	(15.9	–	160)	
D816V	mutation	detected	(n)	 6/8	 2/3	 6/6	
CD2	or	CD25	detected	(n)	 8/8	 2/2	 6/6	
Conventional	allergic	tests	 	 	 	
Intradermal	tests	for	wasp	positive	(n)	 N/A	 0/4	 7/9	
Specific	IgE	to	Hymenoptera	venom	(n)	 0/16	 1/4	 6/9	
Specific	IgE	levels	in	kU/l*	 -	 0.29	 0.60	(0.22-4.61)	
Specific	IgE	to	bee	venom	(n)	 0/16	 0/16	 1/9	
*	Values	are	given	as	median	(range).	
†	ISM:	indolent	systemic	mastocytosis.	ISMs+:	ISM	with	skin	lesions.	ISMs-:	ISM	without	skin	lesions.	ASM:	aggressive	systemic	
mastocytosis.	N/A:	not	applicable	
‡	Some	data	are	missing	because	initial	workup	for	SM	was	performed	in	other	medical	centres.	
¶	1	patient	had	negative	bone	marrow	biopsy	for	SM,	but	fulfilled	all	three	minor	WHO	criteria	for	SM.	
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Discussion
We studied the feasibility of BAT as a screening tool for Hymenoptera sen-
sitization in patients with SM. Of all patients, only 1 had a positive BAT and 
this patient also tested positive for the conventional allergy tests (sIgE and 
skin test). However, 8 other patients with a clinical history of HVA, of whom 
5 also had demonstrable sIgE to Hymenoptera and 6 had positive intradermal 
tests, tested negative with BAT. These tests thus did not correlate well in our 
population, nor did BAT add useful information to the standard combination 
of clinical history, sIgE and skin tests. In addition to new data about the BAT, 
our studie provides additional evidence on the difference between ISMs+ and 
ISMs- patients. It is becoming increasingly clear in recent research that these 
two subtypes of ISM have entirely different clinical phenotypes. [6 + unpub-
lished data] Our results confirm that anaphylaxis is more common in ISMs- 
patients vs. ISMs+. 
The role and usefulness of BAT remains a topic of discussion in the current 
literature with earlier studies reporting conflicting evidence. Bidad et al. stud-
ied the role of BAT in diagnosing and monitoring of HVA in SM patients. 119 
They found a sensitivity of 87% and a specificity of 100% in their population. 
However, all patients with HVA also had a positive intradermal test, render-
ing the addition of BAT redundant. Moreover, sIgE was significantly higher in 
this group compared with our population. We would therefore postulate that 
BAT does not add useful information to the conventional diagnostic tests for 
HVA. This hypothesis is supported by the results of Bonadonna et al. 120. They 
investigated the role of BAT in SM patients with or without a reported reac-
tion to Hymenoptera stings but all without demonstrable sIgE. In this popu-
lation, BAT results were all negative and performing a BAT on top of sIgE and 
intradermal tests did not contribute to the diagnosis of HVA. Furthermore, 
Gonzalez et al. investigated BAT in patients with HVA and SM compared with 
patients with HVA but no SM. 121 Specific IgE was detected in 15 out of 22 SM 
patients, of whom 9 had a positive BAT result. Of the 7 SM patients without 
sIgE, 3 had a positive BAT. By using extracts of different wasp and bee spe-
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cies, they even found the culprit insect in two of these sIgE-negative patients. 
Another study by Eberlein-König et al. also concludes that they were able to 
identify the culprit insect by BAT in a few complicated cases in which intra-
dermal tests and sIgE measurement could not lead to a diagnosis. 112
In addition to the different populations studied, an explanation for the strik-
ingly different outcomes in all these studies can be found in technical dif-
ferences. The BAT has not been standardized completely yet, and different 
laboratories use different techniques. For instance, some laboratories use 
purified cells in their analyses which can increase the sensitivity of BAT. 122 
Cut off values and incubation substances also vary. Moreover, when working 
with basophils, one has to realize that basophils differ from (neoplastic) mast 
cells in certain ways, mainly non-IgE-mediated activation.123 The main limita-
tion of this specific study is the small number of patients investigated and the 
heterogeneity within our population. However, we chose this method on pur-
pose to resemble daily practice. Moreover, the main aim was to investigate 
the role of BAT as a screening method, rather than to confirm the presence of 
an allergy that had already been confirmed by either clinical anaphylaxis or 
conventional tests. Therefore, we also included patients without a history of 
anaphylaxis which leads to a lower a priori incidence of HVA and, thereby, a 
lower sensitivity of BAT in this group.
Lastly, two patients with HVA had received immunotherapy several years be-
fore this study, which can obviously influence the results of BAT, since this is 
expected to become negative after immunotherapy. One of these patients, how-
ever, experienced an episode of wasp-related anaphylaxis after immunothera-
py and therefore the effect of immunotherapy apparently was negligible.
Conclusions
Considering our results in relation to previous studies, we prudently con-
clude that BAT is not a useful test to screen random SM patients for their risk 
of HVA. Furthermore, by combining the patient’s clinical history, intrader-
mal testing and sIgE measurement, a diagnosis of HVA can be confirmed or 
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declined in most patients. BAT may be of additional use in very complicated 
patients with conflicting results of conventional tests, but we could not con-
firm this in our study. More systematic research in a carefully selected popu-
lation might provide more insight in the role of BAT in this niche. 
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3.3 Abdominal ultrasonography has limited value in the care 
for patients with indolent systemic mastocytosis. 
C.L. de Mol, M.A.W. Hermans, R. Gerth van Wijk, P.M. van Hagen, P.L.A. van 
Daele
Hematology 2017 Oct;22(9):544-547
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Abstract
Objectives: Systemic mastocytosis (SM) is a myeloproliferative disease charac-
terized by the accumulation of aberrant mast cells. Since advanced subtypes 
of SM can lead to organ dysfunction and shortened survival, timely recog-
nition of progressive disease is important for the adequate treatment of SM 
patients. 
Methods: Here, we report the results of our cohort study on the value of rou-
tine abdominal ultrasonography for the detection of progression of indolent 
systemic mastocytosis (ISM).
Results: We included 95 patients with SM, of whom 9 developed new hepat-
osplenomegaly during follow-up. In this group, the median serum tryptase 
level increased by 11.60 mg/L, compared with a decrease of -0.20 mg/L in the 
79 patients with unchanged ultrasonography results (p=0.016). A change in 
liver and/or spleen size never led to a change in clinical classification, nor 
management. 
Discussion: Based on the finding that a change in ultrasonography findings did 
not correlate to disease progression in general, it appears that isolated hepa-
tosplenomegaly does not have prognostic implications in patients with ISM. 
Conclusions: Routine abdominal ultrasonography is redundant in the fol-
low-up of patients with SM. A combination of physical examination with se-
rum tryptase levels can be used to screen for hepatosplenomegaly.
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Introduction
Mastocytosis is a rare myeloproliferative disease in which there is uncontrolled 
proliferation of aberrant mast cells.1 The World Health Organisation (WHO) 
distinguishes cutaneous from systemic  mastocytosis. 76 Systemic mastocytosis 
(SM) is further divided into different subtypes, each having their own criteria, 
clinical manifestations, and prognosis.40,124  Indolent systemic mastocytosis 
(ISM) is the most common subtype which has a favourable prognosis, with pa-
tients mainly suffering from mast cell mediator-related symptoms. More re-
cently, it was recognized that the clinical symptoms of ISM patients with skin 
lesions are distinct from the ISM patients without skin lesions (ISMs+ vs. ISMs-, 
respectively).103 In contrast to ISM, advanced subtypes are characterized by or-
gan infiltration by mast cells (smouldering SM and aggressive SM), or a second 
haematological (non-mast cell) neoplasm (SM-AHN). To diagnose smouldering 
SM, 2 or more B-findings have to be present: hepato- or splenomegaly, lym-
phadenopathy, >30% mast cell infiltration of bone marrow, a serum tryptase 
level >200 mg/L, or signs of dysplasia without reaching criteria for myelodys-
plastic syndrome. For aggressive SM, C-findings were formulated: cytopaenia, 
signs of liver cirrhosis, malabsorption, or osteolytical bone lesions. The differ-
ence between smouldering and aggressive SM is the respective absence or pres-
ence of organ dysfunction. These advanced subtypes can shorten survival and 
often warrant cytoreductive treatment. 75,124 Hence, an important goal of outpa-
tient follow-up of SM patients is to screen for progression of the disease or de-
velopment of a second haematological disease. (3) There is some evidence that 
radiological examination of the abdomen can aid in determining the extent of 
systemic involvement of SM. 125 For these reasons, a consensus group of Dutch 
physicians with expertise in mastocytosis previously decided to routinely per-
form abdominal ultrasonography in the follow-up of SM patients. In the Eras-
mus University Medical Centre, it was common practice to perform abdominal 
ultrasonography every 2-3 years to screen for hepatosplenomegaly. However, 
new data show that progression of indolent to advanced SM is rare, and it is 
unclear what would be the best method to screen patients with ISM for progres-
sion. Moreover, in this era where health care costs are an important societal 
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issue, it is important to cut down unnecessary tests. The objective of this study 
was therefore to determine the value of routine abdominal ultrasonography as 
a tool to screen for progression of indolent to more aggressive forms of SM.  
Methods
Patient selection and data collection
We selected all adult patients who visited the Erasmus University Medical 
Centre from January 2009 to February 2016 and who fulfilled the WHO crite-
ria for ISM. 76 Only patients who underwent at least 2 abdominal ultrasonog-
raphy’s, with a minimal interval of 2 years, were included. Patients who had 
SM-AHN or ASM at baseline were excluded. All patients visited the outpatient 
clinic at least once a year.  Bone densitometry was performed every 3 years to 
screen for osteoporosis. We retrospectively collected the findings on abdom-
inal ultrasonography, as well as data on patient baseline characteristics, SM 
subtype and symptoms, tryptase levels and bone densitometry results from 
the electronic patient charts.
Figure 1. Flow chart of the inclusion process. 
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Definitions
Hepatosplenomegaly was defined as either a craniocaudal liver size of >15 
cm., and/or a spleen size of >11 cm. A change in ultrasonography findings 
was defined as a change from a normal size to hepatosplenomegaly on subse-
quent examinations, or vice versa. Cytopenia was defined as either anaemia 
(Hb <10 g/dL), leukopenia (<400 × 106) and/or thrombocytopenia (<1,000 × 
106). Skin involvement was described as all forms of maculopapular cutane-
ous mastocytosis (MPCM).36 
Statistical analysis
We constructed 2 groups, according to their course of ultrasonography re-
sults. The primary endpoint was progression from indolent to smouldering, 
aggressive or SM-AHN, or progression from smouldering to aggressive or SM-
AHN. We used IBM SPSS statistics 21 for all analyses. The Mann-Whitney U 
test was used for the comparison of the tryptase values and unpaired t-tests 
were used for continuous variables.  The chi-square test was used for dichot-
omous variables. 
Results
Study population
Of a total of 154 patients, 95 underwent multiple abdominal ultrasonogra-
phy’s with an interval of >2 years. Seven patients were excluded because they 
fulfilled the WHO criteria for ASM or SM-AHN at baseline. The population we 
analysed thus consisted of 88 patients, of whom 81 had ISM and 7 patients had 
smouldering SM. Ten of these 88 patients had a change in liver and/or spleen 
size over time, 9 of whom newly developed hepatosplenomegaly (10.2% of 
the total population). The liver and spleen size normalised in 1 patient. The 
median follow-up time was 11.20 years.
Group characteristics
We divided the population into two groups, entitled ‘unchanged hepatosple-
nomegaly status’ and ‘new hepatosplenomegaly’. Baseline characteristics and 
issue, it is important to cut down unnecessary tests. The objective of this study 
was therefore to determine the value of routine abdominal ultrasonography as 
a tool to screen for progression of indolent to more aggressive forms of SM.  
Methods
Patient selection and data collection
We selected all adult patients who visited the Erasmus University Medical 
Centre from January 2009 to February 2016 and who fulfilled the WHO crite-
ria for ISM. 76 Only patients who underwent at least 2 abdominal ultrasonog-
raphy’s, with a minimal interval of 2 years, were included. Patients who had 
SM-AHN or ASM at baseline were excluded. All patients visited the outpatient 
clinic at least once a year.  Bone densitometry was performed every 3 years to 
screen for osteoporosis. We retrospectively collected the findings on abdom-
inal ultrasonography, as well as data on patient baseline characteristics, SM 
subtype and symptoms, tryptase levels and bone densitometry results from 
the electronic patient charts.
Figure 1. Flow chart of the inclusion process. 
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follow-up data are summarised in table 1. The patient with normalisation of 
liver/spleen size was included in the ‘unchanged hepatosplenomegaly status’ 
group. The age of the patients did not differ significantly between the two 
groups. Two patients in the ‘unchanged hepatosplenomegaly status’ group 
had cytopenia at baseline. No-one had other B- or C-findings. The develop-
ment of hepatosplenomegaly during follow-up was not associated with a de-
crease in bone density.
Figure 2. Change in serum tryptase levels during follow-up correlat-
ed with the development of new hepatosplenomegaly. 
A) No hepatosplenomegaly; B) Hepatosplenomegaly at baseline; C) 
New hepatosplenomegaly during follow-up. 
*p<0.05 compared with group A. 
Follow-up findings
The median change in serum tryptase level during follow-up was  -0.20 mg/L 
(SD 28.3) for the ‘unchanged hepatosplenomegaly status’ group, versus an 
increase of 11.60 mg/L (SD 26.2) in the ‘new hepatosplenomegaly’ group (fig-
ure 2). When comparing the change in tryptase levels over time, a significant 
difference was found between the patients who newly developed hepatos-
plenomegaly compared with the patients with unchanged ultrasonography 
findings (p=0.016). In the patients who newly developed hepatosplenomega-
ly, there was no statistically significant change in liver enzyme levels (mean 
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increase in ASAT levels of 4 U/L (SD 11.86 U/L), mean increase of ALAT levels 
of 7.5 U/L (SD 22.05 U/L)). 
Of the patients with ‘unchanged hepatosplenomegaly status’, 12 (15.2%) had 
hepatosplenomegaly at baseline which did not change during follow-up. 
These patients did not develop clinical signs of liver cirrhosis during fol-
low-up, nor did they show other signs of progression of mastocytosis. Ac-
cordingly, serum tryptase levels remained relatively stable with a median de-
crease of – 1.15 mg/L (SD 48.0 mg/L) in this subgroup.
One patient in the unchanged group went from ISM s+ to smouldering SM 
over time, based on a serum tryptase level of >200 mg/L and >30% bone mar-
row infiltration by mast cells. This patient had no hepatosplenomegaly. A 
change in liver and/or spleen size alone never led to a change in SM subtype, 
nor in a change in the medical management. One patient showed normal-
isation of his liver- and spleen size. This patient was treated with imatinib 
because of extensive skin lesions. In this patient the KIT D816V mutation was 
detected and his tryptase value increased by 6.0 mg/L during follow-up. 
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hepatosplenomegaly.	A	change	in	liver	and/or	spleen	size	alone	never	led	to	a	change	in	SM	subtype,	
nor	in	a	change	in	the	medical	management.	One	patient	showed	normalisation	of	his	liver-	and	spleen	
size.	This	patient	was	treated	with	imatinib	because	of	extensive	skin	lesions.	In	this	patient	the	KIT	
D816V	mutation	was	detected	and	his	tryptase	value	increased	by	6.0	µg/L	during	follow-up.		
	
Table	1:	Patient	characteristics,	grouped	according	to	ultrasonography	findings.	
	 Unchanged	status	
of	hepato-	
splenomegaly	
(n=79)	
New	hepato-	
splenomegaly	
(n=9)	
p-value	
Age	in	years	(median,	SD)	 58.00	(12.89)	
	
54.00	(9.94)	 NS	
Male	sex	(n,	%)	 35	(44.3%)	
	
3	(33.3%)	 NS	
Follow-up	time	in	years	(median,	SD)	 10.00	(6.76)	
	
12.00	(3.24)	 NS	
Subtype	of	SM:	
- ISM	s-	
- ISM	s+	
- SSM		
	
17	
56	
6	
	
2	
6	
1	
N/A	
Absolute	change	in	serum	tryptase	
levels	in	µg/L	(median,	SD)	
	-0.20	
(28.3)	
11.60	
(26.2)	
0.016	
Change	in	subtype	(n)	 1	 0	 N/A	
Change	in	treatment	(n)	 0	 0	 N/A	
Cytopenia	at	baseline	(n,%)	 2	(2.5%)	 0	(0%)	 NS	
Decrease	in	bone	density	during	
follow-up	(n,%)	
11	(13.9%)	
	
0	(0%)	 NS	
Presence	of	KIT	D816V	mutation	(n,	%)	 36	(45.5%)	 4	(44.4%)		 NS	
Presence	of	lymphadenopathy	(n,%)	 4	(5.1%)	 0	(0%)	 NS	
SD:	standard	deviation;	SM:	systemic	mastocytosis;	ISM	s-:	indolent	systemic	mastocytosis	
without	skin	lesions;	ISM	s+:	indolent	systemic	mastocytosis	with	skin	lesions;	SSM:	
smouldering	systemic	mastocytosis;	SM-AHN:	systemic	mastocytosis	with	associated	
haematological	neoplasm;	ASM:	aggressive	systemic	mastocytosis;	NS:	non-significant,	N/A:	not	
applicable.	
*’New	hepatosplenomegaly’	compared	to	‘unchanged	ultrasonography	results’	(=	first	two	
groups).	
	
	
Discussion
This study shows that routine abdominal ultrasonography has limited value 
in the follow-up of patient  with indolent systemic mas ocytosis: 10.2% de-
veloped new hepatosplenomegaly, but no-one showed progression to a more 
advanced type of SM. The development of new hepatosplenomegaly had no 
clinical consequences in any of them. Until this study, abdominal ultrasonog-
raphy was part of the routine follow-up in the Erasmus University Medical 
Centre to screen for progression of ISM. However, it has become clear that 
progression of ISM is very rare. 40,86 Our results confirm this, as only one pa-
tient (1.1%) progressed from indolent to smouldering SM in a median fol-
low-up time of 11.20 years. Moreover, this patient did not develop hepatosple-
nomegaly. Furthermore, patients who had hepatosplenomegaly at baseline 
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did not develop clinical signs of liver cirrhosis, or progression of mastocy-
tosis in general. Based on these findings, we hypothesise that the finding of 
isolated hepatosplenomegaly, without other B- or C-findings, does not have 
important prognostic implications. Therefore, looking for hepatosplenomeg-
aly is probably not appropriate when screening for progression of disease 
in ISM. Moreover, badly indicated radiologic investigations lead to higher 
health care costs, and a risk of unwanted incidental findings. 126 Interestingly, 
the median serum tryptase level increased significantly in patients who new-
ly developed hepatosplenomegaly, whereas they remained stable in patients 
with unchanged ultrasonography findings. Besides the serum tryptase level, 
there were no other signs of progression of disease in all patients but one who 
progressed from indolent to smouldering SM. More specifically, patients did 
not develop other B- or C-findings. In another study, serum tryptase levels did 
correlate to clinical progression in general, and patients with rising serum 
tryptase levels more often developed hepatosplenomegaly.127 It would be in-
teresting to know whether the hepatosplenomegaly truly is mast cell related, 
however, this would require biopsies of both organs which is a risky proce-
dure and not feasible in this context. Furthermore, MR elastography or fibro-
scan could be of additional value to estimate a risk of liver cirrhosis in the 
future. Unfortunately, we have not performed these investigations routinely 
and cannot provide data on this yet.128
To our knowledge, our study is the first to focus on the value of routine ab-
dominal ultrasonography in the screening for progression of disease in ISM 
patients. However, our results should not be extrapolated to patients with 
advanced subtypes of SM.  Follow-up abdominal ultrasonography can be in-
dicated in advanced SM for other reasons. One limitation of this study is the 
retrospective nature, which could have led to incomplete data. We had to ex-
clude 59 patients because they did not have >2 abdominal ultrasonography’s 
during follow-up. This could have led to a selection bias, although the fact 
that their physician did not order more ultrasonography’s probably implies 
that they estimated the risk of progression as low. In that scenario, our re-
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sults would not have changed with inclusion of these patients. Moreover, the 
retrospective design provides ‘real-life’ data and a long follow-up time. Lastly, 
ultrasonography in general has a notoriously large inter-test variability and 
one can argue whether subtle cases of hepatosplenomegaly were missed by 
using this technique.129
In conclusion, routine abdominal ultrasonography has limited value as a 
screening tool for progression of ISM. It appears that isolated hepatospleno-
megaly has no important prognostic implications in ISM, and changes in liver 
and/or spleen size alone in fact never herald progression of SM. Moreover, 
progression of indolent to advanced SM is very rare. Annual follow-up of se-
rum tryptase levels could be used as a first screening tool for the development 
of hepatosplenomegaly, with additional radiologic studies on indication.
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Drug-related anaphylaxis
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4.1 Management around invasive procedures in mastocytosis. 
M.A.W. Hermans, N.J.T. Arends, R. Gerth van Wijk, P.M. van Hagen, J.C. Klu-
in-Nelemans, J.N.G. Oude Elberink, S.G.M.A. Pasmans, P.L.A. van Daele
Annals of Allergy, Asthma and Immunology 2017 Oct;119(4):304-309
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Abstract
Objective: Mastocytosis is a chronic hematologic disorder that is characterized 
by the accumulation of
aberrant mast cells and typically involves the skin and/or bone marrow. Pa-
tients with mastocytosis are at increased risk of anaphylaxis. Based on theo-
retical assumptions, medical procedures requiring general
anesthesia or radiocontrast media are deemed hazardous for patients with 
mastocytosis. The objective of this article is to provide a comprehensive over-
view of the actual risk of iatrogenic anaphylaxis and provide recommenda-
tions for daily practice.
Data Sources: Various scientific search engines were used (PubMed and Med-
line).
Study Selections: Because of the paucity of high-level studies on this topic, all 
available evidence was
considered, including case reports.
Results: Reliable data on the incidence of iatrogenic anaphylaxis in mastocy-
tosis are lacking. However,
although the incidence as reported in (retrospective) cohort studies is higher 
than in the general population, it is still lower than commonly anticipated, 
with an incidence of 5.4% in 1 study. Adequate premedication and avoidance 
of certain physical stimuli can further decrease this risk by 10-fold. The role 
of drugs as elicitors of anaphylaxis is perhaps overestimated, and physical 
stimuli are at least as important in inducing release of mast cell mediators.
Conclusion: This article provides practical recommendations for the manage-
ment of invasive procedures in patients with mastocytosis based on current 
knowledge of this topic.
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Introduction
Mastocytosis is a chronic myeloproliferative disorder of mast cells. It is a rare 
disease, with an estimated prevalence of 10-13:100,000.38,130 To establish the 
diagnosis of systemic mastocytosis (SM), an accumulation of neoplastic mast 
cells must be detected in the bone marrow, as opposed to cutaneous masto-
cytosis which is confined to the skin. However, recent experience shows that 
adult-onset mastocytosis in the skin is associated with systemic mastocytosis 
in most cases if adequate work-up is performed.37 The WHO has defined di-
agnostic criteria for systemic mastocytosis (SM) and various subtypes, rang-
ing from indolent systemic mastocytosis (ISM) to more advanced subtypes.76 
When mast cells are activated, they release large amounts of granule-stored 
mediators. Consequently, anaphylaxis is a threat for all patients with SM as 
a result of their high mast cell load, with a lifetime prevalence of up to 50% 
for adult patients.131 The most well-known trigger for anaphylaxis in patients 
with SM is Hymenoptera venom, but many cases of anaphylaxis in SM are 
idiopathic or the result of a combination of stimuli.47,132 Conventional allergy 
tests such as measurement of specific IgE and skin tests for the suspected al-
lergens are often negative. There are various non-IgE-mediated mechanisms 
that can cause mast cell degranulation, including physical stimuli (temper-
ature change, exercise, strong odors, pressure and friction),  and emotional 
stress. Another often feared elicitor is medication, with anesthetic agents, 
opiates, and radiocontrast media as the main culprit drugs.57 In the past dec-
ades, several case reports mentioned severe, sometimes fatal, iatrogenic an-
aphylaxis in mastocytosis, reinforcing the now common notion that this is a 
serious risk for patients with SM.133-137 
Based on the aforementioned data and hypotheses, undergoing an invasive 
procedure often causes anxiety for both patients with SM and the involved 
professionals. The insecurity is often aggravated by a lack of experience with 
this rare disease and the diversity of protocols between different hospitals 
regarding the perioperative management of patients with SM. However, anes-
thetic techniques have changed and several potentially hazardous drugs are 
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now obsolete. Furthermore, modern anesthesiologists pay more attention to 
the general perioperative environment such as temperature and stress.57,138 
Therefore, the actual risk of perioperative anaphylaxis might be overestimat-
ed and current protocols could probably be adjusted. In this review, we focus 
on the actual risk of anaphylaxis around invasive procedures in patients with 
mastocytosis and give recommendations for prophylactic measures. 
Incidence of iatrogenic anaphylaxis in mastocytosis
Several population studies on mastocytosis illustrate the rarity of iatrogenic 
anaphylaxis. These data are summarized in table 1.
Anesthesia and surgery
The most complete study on this topic reviewed the medical records of 459 
adult mastocytosis patients, who underwent 676 anesthetic procedures of 
which 66 involved general anesthesia.139 According to the authors (Matito et 
al.), 8/676 (1.2%) procedures were complicated by a mild reaction and 3 (0.4%) 
by anaphylaxis. However, the majority were low-risk procedures, namely lo-
cal anesthesia (76%), epidural anesthesia (11%) or sedation (10%). The risk 
of mast cell (MC) mediator-related symptoms was considerably higher with 
general anesthesia, where 4/66 procedures were complicated by a reaction 
(6%). Anaphylaxis occurred in 2/4 patients, both of whom had not received 
premedication. Information on the exact procedures is not provided. These 
rates are higher than the incidence of hypersensitivity reactions due to an-
esthesia in the general population, which is estimated to be between 1:1250 
and 1:18,600 procedures, dependent on the country of investigation.140 When 
looking at the whole cohort of Matito et al., the patients who developed any 
type of reaction less frequently received premedication than asymptomat-
ic patients: 45% versus 87%, respectively. The incidence of anaphylaxis was 
significantly higher in patients who did not receive any premedication: 5.4% 
versus 0.4%, respectively.139 Other risk factors for anaphylaxis were major 
surgery and a history of anaphylaxis in general, regardless of the trigger of 
anaphylaxis.139 
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Other, smaller, cohort studies report even lower rates of perioperative ana-
phylaxis in SM patients; of a combined total of 457 adult patients, only 1 had 
a history of perioperative anaphylaxis. A reaction to local anesthesia was not 
reported in any of these studies.47,48,103,132 Table 1 summarizes the published 
data from cases. Of course, these numbers can be biased since most of them 
relied on the medical history of patients as recalled by themselves. 
Radiocontrast media
To date, there have been no studies that were specifically designed to identify 
the risk of anaphylaxis due to radiocontrast media in patients with SM. In 
the general population, the incidence of mild immediate reactions is 0.5-3%, 
and the incidence of severe immediate reactions is 0.01-0.04% of all intrave-
nous administrations.141,142 Indirect evidence shows similarly low numbers of 
adverse reactions in patients with SM; in four cohort studies encompassing 
457 adult patients, radiocontrast-related hypersensitivity reactions were re-
ported in 3 patients, of whom only one experienced anaphylaxis.47,48,103,132 Data 
on premedication are incomplete for these patients. Furthermore, a review 
on fatal anaphylaxis due to radiocontrast media described 34 cases of whom 
none were known to have mastocytosis. Autopsy of 8 of these fatalities failed 
to diagnose SM after adequate investigation.58
Pregnancy and delivery
Data from 2 cohort studies on pregnancy and delivery in patients with SM are 
reassuring although the number of patients is small. In the first cohort, labor 
was uneventful in all 23 women. However, details on the administration of 
premedication were not provided.143 The second study describes the course 
of 45 pregnancies.144  Five women experienced MC mediator-related symp-
toms during delivery, consisting of pruritus, erythema or flushing. No-one 
developed anaphylaxis. Premedication was administered prior to 17 deliver-
ies (38%). One case report described a woman with ISM in whom delivery was 
complicated by anaphylactic shock despite pretreatment with dexametha-
sone and diphenhydramine. This patient had previously experienced one ep-
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isode of idiopathic anaphylaxis during another pregnancy.145 For comparison, 
the risk of anaphylaxis during delivery is 2.7:100,000 deliveries in the general 
population. However, these reactions are virtually always due to IgE-mediat-
ed drug allergies.146
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Table	1.	Summary	of	published	data	on	iatrogenic	anaphylaxis	in	adult	patients	with	mastocytosis.	
	 Anaphylaxis	
due	to	
general	
anesthesia	
Mild	
reaction	
due	to	
general	
anesthesia	
Anaphylaxis	
due	to	
radiocontrast	
media	
Mild	reaction	
due	to	
radiocontrast	
media	
Anaphylaxis	
related	to	
delivery	
Other	cause	of	
iatrogenic	MC	
mediator	
related	
symptoms	
González	de	
Olano	et	al.	
20077	
1/163	 0/163	 0/163	 1/163	 N/A	
	
NSAID	(4)	
Bèta	lactam	(2)	
Streptomycin	(1)	
Phenylephrine	
(1)	
Codeine	(1)	
Matito	et	al.	
200715	
2/66	 1/66	 N/A	 N/A	 N/A	 Epidural	(3/76)*	
Sedation	(1/67)	
Local	anesthesia	
(4/515)	
Brockow	et	
al.	
20086	
0/74	 N/A	 2/74	 N/A	 N/A	 Local	anesthesia	
(1)	
NSAID	(1)	
Codeine	(1)	
Amoxicillin	(1)	
Gülen	et	al.	
201317	
0/84	 0/84	 0/84	 0/84	 N/A	 NSAID	(2)	
Hermans	et	
al.	201618	
0/136	 0/136	 1/136	 0/136	 N/A	 NSAID	(2)	
Case	
reports10-
14,24	
3	 N/A	 1	 N/A	 1	 Percutaneous	
coronary	
intervention	(1)	
Worobec	et	
al.	200060	
-	 -	 -	 -	 0/11	 N/A	
Matito	et	al.	
201123	
-	 -	 -	 -	 0/45†	 N/A	
Ciach	et	al.	
201622	
-	 -	 -	 -	 0/23	 N/A	
Totalǂ	 3/523	 1/449	 3/457	 1/383	 0/79	 26/602	
N/A:	not	available;	MC:	mast	cell;	NSAID:	non-steroidal	anti-inflammatory	drug.	
*	1	patient	anaphylaxis,	2	patients	mild	reaction	(flushing,	erythema	or	hives).	
†	5/45	patients	had	mild	MC	mediator	symptoms	(pruritus,	generalized	exanthema,	flushing).	
ǂ	Excluding	case	reports.	
	
	
Theoretical	background	Theo tic l background
Known triggers of mast cell activation
As previously stated, many substances other than IgE can trigger release of 
MC mediators. Interestingly, mast cells in the skin and airways of patients 
with mastocytosis are not more reactive compared with patients with asthma 
or healthy controls.147 Specific drugs that are known to induce histamine re-
lease are codeine, morphine, benzylisoquionolins (e.g. mivacurium, atracu-
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rium) and some antibiotics (e.g. vancomycin, polymyxin B).148 The potential 
of codeine and morphine to induce MC degranulation was proven extensively 
both in vitro as in vivo.59 Most other opiates do not have this effect when tested 
in vitro, revealing a certain class effect.149,150 For muscle relaxants, there also 
appears to be a large variety in their ability to induce release of MC mediators, 
with succinylcholine and cis-atracurium appearing as the most safe drugs in 
this context.151,152 Radiocontrast media could theoretically trigger MC degran-
ulation via multiple mechanisms, for instance the direct effect of their high 
osmolality on the cell membrane, or nonspecific binding of contrast mole-
cules to membrane receptors and components of the complement system.58 
However, in vitro tests did not show degranulation after stimulation of human 
MCs with radiocontrast media.153 Unfortunately, most of these assumptions 
are based on in vitro research, which is notoriously complicated for mast cells 
since they are continually interacting with adjacent cells in vivo.26 
Next to medication, several physical stimuli might induce MC mediator re-
lease during invasive medical procedures, or act as costimulatory factors.47 
Among these are friction, pressure, temperature changes, and emotional 
stress. The reaction to physical stimuli can vary between patients but severe 
anaphylaxis due to physical stimuli alone is rare. Mostly they serve as cofac-
tors in combination with other stimuli.47  Moreover, MC have a great pheno-
typic variation depending on the tissue they reside in. The composition of 
released mediators may vary accordingly, and also ranges depending on the 
kind of stimulus. For instance, procedures involving the gastrointestinal tract 
might theoretically be more prone to MC degranulation since these organs 
contain many MC.154 
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Table	2.	High-risk	procedures	that	form	indications	for	
premedication:	any	of	the	following	criteria.	
Characteristics	of	procedure	
General	anesthesia	
Major	surgery	
Gastrointestinal	or	cardiac	surgery*	
Patient	characteristics	
Previous	MC	mediator-related	symptoms	during	procedure	
History	of	anaphylaxis	(regardless	of	trigger)	
Use	of	beta-blockers†,	ACE-inhibitorsǂ,	NSAIDsǂ	
Severe	mastocytic	infiltration	of	the	skin	
*	risk	factor	on	theoretical	grounds;	no	clinical	evidence.	
†	beta-blockers	may	attenuate	the	effect	of	epinephrine	in	
case	of	anaphylaxis	but	are	no	risk	factor	in	itself.	
ǂ	ACE-inhibitors	and	NSAIDs	can	augment	an	anaphylactic	
reaction	as	cofactors.	
	
	
Risk	factors	for	anaphylaxis	
Previous	cohort	studies	have	shown	that	anaphylaxis	is	more	common	in	patients	with	mastocytosis	
who	have		a	history	of	idiopathic	anaphylaxis,	and	particularly	those	with	ISM	without	skin	
involvement.47,50,77,103	Furthermore,	higher	total	serum	IgE	levels	and	older	age	are	associated	with	an	
increased	risk	of		anaphylaxis.50,57	Of	note,	many	studies	on	risk	factors	for	anaphylaxis	focus	on	
Hymenoptera	venom-related	anaphylaxis	and	it	is	not	clear	whether	these	data	can	be	extrapolated	to	
iatrogenic	anaphylaxis	in	patients	with	mastocytosis.	Moreover,	most	studies	included	patients	without	
mastocytosis	which	is	an	essentially	different	population.	For	instance,	increased	serum	tryptase	levels	
are	associated	with	a	higher	risk	of		anaphylaxis	in	patients	without	mastocytosis	155-157,	whereas	a	bell	
shaped	curve	is	described	in	mastocytosis.	158	In	the	latter,	patients	with	a	serum	tryptase	level	between	
circa	12	and	40	μg/L	had	the	highest	risk	of	Hymenoptera	venom	related	anaphylaxis,	and	this	risk	
decreased	with	a	further	increase	of	serum	tryptase	levels.158	A	higher	mast	cell	load	might	thus	be	
“protective”	of	anaphylaxis,	possible	through	a	favorable	antigen:mast	cell	ratio,	however	this	is	purely	
speculative.	
	
Rationale	for	premedication	
Since	the	available	data	on	the	risk	of	iatrogenic	anaphylaxis	are	conflicting,	the	value	of	premedication	
remains	unclear.	Although	the	overall	risk	of	severe	anaphylaxis	appears	to	be	low,	a	distinction	must	be	
made	between	low-	and	high-risk	procedures	(table	2).	For	the	latter,	it	seems	reasonable	to	give	
premedication.	However,	it	is	less	evident	which	drugs	should	be	used	as	prophylaxis.	The	most	
important	mediators	in	acute	anaphylaxis	are	histamine,	leukotrienes,	prostaglandins,	proteoglycans,	
TNF-α	and	platelet	activating	factor.159	Therefore,	premedication	should	consist	of	drugs	that	block	
Risk factors for anaphylaxis
Pr i us cohort studies ave s own th t anaphylaxis is more common in pa-
tients with mastocytosis who have  a history of idiopathic anaphylaxis, and 
particularly those with ISM without skin involvement.47,50,77,103 Furthermore, 
higher total serum IgE levels and older age are associated with an increased 
risk of  anaphylaxis.50,57 Of note, many studies on risk factors for anaphylaxis 
focus n Hymenoptera venom-related anaphylaxis and it is not clear wh th-
er these data can be extrapolated to iatrogenic anaphylaxis in patients with 
mastocytosis. Mor over, m st studies included patients without mastocyto-
sis which is an essentially different population. For instance, increased se-
rum tryptase levels are associated with a higher risk of  anaphylaxis in pa-
tients without mastocytosis 155-157, whereas a bell shaped curve is described 
in mastocytosis. 158 In the latter, patients with a serum tryptase level between 
circa 12 and 40 μg/L ad the highest risk of Hymenoptera venom related ana-
phylaxis, and this risk decreased with a further increase of serum tryptase 
levels.158 A higher mast cell load might thus be “protective” of anaphylaxis, 
possible through a favorable antigen:mast cell ratio, however this is purely 
speculative.
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Rationale for premedication
Since the available data on the risk of iatrogenic anaphylaxis are conflicting, 
the value of premedication remains unclear. Although the overall risk of se-
vere anaphylaxis appears to be low, a distinction must be made between low- 
and high-risk procedures (table 2). For the latter, it seems reasonable to give 
premedication. However, it is less evident which drugs should be used as pro-
phylaxis. The most important mediators in acute anaphylaxis are histamine, 
leukotrienes, prostaglandins, proteoglycans, TNF-α and platelet activating 
factor.159 Therefore, premedication should consist of drugs that block these 
mediators. Histamine receptor antagonists only provide relief of cutaneous 
symptoms like erythema and pruritus, and do not protect against anaphy-
laxis.160 There is additional evidence showing the synergistic effect of H2-re-
ceptor antagonist on the pharmacokinetics of H1-receptor antagonists, argu-
ing for combining these two.161 Leukotriene antagonists appear less effective 
in attenuating mast cell mediator related symptoms, although randomized 
trials in patients with mastocytosis are lacking.162 Furthermore, benzodiaze-
pines are valuable to remove the trigger of emotional stress and thereby may 
reduce the risk of perioperative anaphylaxis in SM patients.139
Despite the paucity of randomized clinical studies on this topic, corticoste-
roids are widely used in  protocols for the prophylaxis of acute anaphylaxis. 
There are several well-designed in vitro studies that prove that corticosteroids 
have an acute effect on MC degranulation and activation, probably through 
membrane-bound glucocorticoid receptors.59,163-165 Studies that have used skin 
tests with allergens as a model for MC reactivity have contradictory results, 
possibly reflecting the difference in duration of corticosteroid use, since only 
corticosteroid use of short duration suppressed skin test reactivity.166,167 Last-
ly, one randomized clinical trial performed in the ‘90s compared prophylaxis 
with 32 mg methylprednisolone at 12 and 2 hours prior to the administration 
of radiocontrast media, with placebo. Methylprednisolone reduced the risk 
of hypersensitivity reactions from 4.9% to 1.7%.168 Although the total number 
of reactions was low and both studies did not include mastocytosis patients, 
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these data suggest some benefit from the inclusion of corticosteroids in a pre-
medication regime. Hence, the administration of corticosteroids shortly be-
fore a procedure might attenuate MC degranulation, and makes more sense 
than giving corticosteroids only once a patient is anaphylactic and extensive 
degranulation has already occurred.  
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Previously	published	protocols	for	perioperative	prophylaxis	
In	brief,	there	are	few	published	practical	guidelines	on	prophylaxis	around	invasive	procedures	in	
patients	with	mastocytosis.	An	EAACI	position	paper	on	drug	hypersensitivity	in	mast	cell	disease	states	
that	the	evidence	on	the	risk	of	iatrogenic	anaphylaxis	is	low,	as	well	as	the	evidence	for	premedication.	
Mainly	based	on	expert	opinion,	the	authors	recommend	to	consider	the	administration	of	H1	
antagonists,	benzodiazepines	and	corticosteroids	prior	to	invasive	procedures.	Also,	the	importance	of	
cofactors	such	as	temperature	changes	and	pressure	is	stressed.	57	Other	published	reviews	make	similar	
statements	but	often	do	not	go	further	than	generalities,	without	providing	tangible	advice	regarding	
which	medication	and	dosages	to	use	as	premedication.	Lists	of	drugs	that	should	be	avoided	in	
mastocytosis	are	based	on	theoretical	assumptions	and	some	case	reports.154,169,	170		In	order	to	create	a	
protocol	which	is	as	evidence-based	as	possible,	well-established	guidelines	for	prevention	of	
radiocontrast	in	general	were	taken	into	account	in	writing	these	recommendations.171-173	
	
Practical	recommendations	
Table	3.	Safety	of	perioperative	drugs	for	patients	with	mastocytosis.	
	 I.V.	hypnotics	 Inhaled	
hypnotics	
Local	
anesthetics*	
Neuromuscular	
blocking	agents	
Recommende
d	
Etomidate	
Propofol	
Desflurane	
Isoflurane	
Amide-type	(e.g.	
lidocaine)	
Succinylcholine	
Cis-atracurium		
	 Ketamine	 Nitrous	oxide	 	 Pancuronium	
	 	 Sevoflurane	 	 Vecuronium		
Unclear	
	
Thiopental	 	 Ester-type	
(e.g.	procaine)	
Rocuronium	
Discouraged	 	 	 	 Rapacuronium	
	 	 	 	 Atracurium	
	 	 	 	 Mivacurium		
	 Analgesics	 Antiseptics	 Plasma	
substitutes	
Miscellaneous	
agents	
Recommende
d	
Fentanyl	 Chlor-hexidine	 Albumin	 Atropine	
	 Sufentanil	 Povidone	
iodide	
Gelatin		 Ondansetron		
	 Remifentanil	 	 	 Oxytocin		
	 Alfentanil	 	 	 	
	 Acetaminophen	 	 	 	
Unclear	
	
Morphineǂ		
NSAID’s†	
	 HES	starch	 Protamine		
Discouraged	 Codeine	
Nefonam		
	 	 Aprotinin		
(fibrin	glue)	
*	Severe	systemic	reactions	to	local	anesthetics	are	very	rare,	and	often	IgE-related.	
†	NSAID	=	nonsteroidal	anti-inflammatory	agents.	Avoid	if	not	used	before.	
ǂ	Titrate	slowly;	rapid	infusion	can	aggravate	MC	mediator	release.	
Previously published protocols for perioperative prophylaxis
In brief, there are few published practical guidelines on prophylaxis around 
invasive procedures in patients with mastocytosis. An EAACI position paper 
on drug hypersensitivity in mast cell disease states that the evidence on the 
risk of iatrogenic an phylaxis is low, a  well as the evid nce for premedica-
tion. Mainly based on expert opinion, the authors recommend to consider 
the administration f H1 antagonists, be zodiazepin s and corticosteroids 
prior to invasive procedures. Also, the importance of cofactors such as tem-
perature changes and pressure is stressed. 57 Other published reviews make 
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similar statements but often do not go further than generalities, without pro-
viding tangible advice regarding which medication and dosages to use as pre-
medication. Lists of drugs that should be avoided in mastocytosis are based 
on theoretical assumptions and some case reports.154,169, 170  In order to create 
a protocol which is as evidence-based as possible, well-established guidelines 
for prevention of radiocontrast in general were taken into account in writing 
these recommendations.171-173
Practical recommendations
Based on the aforementioned considerations and published expert reviews 
and protocols on this topic 57,154,160,169,170,172-174, we have composed structured 
recommendations for lowering the risk of anaphylaxis around medical pro-
cedures in patients with all forms of mastocytosis. 
General considerations
First, a risk analysis should be made to determine whether premedication 
is indicated. Risk factors that could necessitate premedication are summa-
rized in table 2, but this list is not complete and individual considerations 
are necessary for each patient. We recommend that a plan of action is made 
before the procedure by a multidisciplinary team consisting of a specialist in 
the field of mastocytosis, anesthesiologist, and the physician performing the 
procedure. It is preferable to involve the patient in this stage to reduce any in-
securities on their side. A detailed survey on previous anaphylaxis and known 
drug allergies is of paramount importance in the prevention of iatrogenic an-
aphylaxis. A comprehensive work-up for specific drug allergies should only 
be considered if a patient has previously experienced drug-related anaphy-
laxis, since patients with mastocytosis can also develop ‘ordinary’ IgE-medi-
ated allergies. When drug sensitization testing is not possible, drugs that have 
caused adverse reactions in the past need to be avoided. There is no current 
role for preoperative drug sensitization testing in the absence of previous al-
lergic reactions.170 Non-steroidal anti-inflammatory drugs (NSAID’s) should 
be avoided if the patient has never used them before. On the contrary, if 
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NSAID’s have been used before without any problems, they can be continued. 
As outlined before, several physical stimuli can induce MC degranulation, 
and all members of the treatment team need to be aware of this. Ambulatory 
surgery is also possible in patients with mastocytosis, since premedication 
can be given orally in most cases.
Prophylactic treatment prior to high-risk procedures.
Here, we have outlined our protocol for the management around high-risk 
procedures in patients with mastocytosis. Specific medications and dosages 
can vary between countries. Also, physicians can choose to partially follow 
the protocol, for example to only give a histamine receptor antagonist prior 
to low-risk procedures.
Preoperative
- Provide benzodiazepine to reduce anxiety 1-2 hours before proce-
dure.
- Corticosteroids:
o Twelve hours and 2 hours before procedure: 0.5 mg/kg pred-
nisolone or equivalent for oral administration, with a maxi-
mum dose of 60 mg.
-or-
o In case of emergency procedure: 200 mg hydrocortisone 
intravenously.
- Histamine receptor antagonists:
o 2 hours before procedure: 10 mg levocetirizine or equivalent 
fast-working  H1-receptor antagonist orally and 300 mg ran-
iditine or equivalent H2-receptor antagonist orally
-or-
o 15 minutes before procedure: 2 mg clemastine or equivalent 
H1-receptor antagonist intravenously and 300 mg raniditine 
or equivalent H2-receptor antagonist intravenously.
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Perioperative
- Close monitoring and anesthesiologist present in the room.
- Limit changes in room temperature, both increase or decrease.
- Avoid pressure or friction of the skin as much as possible , especial-
ly in patients with extensive cutaneous mastocytosis.
- Avoid drugs as noted in table 3. 
- Keep epinephrine ready to use (adjust to patient weight).
Postoperative
- Avoid drugs as noted in table 3. 
- General considerations for avoidance of physical stimuli still need 
to be adhered to.
Local anesthesia
Local anesthesia is generally safe in mastocytosis patients. Rare cases of ana-
phylactoid reactions associated with local anesthetic procedures were prob-
ably the result of physical stimuli or IgE-mediated allergies. Moreover, vaso-
vagal collapse is sometimes mistaken for anaphylaxis. Premedication is not 
advised in procedures where only local anesthesia or epidural anesthesia is 
used. 
Radiological contrast media
Iodized radiocontrast media have a higher risk of anaphylaxis than gadolin-
ium, although there are some (rare) cases of severe anaphylaxis after gado-
linium administration in the general population.171 There is no rationale for 
the avoidance of contrast media. Premedication is only indicated when a pa-
tient has previously experienced anaphylaxis due to radiocontrast media, or 
in patients whom are estimated to have a high risk of radiocontrast induced 
anaphylaxis (table 2). 
Cardiologic interventions
Mastocytosis can first present with cardiac symptoms such as unexplained 
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syncope or Kounis syndrome (coronary spasms). Since mast cells are consti-
tutively present in the heart, a cardiologic intervention might theoretically 
pose a risk for anaphylaxis. To date, merely one case report was published of 
anaphylactic shock during percutaneous coronary intervention in a patient 
who had a history of unexplained syncope.175 Of course, the administration of 
radiocontrast media can trigger anaphylaxis in itself. We therefore suggest to 
use the same considerations for prophylaxis before percutaneous cardiologic 
interventions, as for radiocontrast media. However, it must be noted that this 
suggestion is mostly based on theoretical assumptions as randomized studies 
are lacking. 
Delivery
Based on the available data, premedication before an uncomplicated delivery 
is not strictly necessary. However, it can be considered for patients who have 
experienced anaphylaxis unrelated to delivery before, especially for those 
with previous idiopathic or iatrogenic anaphylaxis. Premedication is  also 
indicated for deliveries for which general anesthesia is required. No terato-
genicity was described for H1-antagonists, although sedative H1-antagonists 
can induce sedation in the newborn child when used directly prior to the 
delivery. Cetirizine is the preferred H1-antagonist in pregnant women. Ranit-
idine can also be used safely during pregnancy and labour.176
Children 
Prophylaxis of anaphylaxis in children with mastocytosis is outside the scope 
of this review. Although the incidence of anaphylaxis is much lower in pediat-
ric mastocytosis than in adults, iatrogenic anaphylaxis is reported in children 
and the same recommendations for premedication probably apply, with dose 
reductions if necessary.
Acute treatment of anaphylaxis
In the case of anaphylaxis, the patient should be treated according to cur-
rent guidelines for anaphylaxis.160 The first step is to remove the trigger. Next, 
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timely administration of epinephrine is the single-most important lifesaver 
in this context. Of note, the dosage of epinephrine for anaphylaxis is lower 
than in the setting of a cardiac arrest (0.5 mg if body weight >60 kg), and it 
should be given intramuscularly in the mid-outer thigh. Epinephrine i.m. can 
be repeated after 5-10 minutes when the first dose is not effective. If intra-
muscular epinephrine appears ineffective after 2-3 doses, continuous intra-
venous administration can be considered.160 After stabilizing the patient, his-
tamine receptor antagonists are mainly effective for the relief of cutaneous 
symptoms.161  Although the evidence is weak, corticosteroids might attenuate 
protracted anaphylaxis and can be administered once all first-line treatment 
steps are completed.160,177
Conclusion
The risk of iatrogenic anaphylaxis in mastocytosis patients is generally low-
er than most physicians anticipate. However, the risk is increased compared 
with the general population, and anaphylaxis might be more severe in masto-
cytosis patients. Adequate perioperative management reduced the incidence 
of anaphylaxis from 5.4% to 0.4% in one study, securing the indicated treat-
ment.  A structural, patient-tailored risk assessment and subsequent thera-
peutic plan is pivotal in this context. The role of drugs as elicitors of anaphy-
laxis is probably overestimated, and physical stimuli are at least as important 
in inducing release of mast cell mediators. 
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4.2 Low frequency of acetyl salicylic acid hypersensitivity 
in mastocytosis: the results of a double-blind, placebo-con-
trolled challenge study. 
M.AW. Hermans, S.Q.A. van der Vet, P.M. van Hagen, R. Gerth van Wijk, 
P.L.A. van Daele
Allergy 2018;73:2055-2062
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Abstract
Background: Patients with mastocytosis are at increased risk of anaphylaxis. 
The use of nonsteroidal anti-inflammatory drugs (NSAIDs) is often discour-
aged because of this reason. However, the actual prevalence and severity 
of NSAID-related hypersensitivity among patients with mastocytosis is un-
known. 
Methods: A double-blind, placebo-controlled acetylsalicylic acid (ASA) chal-
lenge up to a cumulative dose of 520 mg was performed among adult patients 
with mastocytosis. In addition, a retrospective search of the entire outpatient 
cohort was performed to obtain ‘real life’ data on NSAID hypersensitivity. 
Results: Fifty patients underwent an ASA challenge. Seventy percent had in-
dolent systemic mastocytosis, 18% mastocytosis in the skin, 12% advanced 
mastocytosis. The ASA challenge was positive in 1 patient who developed ur-
ticaria. The additional retrospective chart review revealed that 8 out of 191 
patients had a history of NSAID-related hypersensitivity reaction(s), of whom 
3 reported severe systemic reactions. All 8 patients had already experienced 
NSAID-related hypersensitivity reactions before mastocytosis was diagnosed. 
Conclusions: The frequency of ASA hypersensitivity as determined by a pro-
spective challenge study was 2%, and 4.1% in a retrospective chart review of 
191 patients with mastocytosis.  NSAIDs can be administered safely to most 
patients with mastocytosis. Extra caution should be taken in patients with a 
history of hypersensitivity reactions to other drugs, or traditional risk factors 
for NSAID hypersensitivity. 
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Introduction
Mastocytosis is a disease in which aberrant mast cells accumulate. The WHO 
recognises different subtypes of SM 33,76. The prevalence of anaphylaxis is 
higher in patients with mastocytosis compared to healthy persons 178,179. A 
wide variety of stimuli can trigger mast cell degranulation and thereby lead 
to anaphylaxis 7. Historically, the use of certain medications that could the-
oretically trigger mast cell degranulation is discouraged in patients with 
mastocytosis. Among these are radiocontrast media, general anaesthetics, 
opioid analgesics and nonsteroidal anti-inflammatory drugs (NSAIDs) 178. For 
general anaesthetics and radiocontrast media, case reports on severe (and 
sometimes lethal) anaphylaxis in patients with mastocytosis are available, al-
though the absolute risk still appears low 133,180,181.  
The prevalence and severity of anaphylaxis due to NSAIDs in patients with 
mastocytosis is actually not known. Anxiety for NSAID related hypersensi-
tivity reactions leads to  confusion among both physicians and patients, and 
different advices between practices.  The use of NSAIDs is therefore often 
avoided, resulting in the risk of mistreatment of patients with mastocytosis 
for several reasons. Firstly, these patients are at increased risk of cardiovas-
cular morbidity, which often necessitates acetylsalicylic acid (ASA) for sec-
ondary prevention 61,179. Secondly, ASA is a well-known treatment for flushing 
in mastocytosis 182,183. Thirdly, patients with mastocytosis relatively often suf-
fer from various types of pain for which analgesics might be necessary 79,184. 
Currently, they are often advised to only take acetaminophen which is not 
always sufficient. 
In our practice, we noted that many patients used NSAIDs uneventfully, until 
they received were diagnosed to have mastocytosis. Furthermore, previously 
performed NSAID challenges were always negative. We therefore hypothe-
sized that the frequency and severity of NSAID related hypersensitivity is over-
estimated in patients with mastocytosis. For drug hypersensitivity in general, 
drug challenge tests are the gold standard diagnostic procedure185. ASA is of-
ten used to test for general NSAID hypersensitivity because of its strong COX-
1 inhibiting properties186. Therefore, we designed a study using standardised 
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drug challenge tests with ASA to investigate the exact prevalence and severity 
of NSAID hypersensitivity reactions in patients with mastocytosis. 
Methods
Patient eligibility
Patients were recruited from the mastocytosis outpatient clinic of the Eras-
mus University Medical center. All adult patients with biopsy-proven cutane-
ous or systemic mastocytosis were eligible. Patients were excluded if they had 
a history of a prior NSAID-related hypersensitivity reaction(s), uncontrolled 
asthma, rhinosinusitis, nasal polyps, active pregnancy, high dosage of beta 
blocking drugs (equivalent to > 100 mg. of metoprolol), when they were not 
able to stop antihistamines or prednisolone, or were not deemed capable of 
handling possible delayed anaphylactic reactions at home. Pre-existent mast 
cell mediator-related symptoms such as pruritus or flushing were not consid-
ered to be exclusion criteria in order to represent the real life situation at an 
outpatient clinic. Moreover, flushing can be an indication for ASA. 
Study protocol
All patients underwent a double-blind, placebo-controlled ASA challenge in 
a randomized order. The minimum interval between the two test days was 14 
days. The study medication was provided in a blinded fashion by the pharma-
cy of the Erasmus MC. Patients had to stop H1-antagonists and leukotriene 
antagonists for three days prior to the drug challenge. The challenge took 
place at the Allergy outpatient clinic. Patients received three incremental 
doses of ASA of 40 mg., 80 mg., and 400 mg. (or matched placebo tablets), 
leading to a cumulative dose of 520 mg. The interval between each dose was 
one hour and patients were observed for an additional two hours after the 
administration of the third dose. 
Mast cell mediator-related symptoms were systematically scored before the 
start of each drug challenge and after one, two and four hours. We used an 
adapted form of the scoring system for food challenges as proposed by Gra-
benhenrich et al.187 This form scores symptoms according to organ system 
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and severity and is in our practice routinely used for both food and drug 
challenges. In addition, numerous rating scale (NRS) score were obtained 
for mast cell mediator-related symptoms such as pruritus and headache. An 
increase of 3 points in this scale during the challenge was considered signifi-
cant. All challenges were conducted and assessed by MH and/or SdV. In cases 
of doubt, a second investigator (RGvW or PvD) was consulted to assess the 
symptoms. Deblinding of the investigators and patients took place 24 hours 
after all 50 patients completed both challenge days. 
Outcomes and definitions
The ASA challenge was considered positive when a patient developed objec-
tive mast cell mediator-related symptoms within 12 hours after the admin-
istration of the third dose on the day they received the verum, and had no 
symptoms on the placebo day. The challenge was considered negative when 
a patient developed no symptoms on the verum day, regardless of any symp-
toms on the placebo day. 
The WHO criteria were used to define the subtype of mastocytosis 76. Patients 
with maculopapular cutaneous mastocytosis (MPCM) who never underwent 
bone marrow biopsy, or had negative bone marrow investigation, were cate-
gorized as mastocytosis in the skin (MIS). An atopic background was defined 
as a history of atopic dermatitis, asthma, rhinoconjunctivitis, and/or positive 
specific IgE for inhalation or food allergens. Next to atopy, other traditional 
risk factors for NSAID hypersensitivy were defined as the presence of: asth-
ma, nasal polyps, chronic rhinosinusitis. Eosinophilia was defined as an ab-
solute eosinophil count of > 500x106 in peripheral blood. 
Additional retrospective cohort study
Next to the prospective challenge study, we retrospectively searched the 
electronic patient records of all adult patients who visited the mastocytosis 
centre from January 2009 until January 2017 and who fulfilled the criteria 
for mastocytosis in the skin (MIS), cutaneous or systemic mastocytosis (SM). 
Patients who already participated in the challenge study were excluded from 
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the retrospective cohort. Patients with a history of NSAID-related hypersen-
sitivity reactions, or patients who had proven NSAID tolerance prior to the 
start of this study, were subsequently contacted to obtain further clinical de-
tails. NSAID tolerance was considered as proven when a drug challenge was 
negative or when (accidental) NSAID ingestion was uneventful after the diag-
nosis of mastocytosis was made. The characteristics of the patients with and 
without NSAID tolerance from this retrospective cohort were compared to 
identify possible differences. 
Ethical considerations
This trial was performed according to the latest Helsinki guidelines. The 
study was approved by the local medical ethics committee. All participants 
provided written informed consent. The trial was registered in the EudraCT 
database, number 2015-004604-37.
Statistical analysis
We used IBM SPSS 21 for all analyses. Patient characteristics were noted as 
median with interquartile range (IQR) for continuous variables and as the 
number with percentage for dichotomous variables. To calculate potential dif-
ferences between the groups with and without NSAID hypersensitivity, the 
Mann Whitney U test was used for continuous variables and the chi square 
test for dichotomous variables. 
Power calculation
The prevalence of NSAID-related hypersensitivity reactions in the general 
population is less than 1%. We hypothesized that the risk in patients with sys-
temic mastocytosis is only marginally higher than in the general population. 
With an estimated frequency of allergic reactions of 4% in our study popula-
tion, inclusion of 50 subjects in total will lead to a 95% confidence interval of 
1-13%. The estimated frequency was based on self-reported reactions by pa-
tients in the Erasmus MC cohort combined with circumstantial data of other 
cohort studies on mastocytosis (see Discussion section for references).
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Results 
Study population 
At the moment of inclusion in April 2017, 173 patients were considered eligi-
ble to participate in the trial (figure 1), and 58 patients signed the informed 
consent. After inclusion, 8 patients dropped out before the ASA challenge was 
performed completely. One of these patients was excluded after the first chal-
lenge day because she started to use prednisolone for arthritis which was not 
related to the trial. Two patients experienced anaphylactoid reactions related 
to their mastocytosis within days after cessation of the antihistamines. The 
other patients withdrew consent. The inclusion process was stopped after 
50 subjects completed both days of the challenge. The final study population 
thus consisted of 50 patients. The median age was 55 years, and most partici-
pants had indolent SM (table 1).
	
	
	
	
	
	
	
	
	
Figure	1.	Flow	chart	of	the	inclusion	process.	
Patients	excluded	(n=18)	
-	history	of	reaction	to	NSAID	(n=8)	
-	pregnancy	(n=2)	
-	use	of	high	dose	beta-blocker	(n=3)	
-	inability	to	stop	antihistamines	(n=3)	
-	inability	to	handle	delayed	anaphylaxis	(n=1)	
-	renal	dysfunction	CKD	stage	3	(n=1)	
	
Patients	who	provided	
informed	consent	
n=58	
Exclusion	after	informed	consent	(n=8)	
-	withdrawal	of	consent	(n=5)	
-	inability	to	stop	antihistamines	(n=2)	
-	treatment	with	prednisolone	(n=1)	
	
Patients	who	underwent	ASA	challenge	
(n=50)	
Eligible	patients		
n=173	
Patients	with	history	of	
hypersensitivity	reaction	to	
NSAID	
n=8	
Patients	with	proven	NSAID	
tolerance	prior	to	study	
n=15	 Patients	in	final	analysis	
n=73	
Total	adult	population	mastocytosis	
center	Erasmus	MC	
n=191	
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Table	1.	Baseline	characteristics	study	population	(n=50).	
Age	in	years,	median	(IQR)	 55	(16)	
Male,	n	(%)	 16	(32)	
Subtype,	n	(%)	
	• MIS	 9	(18)	
• ISM	
	with	skin	lesions	 26	(52)	
without	skin	lesions	 9	(18)	
• SSM	 3	(6)	
• SM-AHN	 2	(4)	
• ASM	 1	(2)	
Serum	tryptase	level	at	diagnosis	in	μg/l,	median	(SD)	 25.0	(17.8)	
Atopic	background,	n	(%)	 13	(26)	
Eosinophilia,	n	(%)	 2	(4)	
Previous	hypersensitivity	reaction	to	any	drug,	n	(%)	 5	(10)	
Previous	anaphylaxis	due	to	any	trigger,	n	(%)	 23	(46)	
• Wasp	 7	
• Unknown	 7	
• Physical	stimuli	 4	
• Other	drugs*	 5	
• Miscellaneous†	 6	
MIS:	mastocytosis	in	the	skin;	ISM:	indolent	systemic	mastocytosis;	SSM:	
smouldering	systemic	mastocytosis;	SM-AHN:	systemic	mastocytosis	
with	associated	hematological	neoplasm;	ASM:	agressive	systemic	
mastocytosis.	
*Other	drugs:	proton	pump	inhibitor	(1x),	morphine	(2x),	penicillin	(1x),	
and	codeine	(1x).	
†Miscellaneous	triggers:	horsefly	(n=2),	jellyfish	sting	(n=1),	fire	ant	
(n=1),	anesthesia	(n=1),	codeine	(n=1).	
	
Results	of	ASA	challenge	
The	challenge	was	positive	in	one	patient	(2%),	who	developed	an	urticarial	rash	4	hours	after	ingestion	
of	the	third	dose	of	ASA,	which	corresponds	with	a	cumulative	dose	of	520	mg.	The	rash	subsided	after	
she	took	10	mg.	of	hydroxyzine.	This	patient	had	smouldering	SM	based	on	a	serum	tryptase	level	of	>	
200	µg/L	and	hepatosplenomegaly.	She	had	never	used	NSAIDs	before.	She	had	previously	developed	a	
rash	after	the	administration	of	radiocontrast	media	and	reported	an	increase	in	mast	cell	mediator-
related	symptoms	after	the	consumption	of	alcoholic	beverages	and	histamine	rich	food.			
Three	other	patients	reported	subjective	symptoms	on	the	day	of	the	verum	but	not	on	the	day	
they	received	placebo.	These	symptoms	consisted	of	mild	flushing	in	1	patient,	generalized	pruritus	in	1	
patient,	and	lightheadedness	in	1	patient.	The	flushing	was	not	considered	as	a	positive	challenge	
because	it	occurred	after	the	second	dose	of	80	mg.	and	subsided	spontaneously	despite	the	next	
increasing	dose	of	ASA	was	administered	according	to	protocol.	Moreover,	this	patient	has	spontaneous	
Results of ASA challenge
The challenge was positive in one patient (2%), who developed an urticarial 
rash 4 hours after ingestion of the third dose of ASA, which corresponds with 
a cumulative dose of 520 mg. The sh subsided after she took 10 g. of hy-
droxyzine. This patient had smouldering SM based on a serum tryptase level 
of > 200 mg/L and hepatosplenomegaly. She had never used NSAIDs before. 
She had previously eveloped a rash after the administration of radiocontrast 
media and reported an increase in mast cell mediator-related symptoms after 
the consumption of alcoholic beverages and histamine rich food.  
Three other patients reported subjective symptoms on the day of the verum 
but not on the day they received placebo. These symptoms consisted of mild 
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flushing in 1 patient, generalized pruritus in 1 patient, and lightheadedness 
in 1 patient. The flushing was not considered as a positive challenge because 
it occurred after the second dose of 80 mg. and subsided spontaneously de-
spite the next increasing dose of ASA was administered according to proto-
col. Moreover, this patient has spontaneous flushes multiple times a week. 
Similarly, the patient with pruritus already had pruritus before the start of 
the challenge and the NRS score increased by 2 points throughout the day of 
the challenge which was below the pre-specified threshold of 3 points (see 
Methods section). The last patient experienced lightheadedness 15 minutes 
after the ingestion of the third dose of ASA, but had no other mast cell medi-
ator-related symptoms and stable vital parameters. The serum tryptase level 
did not increase as compared to a baseline measurement. Seven patients had 
a reaction on the placebo day, of whom 1 had objective macular erythema on 
the arms and trunk, and the other 6 patients had subjective symptoms. Four 
patients who had a reaction to placebo already had mast cell mediator-related 
symptoms at the start of the challenge, consisting of pruritus and/or flushing. 
Patients with a history of NSAID-related reactions
In addition to the challenge study, we retrospectively searched the electronic 
records of all adult patients with mastocytosis that visited the Erasmus MC 
from 2009 until 2017. Out of a total of 191 patients, 8 patients had an annota-
tion of ‘NSAID allergy’ in their medical record. This results in a prevalence 
of self-reported NSAID-related hypersensitivity of 4.1% in our entire cohort. 
Fifteen patients had proven NSAID tolerance prior to this study. Table 2 sum-
marizes the clinical characteristics of these patients. 
All patients had experienced NSAID-related reactions before they received the 
diagnosis of mastocytosis. The most frequent symptoms were angioedema, 
erythema and hypotension. Three patients required treatment in an emer-
gency department. Of the patients who could reliably recall their reaction 
at the time of questioning, everyone experienced a reaction within 2 hours 
after the ingestion of the NSAID. Patient number 5 developed a reaction after 
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the combination of naproxen and a wasp sting. Hymenoptera sensitization 
could not be confirmed. Although it is likely that Hymenoptera was the main 
culprit and naproxen acted as a cofactor, the patient was labelled as ‘NSAID 
intolerant’ because of the severity of the reaction and the risk of aggrava-
tion of future reactions with the use of NSAIDs. Patient number 3 later had 
a drug challenge with celecoxib which was negative. Patient number 6 and 
8 both later had a negative drug challenge with naproxen, which excludes a 
general non-specific NSAID hypersensitivity. Notably, seven patients (87.5%) 
reported mast cell mediator-related reactions to other physical stimuli. These 
reactions ranged from flushing or gastrointestinal symptoms to anaphylaxis. 
	
	
	
Table	2.	Characteristics	of	patients	with	hypersensitivity	reaction(s)	to	NSAIDs.	
	
	 Age	at	
diagnosis	
(years)	
Sex	 Subtype
*	
Mastocytosis	
in	the	skin	
Serum	
tryptase	at	
diagnosis	
(μg/l)	
Atopy	 Type	of	
NSAID	
Timing	of	
reaction	
Symptoms	of	
reaction	
Reaction	to	
other	
triggers	
1	 41	 F	 MIS	 TMEP	 8.6	 Yes	 ASA		
80	mg.	
2	hours	 Angioedema	 Penicillin,	
possibly	
lidocaine	
2	 72	 M	 ISM	 No	 20.0	 No	 Ibuprofen	
Diclofenac†	
unknown	 Generalized	
pruritus,	blurry	
vision	
-	
3	 51	 F	 ISM	 MPCM	 125.0	 Yes	 Ibuprofen	
Diclofenac†	
5	min	 Angioedema,	
palpitations,	
collapseǂ	
Heat	
4	 62	 F	 ISM	 MPCM	 118.0	 No	 Diclofenac	 unknown	 Angioedema	 Alcohol	
consumptio
n	
5	 42	 M	 ISM	 MPCM	 31.4	 No	 Naproxen	 10	min	 Erythema,	
stridor,	
hypotensionǂ	
Alcohol	
consumptio
n,	wasp	
sting,	
temperature	
changes	
(cold)	
6	 40	 M	 ISM	 No	 24.7	 Yes	 Acetamino-
phen	
5	min	 Diffuse	erythema	 Strong	odors	
or	dust		
7	 48	 F	 ISM	 MPCM	 43.5	 	 Naproxen	 5	min	 Diffuse	
erythemaǂ	
-	
8	 68	 F	 ISM	 MPCM	 17.8	 No	 Diclofenac	 20	min	 Hypotension,	
collapseǂ	
Iodated	
contrast	
media	
MIS:	mastocytosis	in	the	skin.	TMEP:	teleangiectasia	macularis	eruptiva	perstans.	MPCM:	maculopapular	cutaneous	mastocytosis.	ASA:	
acetylsalicylic	acid.	NSAID:	nonsteroidal	anti-inflammatory	drug	
*Bone	marrow	biopsy	was	performed	in	all	patients.	
†	Two	separate	reactions	at	different	occurrences.	
ǂ	Treatment	at	emergency	department	required.	
	
Characteristics	associated	with	NSAID	hypersensitivity		
Since	only	one	patient	had	a	positive	ASA	challenge,	the	data	from	the	prospective	study	could	not	be	
used	to	reliably	identify	any	potential	clinical	characteristics	that	are	associated	with	NSAID	
hypersensitivity.	Therefore,	data	from	the	retrospective	cohort	were	analyzed	for	this	purpose	(table	3).		
	
Overall,	patients	with	NSAID	tolerance	appear	to	have	more	daily	mast	cell	mediator-related	symptoms	
such	as	flushing,	cognitive	problems,	fatigue	and	pruritus.	Only	the	latter	was	statistically	significant	(p	
0.021,	chi	square	test),	probably	due	to	the	small	numbers	of	patients.	Patients	with	NSAID	
hypersensitivity	reported	more	reactions	to	other	drugs,	although	this	difference	did	not	reach	
CHAPTER 4
108
Characteristics associated with NSAID hypersensitivity 
Since only one patient had a positive ASA challenge, the data from the pro-
spective study could not be used to reliably identify any potential clinical 
characteristics that are associated with NSAID hypersensitivity. Therefore, 
data from the retrospective cohort were analyzed for this purpose (table 3). 
Overall, patients with NSAID tolerance appear to have more daily mast cell 
mediator-related symptoms such as flushing, cognitive problems, fatigue 
and pruritus. Only the latter was statistically significant (p 0.021, chi square 
test), probably due to the small numbers of patients. Patients with NSAID hy-
persensitivity reported more reactions to other drugs, although this differ-
ence did not reach statistical significance (p 0.063). The same accounted for 
peripheral blood eosinophilia (p 0.181), osteoporosis (p 0.186) and alcohol 
intolerance (p 0.308). Strikingly, traditional risk factors for NSAID hypersen-
sitivity in the general population such as atopy, asthma or rhinitis were not 
more frequent in the NSAID hypersensitivity group of our cohort. Neither 
were there any relevant differences in age, sex, serum tryptase levels, or skin 
involvement of mastocytosis.  
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statistical	significance	(p	0.063).	The	same	accounted	for	peripheral	blood	eosinophilia	(p	0.181),	
osteoporosis	(p	0.186)	and	alcohol	intolerance	(p	0.308).	Strikingly,	traditional	risk	factors	for	NSAID	
hypersensitivity	in	the	general	population	such	as	atopy,	asthma	or	rhinitis	were	not	more	frequent	in	
the	NSAID	hypersensitivity	group	of	our	cohort.	Neither	were	there	any	relevant	differences	in	age,	sex,	
serum	tryptase	levels,	or	skin	involvement	of	mastocytosis.			
		
Table	3.	Comparison	of	clinical	characteristics	of	patients	with	and	without	NSAID	hypersensitivity	of	
mastocytosis	cohort	EMC,	as	proven	by	drug	challenges.	
	 No	NSAID	hypersensitivity	
(n=64)	
NSAID	hypersensitivity	(n=9)	 p-value	
Age,	median	(IQR)	 55	(10)	 51	(9)	 NS	
Male	sex,	n	(%)	 22	(34.4)	 3	(33.3)	 NS	
Subtype,	n	(%)	 	 	 NS	
- MIS	 14	(21.9)*	 1	(11.1)†	 	
- ISM	 45	(70.3)	 7	(77.8)	 	
- SSM	 2	(3.1)	 1	(11.1)	 	
- SM-AHN	 2	(3.1)	 0	 	
- ASM	 1	(1.6)	 0	 	
Presence	of	skin	mastocytosis,	n	(%)	 50	(78.1)	 6	(66.6)	 NS	
Serum	tryptase	at	diagnosis,	median	
(IQR)	
25	(7.8)	 31.4	(11.4)	 NS	
History	of	anaphylaxis,	n	(%)	 27	(42.2)	 5	(55.6)	 NS	
Pruritus,	n	(%)§	 50	(78.1)	 1	(11.1)	 NS	
Flushing,	n	(%)§	 27	(42.2)	 2	(22.2)	 NS	
Dyspepsia,	n	(%)§	 10	(15.6)	 2	(22.2)	 NS	
Diarrhea,	n	(%)§	 15	(23.4)	 0	 NS	
Fatigue,	n	(%)§	 37	(57.8)	 2	(22.2)	 0.04	
Subjective	cognitive	problems,	n	(%)	 22	(34.4)	 0	 0.045	
Osteoporosis,	n	(%)	 8	(12.5)	 3	(33.3)	 NS	
Eosinophilia,	n	(%)	 4	(6.3)	 3	(33.3)	 0.01	
Atopy,	n	(%)	 17	(26.6)	 3	(33.3)	 NS	
History	of	hypersensitivity	reaction	
to	other	drugs,	n	(%)‡	
5	(7.8)	 4	(44.4)	 0.002	
Alcohol	intolerance,	n	(%)ǁ	 29/50	(58)	 4/5	(80)	 NS	
MC	mediator	related	reaction	to	
physical	triggers,	n	(%)¶	
48	(75)	 5/6	(83.3)	 NS	
*bone	marrow	investigation	negative	in	2	patients,	other		12	never	underwent	bone	marrow	punction	
§	Symptom	present	>3	days	per	week.	
†	Bone	marrow	investigation	negative	for	bone	marrow	mastocytosis.	
‡	See	text	for	further	explanation.	
ǁ	Not	known	for	all	patients	because	some	patients	never	consume	alcohol.	
¶	Physical	triggers:	heat,	cold,	stress,	exercise,	alcohol	consumption.	
	
Discussion
This is the first double-blind, placebo-controlled challenge study to investi-
gate the prevalence and severity of ASA hypersensitivity among patients with 
mastocytosis. Only 1/50 participants (2%) had a positive ASA challenge, con-
sisting of an urticarial rash. Three other patients had subjective symptoms to 
ASA. The characteristics of the study population were overall representative 
of a patient cohort in a tertiary centre for mastocytosis, except for a relatively 
low number of male participants 77,83,103. 
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However, the exclusion of patients with known risk factors for NSAID hyper-
sensitivity might have led to a selection bias. Therefore, we performed an addi-
tional retrospective analysis of our entire cohort of 191 patients. This resulted 
in a prevalence of self-reported NSAID-related hypersensitivity of 4.1%. Im-
portantly, all patients with NSAID hypersensitivity experienced one or more 
reactions before the diagnosis of mastocytosis was established. Although in-
terpretation of any differences between the patients with and without NSAID 
hypersensitivity is difficult due to the small patient numbers, it appears from 
the retrospective cohort that patients with NSAID hypersensitivity more often 
experienced hypersensitivity reactions to other drugs and/or alcohol. It must 
be noted that three patients reported a hypersensitivity reaction to amoxicil-
lin, which is the third most reported culprit for drug-related reactions in The 
Netherlands. We cannot exclude that the relationship between amoxicillin and 
the reported reactions was based on coincidence.  Another notable difference 
is the higher prevalence of mast cell mediator-related symptoms among NSAID 
tolerant patients. Possibly, this difference represents the clinical practice, be-
cause patients with symptoms such as flushing are more often in need for ASA 
and therefore were more likely to undergo an NSAID challenge out of medical 
necessity. A causal explanation seems unlikely.
Interestingly, 2/8 patients with a history of NSAID-related hypersensitivity re-
actions later had  negative un-blinded challenges with another NSAID. This 
can be explained in multiple ways: they might have a specific, IgE mediated, 
allergy to the culprit NSAID. Another, more likely, explanation is the fact that 
NSAIDs can be a cofactor to augment anaphylaxis 47,188. The current trial does 
not provide prospective data on the role of NSAIDs as a cofactor in patients 
with mastocytosis. Also, although the use of ASA as a model for general NSAID 
hypersensitivity is widely accepted, a specific allergy for one type of NSAID 
is potentially missed with this approach. Moreover, the currently presented 
data cannot be extrapolated to patients with traditional risk factors for NSAID 
hypersensitivity, such as asthma, nasal polyposis or atopic constitution. How-
ever, most patients with mastocytosis do not have such risk factors 132, thus 
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most patients would fulfill the currently used inclusion criteria. Lastly, a pos-
sible caveat of drug challenges in patients with mastocytosis is the fact that 
many of them already have mast cell mediator-related symptoms on a daily 
basis, especially since anti-mediator medications need to be interrupted pri-
or to a challenge. By using NRS scores, we tried to score these symptoms as 
objectively as possible, however, some degree of bias in the assessment of 
challenge studies cannot be excluded in this patient category.  
The prevalence of NSAID hypersensitivity in our cohort of patients with masto-
cytosis is only slightly higher compared to the prevalence of 1-2% of self-re-
ported NSAID-related hypersensitivity in a general population 189. There are few 
comprehensive data on NSAID hypersensitivity among patients with mastocy-
tosis published to date. One retrospective study described 20 patients who re-
ceived ASA in varying dosages and schedules. Two patients (10%) reported a 
mild reaction: either delayed urticaria or immediate flushing 182. Other descrip-
tive population studies reported a prevalence ranging between 2.3% and 6%, of 
mostly mild immediate-type reactions 47,48,190. We could not find published proof 
of fatal anaphylaxis due to NSAIDs in patients with mastocytosis. Conversely, in 
a population of 137 persons with drug- or food related anaphylaxis, mastocyto-
sis was found in only 2 patients 191. Moreover, there was no association between 
NSAID hypersensitivity and serum tryptase levels in a general cohort 192. 
An EAACI position paper advises that patients with mastocytosis and known 
NSAID tolerance can safely keep taking NSAIDs, but all others should undergo 
work-up 57. However, that work-up is not further specified in this paper. Based 
on our current results, we suggest that everyone with mastocytosis who has 
never experienced a hypersensitivity reaction to NSAIDs, or other drugs, can 
safely start taking NSAIDs at home. Given the fact that patients who have ex-
perienced a hypersensitivity reaction to another drug appear to be at a higher 
risk for NSAID hypersensitivity reactions, it seems appropriate to administer 
the first dose in a clinical setting, preferably with an incremental challenge 
protocol. As mentioned before, the interpretation of such challenges is very 
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delicate and requires experience in this area. Despite the placebo-controlled 
approach, some patients will have only subjective symptoms to an NSAID, 
and although this is likely to be a ‘placebo reaction’, it cannot be excluded that 
these minor symptoms reflect some reaction to the NSAID. The risk of devel-
oping more serious reactions in the future is unclear for these patients, and 
careful counselling is of paramount importance. 
Possibly, patients with a history of NSAID-related hypersensitivity reactions 
can also be challenged with another NSAID. Depending on the type and severi-
ty of the previous reaction(s), it can be safer to challenge with a selective COX-2 
inhibitor in these cases. Unfortunately, our study cannot corroborate this sug-
gestion. Prospective placebo-controlled studies on these topics would be highly 
interesting, although are hindered by potential safety issues. On a final note, 
although the possible benefits of ASA and NSAIDs in general for patients with 
mastocytosis are clear, the indication must be weighed against possible adverse 
effects. For instance, patients with mastocytosis already are at risk for peptic 
ulcer disease 193, which might be increased by the use of NSAIDs. Moreover, it 
is well-known that NSAIDs can act as a cofactor in anaphylaxis. Ultimately, a 
careful consideration of risks and benefits needs to be made for each individu-
al, and patients should be consulted on the possible risks. 
Conclusions
In summary, the frequency of NSAID hypersensitivity among patients with 
mastocytosis was 2%, as determined by a prospective double-blind ASA chal-
lenge. The frequency of self-reported NSAID hypersensitivity in a retrospective 
cohort was 4.1%. Based on the mild reactions we saw in our study, combined 
with the real-life experience that all patients with severe NSAID hypersensi-
tivity experienced these reactions prior to their diagnosis of mastocytosis, we 
conclude that it is safe to administer NSAIDs to most patients with mastocytosis 
íf they do not have a history of prior NSAID hypersensitivity reactions. Extra 
caution might be taken in patients with previous hypersensitivity reactions to 
other drugs, or with traditional risk factors for NSAID hypersensitivity.
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Chapter 5
Translational data to improve 
future treatment options
CHAPTER 5
114
CHAPTER 5
5.1 The JAK1/JAK2‐ inhibitor ruxolitinib inhibits mast cell de-
granulation and cytokine release.
M.A.W. Hermans, B.J. Schrijver, J.C.P.A. van Holten-Neelen, R. Gerth van 
Wijk, P.M. van Hagen, P.L.A. van Daele, W.A. Dik
Clinical and Experimental Allergy. 2018 Oct;73(10):2055-2062
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Abstract
Background: Mastocytosis is characterized by the accumulation of aberrant 
mast cells (MC). Patients suffering from mastocytosis suffer from a wide 
range of symptoms due to increased levels of MC mediators. It would there-
fore be of great benefit to inhibit MC mediator release. However, to date there 
are few drugs available that are known to effectively lower MC mediator lev-
els. The evidence for the involvement of the janus kinase 2 (JAK2) - signal 
transducer and activation of transcription 5 (STAT5) signaling pathway in MC 
activation is slowly accumulating. Interference with the JAK2-STAT5 pathway 
might inhibit MC mediator release. Ruxolitinib, a JAK1/JAK2 inhibitor, indeed 
decreases symptoms like pruritus and fatigue in patients with myeloprolifer-
ative neoplasms. Yet, detailed studies on how ruxolitinib affects human mast 
cell activity are lacking. 
Objective: To investigate the effect of JAK1/2-inhibition with ruxolitinib in the 
human mast cell lines LAD2 and HMC1.
Methods: LAD2 and HMC1 were stimulated with substance P, codeine or the 
calcium ionophore A23817. The effect of ruxolitinib on mast cell degranu-
lation (via measurement of β-hexosaminidase, histamine release and CD63 
membrane expression ) and IL-6, IL-13, MCP-1 and TNF-α production was 
investigated. The involvement of STAT5 activation was explored by using the 
selective STAT5 inhibitor pimozide. 
Results: Ruxolitinib effectively inhibited codeine- and substance P-induced 
degranulation in a concentration-dependent manner. Ruxolitinib also sig-
nificantly inhibited the production of IL-6, TNF-α and MCP-1 as induced by 
A23817 and substance P. Selective STAT5 inhibition with pimozide resulted in 
diminished degranulation and inhibition of cytokine production as induced 
by A23817 and substance P.  
Conclusions & clinical relevance: This study demonstrates that the JAK1/JAK2 
inhibitor ruxolitinib can inhibit MCactivity, possibly through prevention of 
STAT5 activation. This renders the JAK-STAT pathway as an interesting target 
for therapy to release symptom burden in mastocytosis and many other MC 
mediator-related diseases.
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Introduction
Mast cell related diseases such as systemic mastocytosis or mast cell activa-
tion syndrome often cause debilitating symptoms mainly due to mast cell 
(MC)-derived mediators.91,103,194 Currently, these symptoms are treated symp-
tomatically with histamine antagonists, leukotriene antagonists, cromolyn 
acid and acetylsalicylic acid.124 However, this regime is often insufficient to 
reduce symptoms to an acceptable level in the daily life of patients: especially 
anaphylaxis, gastrointestinal symptoms or flushing can greatly influence the 
quality of life.52 
Most recent studies on the treatment of mastocytosis focus on the application 
of tyrosine kinase inhibitors (TKI) in the advanced forms of systemic masto-
cytosis (SM). These inhibitors mainly act through targeting of the KIT-recep-
tor to  inhibit MC growth.75,124,195 Some of these TKI are only effective in MC 
with wild-type KIT while most patients with mastocytosis harbor the activat-
ing D816V KIT mutation.80 Although newer TKI like midostaurin are also ef-
fective  in patients with the D816V KIT mutation ,its use is often hampered by 
gastrointestinal adverse effects.75 Whereas the search for effective therapies 
for advanced mastocytosis has been going on for years, it is recognized only 
recently that TKI might also be of benefit in patients with indolent mastocy-
tosis. The indolent subtype has an excellent prognosis regarding survival, but 
patients regularly experience symptoms caused by the released MC-media-
tors rather than from actual tissue invasion by MC. Clinical experience with 
KIT-targeting TKI in indolent systemic mastocytosis is limited. The multi-TKI 
masitinib was found to diminish MC mediator-related symptoms such as fa-
tigue and pruritus in 8-25% of patients.70 Next to well-known mediators such 
as histamine, leukotrienes and tryptase, MC produce numerous cytokines 
which are associated with constitutional symptoms in mastocytosis.7,64,196,197 
Therefore, medication that inhibits the release of these MC mediators would 
be a valuable addition to the, currently limited, therapeutic arsenal for indo-
lent systemic mastocytosis. 
CHAPTER 5
117
Janus kinase (JAK) molecules are involved in the intracellular transduction of 
signals from multiple receptors, leading to downstream activation of signal 
transducer and activation of transcription (STAT) molecules and subsequent 
cellular responses.198 Of the different JAK- and STAT molecules and signaling 
pathways currently known, the JAK2-STAT5 pathway is considered the most 
important for growth and survival of MC.199 STAT5 also plays a role in IgE-me-
diated MC degranulation, rendering the JAK2-STAT5 pathway an interesting 
target for the inhibition of MC activation.200 In support of this, it has previ-
ously been shown that the JAK1/JAK2 inhibitor ruxolitinib attenuates oval-
bumin-induced passive systemic anaphylaxis in mice, while another study 
demonstrated that several JAK2- and STAT5-inhibitors were able to inhibit ac-
tivation of canine mastocytoma cell lines.201,202 Furthermore, two recent case 
studies of patients with systemic mastocytosis reported that MC mediator-re-
lated symptoms decreased upon treatment with ruxolitinib.203,204 
Although these data suggest that JAK2-STAT5 inhibition might effectively re-
duce the release of MC mediators, basal data on its actual effect on human 
MC are scarce. The next step towards safe implementation of JAK-STAT inhib-
itors in the treatment of mastocytosis would be to further explore their exact 
effects on human MC. To investigate this, we conducted in vitro studies with 
ruxolitinib, using two different human mast cell lines and several parameters 
of MC activation.
Materials and methods
Cell culture
Two different human mast cell lines were used: HMC1 and LAD2. HMC1 cells 
grow independently of stem cell factor (SCF) as a result of an activating KIT 
mutation (kindly provided by dr. Butterfield, Mayo Clinic, Rochester, Min-
nesota)205. DNA sequencing confirmed the presence of the G560V and D816V 
mutation in KIT. LAD2 is a SCF dependent mast cell line representing wild-
type human MC (kindly provided by  drs. Kirshenbaum and Metcalfe, Nation-
al Institute of Allergy and Infectious Diseases, Bethesda, Maryland)22. 
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HMC1 cells were cultured in RPMI+ medium (Lonza, Verviers, Belgium) 
supplemented with 10% fetal calf serum, 50 μM β-mercapto-ethanol (Sig-
ma-Aldrich, St. Louis, Missouri), and antibiotics (penicillin/streptomycin, 
Lonza). LAD2 cells were cultured in Stem Pro-34 medium supplemented with 
2.6% nutrient supplement (both Life Technologies, Grand Island, New York), 
2 mM ultraglutamine (Lonza), 100 ng/ml SCF (R&D systems, Abbingdon, 
U.K.), and antibiotics (penicillin/streptomycin).
Beta-hexosaminidase release 
MC degranulation was measured by β-hexosaminidase assay, as adopted 
from Rådinger et al.206  In brief, 2x104 LAD2 cells in 100 μL per condition were 
transferred to a 96-well plate in calcium free phosphate-buffered saline (PBS). 
The cells were incubated for 30 minutes with varying concentrations of rux-
olitinib (Apex Bio, Houston, Texas) or the STAT5-inhibitor pimozide (R&D 
systems) before further stimulation. Cells were stimulated with 40 μg/ml of 
codeine (Clinical pharmacy of Erasmus MC, Rotterdam, The Netherlands) or 
5 μM of substance P (R&D systems) for  15 minutes at 37oC. Hereafter, plates 
were centrifuged at 400 G for 4 minutes. Subsequently, 50 μL of supernatant 
was added to 100 μL of p-nitrophenyl N-acetyl-β-D-glucosaminide (p-NAG, 
Sigma-Aldrich) in citrate buffer (pH 4.5), while the cells were lysed by add-
ing 150 μL 0.1% Triton X solution (Sigma-Aldrich). Fifty μL of the cell lysate 
was added to 100 μL of p-NAG in a different plate. After  incubation for 90 
minutes at 37oC, the reaction was stopped by adding 100 μL  of glycine 400 
mM to each well.  Optical density (OD) values were measured at 405 and 620 
nm using a ELISA plate reader. The relative β-hexosaminidase release was 
calculated as follows: (2x Δsupernatant)/(Δsupernatant + (4*Δcell lysate)) = % 
β-hexosaminidase release. Δsupernatant = OD value supernatant – OD value 
blank condition. 
Histamine release
For the determination of histamine release, LAD2 cells were used. The cells 
were incubated with varying concentrations of ruxolitinib and subsequent-
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ly stimulated with codeine for 15 minutes, according to the protocol as de-
scribed above for the β-hexosaminidase assay. Histamine levels in the super-
natant were measured by ELISA (IBL Solutions, Rorsachenberg, Switzerland).
Surface membrane CD63 expression
MC degranulation is accompanied by the movement of CD63 to the exter-
nal surface of the membrane, and CD63 expression can therefore be used to 
measure MC degranulation.207 LAD2 cells were suspended in PBS to a concen-
tration of 3x105 cells in 500 μL per tube. The cells were first incubated with 
ruxolitinib or pimozide for 30 minutes, and subsequently stimulated with co-
deine at a concentration of 40 μg/mL for 15 minutes at 37oC. The cells were 
stained with FITC-conjugated anti-CD63 antibody (ThermoFisher, Waltham, 
Massachusets). Membrane CD63 expression was analyzed on a flowcytome-
ter (LSRII, Becton Dickinson, Franklin Lakes, New Jersey).
Cytotoxicity assay
Cytotoxicity of ruxolitinib and pimozide was tested by several methods. First-
ly, HMC1 and LAD2 cells were cultured for up to 24 hours in the presence of 
varying concentrations of ruxolitinib (from 50 nM to 50 μM) and pimozide (2 
μM to 100 μM). The cells were assessed by microscopy and trypane blue ex-
clusion. Secondly, LDH levels in supernatant of cell cultures of 24 hours were 
measured by a standard colorimetric assay kit (Roche, Basel, Switzerland).
Cytokine production
For the measurement of cytokine and chemokine production, HMC1 cells 
were seeded in a 96-well plate at 2 x 105 cells in 200 μL culture medium per 
condition. Subsequently, the cells were incubated for 30 minutes with rux-
olitinib (or pimozide) before stimulating them with 1 μM of A23187 or 5 μM 
of substance P. After testing several time periods of stimulation ranging be-
tween 6 and 24 hours for the optimal duration, TNF-α levels in the superna-
tant were measured after 6 hours of stimulation, and MCP-1 and IL-6 levels 
were measured after 24 hours of stimulation. See the results section for fur-
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ther details. Cytokines were measured by ELISA (all R&D systems, except for 
IL-6 which was from ThermoFisher). The choice of cytokines was based on 
previous research on cytokine levels in patients with mastocytosis and other 
myeloproliferative diseases.208-210 
 
Statistical analysis
Graphpad Prism 5 (San Diego, California) was used to analyze most data ex-
cept for the flow cytometry data, for which FlowJo (Ashland, Oregon) was 
used. One-way Analysis of Variance (ANOVA) and subsequent Dunnett post-
hoc tests were used to determine the statistical significance between the rux-
olitinib- or pimozide-treated conditions and the positive control conditions. 
IC50 values were calculated for the inhibitory effects on degranulation and cy-
tokine production of both compounds. The results of β-hexosaminidase, his-
tamine and cytokines/chemokine measurements are depicted in bar graphs 
as mean values with standard error of the mean (SE). CD63 expression is de-
picted in histograms as mean fluorescent intensity. 
Results
Compound control
Ruxolitinib was not cytotoxic to either HMC1 as LAD2 cells up to a concen-
tration of 50 μM as determined by microscopy, trypane blue exclusion and by 
LDH release assay for up to 48 hours of incubation. Pimozide was cytotoxic 
to both cell lines from a concentration of 50 μM and higher as determined 
by LDH release assay. The vehicle, DMSO, did not affect degranulation up to 
a concentration of 5%, as measured by β-hexosaminidase release and CD63 
expression (data not shown).
Degranulation
First, titration of the stimuli was performed to find the optimal duration and 
concentration of stimulation for the β-hexosaminidase assay (figure S1) and 
flow cytometry (figure S2). HMC1 cells appeared unsuitable for these degran-
ulation assays because their degranulation could not be further enhanced by 
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stimulation with codeine, as measured by β-hexosaminidase release (figure 
S3). For HMC1 cells, there also was no significant upregulation of CD63 ex-
pression upon stimulation with codeine  (data not shown). Therefore, only 
LAD2 cells were used for all degranulation assays. Optimal concentrations to 
stimulate degranulation were 40 μg/ml for codeine, and 5 μM for substance P, 
for a duration of 15 minutes. 
Ruxolitinib effectively inhibited substance P- and codeine-induced degran-
ulation of LAD2 cells, in a concentration-dependent manner reaching sta-
tistical significance at 50 μM and 10 μM, (p 0.028 and p 0.006, respectively; 
figure 1A and B). This corresponded to an IC50 of 7.9 μM (95% CI 2.3-27.3) for 
substance P-induced degranulation, and an IC50  of 10 μM (95% CI; 8.9 – 12.6) 
for codeine-induced degranulation. Ruxolitinib also inhibited codeine-in-
duced histamine release and CD63 expression of LAD2 cells, however without 
reaching statistical significance (figure 1C and D, respectively). 
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Figure	1.	The	effect	of	ruxolitinib	on	degranulation	of	LAD2	cells.	
Figure	1.	Ruxolitinib	effectively	inhibits	degranulation	of	LAD2	cells	in	a	dose-dependent	manner.		A:	Beta-
hexosaminidase	assay	for	substance	P	induced	degranulation.	Concentration	of	Substance	P:	5	μM.	B:	Beta-
hexosaminidase	assay	for	codeine	induced	degranulation.	Concentration	of	codeine:	40	μg/ml.	C:	Inhibition	of	
histamine	release	after	stimulation	with	codeine	40	μg/ml.	D:	Inhibition	of	CD63	expression	after	stimulation	
with	codeine	40	μg/ml.	MFI=	mean	fluorescent	intensity.	*p<0.05,	and	#p<0.01	as	compared	with	positive	
control.	All	bars	are	depicting	the	mean	of	3	repeated	experiments	with	SE.	
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minutes.		
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Cytokine and chemokine production
HMC1 cells were used for all experiments performed to evaluate cytokine 
and chemokine production. First, experiments were performed to determine 
which substance and duration of stimulation was optimal for the induction of 
IL-6, TNF- α, MCP-1 and IL-13 production in HMC1 cells. This revealed that  the 
optimal stimulation time to induce production of IL-6 and MCP-1 was 24 hours, 
and that a stimulation time of 6 hours was optimal for TNF-α. This trend was 
seen regardless of which stimulus was used. A23187 was a more potent stimu-
lus for  IL-6 and TNF-α production, whereas Substance P was the best stimulus 
for MCP-1 production  (summarized in figure 2A). Since the IL-13 production 
was low, regardless of the stimulus used, this was not further pursued. Codeine 
did not induce the production of detectable levels of any of the tested cytokines. 
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Figure	2.	The	effect	of	ruxolitinib	on	cytokine	and	chemokine	production	by	HMC1	cells.	
Figure	2.	After	establishing	the	effect	of	A23187,	codeine	and	substance	P	on	the	production	of	
various	cytokines	(A),	experiments	were	performed	with	the	optimal	stimulus	for	each	cytokine.	
Incubation	with	ruxolitinib	lead	to	decreased	production	of	IL-6	(B)	and	TNF-α	(C)	after	stimulation	
with	A23187	for	24	or	6	hours,	respectively.	The	production	of	MCP-1	after	stimulation	with	
substance	P	for	24	hours	was	also	inhibited	(D).	*p<0.05,	and	#p<0.01	as	compared	with	positive	
control.	
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Ruxolitinib effectively inhibited the production of IL-6, TNF-α, and MCP-1 by 
HMC1 cells in a concentration-dependent manner (figure 2B-D). For IL-6 pro-
duction, a statistically significant effect was reached at 500 nM of ruxolitinib 
and higher (p 0.047 for 500 nM compared with positive control). For TNF-α, 
the highest level of ruxolitinib (50 μM) displayed significant inhibition (p 
0.038). MCP-1 production was significantly inhibited by ruxolitinib 5 μM and 
higher (p 0.021). The IC50 for the inhibition of IL-6 production by ruxolitinib 
was 7.6 μM (95% CI 6.0 – 9.7), and the IC50 for the inhibition of TNF-α produc-
tion was 1.3 μM (95% CI 0.2 – 9.1). The IC50 for MCP-1 production was 4.1 μM, 
however with a wide 95% CI (0.4 – 43).
124
Pimozide
To determine the contribution of STAT5 to MC degranulation and cytokine 
production, we investigated the effect of pimozide, a selective STAT5 inhib-
itor. Pimozide partly inhibited substance P- and codeine-induced degran-
ulation of LAD2 cells in a concentration-dependent manner, however the 
obtained decrease in beta-hexosaminidase release was not statistically sig-
nificant (figure 3). Pimozide had a more potent inhibitory effect on cytokine 
production by HMC1 cells. The A23187 induced production of IL-6 and TNF- α 
by HMC1 cells was already significantly reduced at the lowest concentration 
of pimozide of 5 μM (p 0.002 and p 0.029 respectively, figure 4A & B). Similar-
ly, the substance P-induced MCP-1 production was also inhibited, reaching 
statistical significance at a concentration of 20 mM (p 0.002; figure 4C). Of 
note, the spontaneous production of MCP-1 appeared to be relatively high 
in repeated experiments. The IC50 for the inhibition of IL-6 production by 
pimozide was 7.4 μM (95% CI 3.1 – 17.9), the IC50 for TNF-α production by 
pimozide was 8.0 μM (95% CI 3.7 – 17.1). The IC50 for MCP-1 production was 
13.9 μM (95% CI 7.1 –27.2).
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Figure	3.	The	effect	of	pimozide	on	degranulation	of	LAD2	cells.	
Figure	3.	As	measured	by	beta-hexosaminidase	release	assay,	pimozide	partly	inhibits	degranulation	
of	LAD2	in	a	dose-dependent	manner.	This	effect	was	similar	for	stimulation	with	substance	P	5	μM	
(A)	and	codeine	40	μg/ml	(B).	All	bars	are	depicting	the	mean	of	3	repeated	experiments	with	SE.	
	
	
Figure	4.	The	effect	of	pimozide	on	cytokine	and	chemokine	production	by	HMC1	cells.	
	
Figure	4.	Incubation	with	pimozide	lead	to	
decreased	production	of	IL-6	(A)	and	TNF-α	(B)	
after	stimulation	with	A23187	for	24	or	6	
hours,	respectively.	The	production	of	MCP-1	
after	stimulation	with	substance	P	for	24	
hours	was	also	inhibited	(C).	*p<0.05,	and	
**p<0.001	as	compared	with	positive	control.	
All	bars	are	depicting	the	mean	of	3	repeated	
experiments	with	SE.		
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Discussion
Here, we provide evidence that the JAK1/JAK2 inhibitor ruxolitinib can effi-
ciently inhibit MC degranulation as well as the production of cytokines. Since 
substance P and codeine are ligands for G-protein coupled receptors (GPCRs) 
13,59, this work implies a link between the JAK2-STAT5 pathway and GPCRs. 
These stimuli were chosen because it is well-known that codeine can cause 
MC degranulation, as is confirmed by the fact that many patients with mas-
tocytosis experience MC mediator related symptoms after ingestion of co-
deine.211 However, since codeine is an exogenous stimulus, we repeated most 
experiments with substance P and/or A23187. 
In our study, ruxolitinib clearly inhibited MC activity, but its exact intracel-
lular mechanism is not fully elucidated yet. JAK2, and subsequently STAT5, 
are situated downstream of KIT in MC 200, and thereby involved in the prolif-
eration and survival of MC.199 The involvement of the JAK2-STAT5 pathway 
in MC degranulation is less well-described, although there is some evidence 
available. The role of STAT5 in IgE-mediated MC degranulation has been in-
vestigated by several groups, and it is now accepted that STAT5 is activated 
downstream of FcεR1.19,200,212 In line with this, previous work has proven that 
JAK2 is involved in IgE-mediated leukotriene production in mice.213 Our cur-
rent data confirm the role of JAK1 and/or JAK2 in MC degranulation and even 
more so in cytokine and chemokine production. We also found that selective 
inhibition of STAT5 with pimozide inhibited MC activity, although this did not 
reach statistical significance for degranulation.  Nevertheless, our data sup-
port the theory that STAT5 is important for MC activation, although possibly 
in a lesser extent than JAK2. 
Substance P and codeine are ligands to GPCRs. 13,59 Ruxolitinib and pimozide 
both effectively blocked MC activation as induced by these stimuli. This points 
at a role for JAK2-STAT5 signaling in GPCR-mediated MC activation. Associa-
tions between GPCRs and JAK2-STAT5 signaling have been described in other 
hematopoietic cell types, for instance for the C-C motif chemokine receptor 
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5 expressed by T-cells and the platelet activating factor receptor expressed 
by monocytic cells214,215 But to our knowledge, our study is the first to suggest 
an association between GPCRs and a JAK-STAT pathway in MC. The most im-
portant signaling pathway downstream of GPCRs involves phosphoinositide 
3-kinase (PI3K), which is a versatile tyrosine kinase that can integrate signals 
from different receptors.21,216,217 There is some evidence for crosstalk between 
PI3K and STAT5, specifically in neoplastic MC.218,219 Possibly, JAK1/JAK2 inhi-
bition by ruxolitinib ultimately interferes with the crosstalk between PI3K 
and STAT5, although this hypothesis obviously needs further testing. 
Ruxolitinib is a rather specific inhibitor of JAK1 and JAK2, yet at high con-
centrations it is known to inhibit JAK3 as well.220,221 The IC50 of ruxolitinib for 
JAK3 inhibition was reported to be  438 + 243 nM in an in vitro model for 
myeloproliferative neoplasms (MPN), which was ~150-200 times higher than 
the IC50 for JAK1 or JAK2 inhibition.220 The IC50 values for ruxolitinib are much 
higher in MC: they ranged between 1.3 and 10 μM  in our study. These values 
are comparable to a study that investigated the effect of ruxolitinib on murine 
MC.201 Since higher concentrations of ruxolitinib are necessary to inhibit MC 
activation compared with the inhibition of myeloid progrenitor cells, it can-
not be formally excluded that the observed effect of ruxolitinib on MC also 
involves inhibition of JAK3 activity. 
Regardless of any (exogenous) stimuli, neoplastic MC constitutively exhibit 
high levels of phosphorylated STAT5.18 Additional evidence for the continu-
ous auto-activation of MC in patients with mastocytosis comes from the ele-
vated levels of MC mediators at random measurements in blood and urine of 
these patients.15,196,197 The inhibition of the release and/or production of var-
ious MC mediators can potentially reduce debilitating symptoms including 
pruritus, flushing, diarrhea and anaphylaxis, thereby improving the quality 
of life of these patients. Excessive MC activity also plays a role in many other 
diseases, including mast cell activation syndrome, chronic spontaneous urti-
caria, allergies and fibrotic disease. 222,223 The reduction of MC mediator levels 
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via the inhibition of JAK-STAT signaling might therefore be of therapeutic in-
terest for these diseases as well. 
Ruxolitinib is currently only approved for the treatment of the classical my-
eloproliferative neoplasms (MPN). In patients with MPN, treatment with 
ruxolitinib leads to a reduction of daily symptoms like abdominal discom-
fort, pruritus and fatigue.224,225 In line with our findings, the COMFORT-II tri-
al showed a decrease in the levels of IL6, TNF-α and VEGF in patients with 
MPN that were treated with ruxolitinib.226 Given the increased number and 
activity of MC in bone marrow of patients with MPN it was hypothesized that 
ruxolitinib exerted its beneficial effect in MPN by inhibition of MC mediator 
release/production.227,228 This hypothesis is corroborated by our current study 
that indeed demonstrates an overall inhibiting effect of ruxolitinib on MC ac-
tivity. In line with this , two recent case studies showed a convincing decrease 
of MC mediator related symptoms in systemic mastocytosis upon ruxolitinib 
treatment 203,204 
Based on our data, combined with other available (pre-)clinical evidence as dis-
cussed above, JAK1/JAK2-STAT5 inhibition might represent a promising new 
therapeutic strategy for patients with mastocytosis and many other MC media-
tor related diseases. Ultimately, randomized clinical trials are necessary. 
Conclusion
We have demonstrated that the JAK1/2 inhibitor ruxolitinib effectively atten-
uates degranulation and cytokine production by human MC. The fact that 
pimozide also partly inhibited degranulation, and cytokine production sub-
stantially,  suggests a role for STAT5 activation in MC activation. JAK2-STAT5 
inhibition thus emerges as a new, highly effective, method to lower MC me-
diator levels. Ruxolitinib, and JAK-STAT inhibition in general, are interesting 
therapeutic options to reduce debilitating symptoms in mastocytosis and a 
wide range of other MC mediator-related diseases such as mast cell activation 
syndrome, chronic spontaneous urticaria, and even fibrotic disease.
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Supplementary	data	belonging	to:	
The	JAK1/JAK2-	inhibitor	ruxolitinib	inhibits	mast	cell	degranulation	and	cytokine	release.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 	
Figure	S2.	Titration	of	codeine	concentration	for	detection	of	CD63	expression	by	flow	cytometry.	
	
CD	63	expression	
Figure	 S1.	 Titration	 of	 the	 optimal	 concentration	 of	 the	 used	 stimuli	 for	 β-
hexosaminidase	assay	using	LAD2	cells.	
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Figure	S3.	Substance	controls	for	measurement	of	CD63	expression	by	flow	cytometry	
(A)	and	for	measurement	of	beta-hexosaminidase	assay	(B).	For	the	ruxolitinib	control,	
cells	were	incubated	with	ruxolitinib	50	mM	for	30	minutes,	after	which	the	beta-
hexosaminidase	release	was	measured	as	described.	For	the	DMSO	control,	cells	were	
incubated	in	PBS	supplemented	with	DMSO	5%	and	subsequently	stimulated	with	
codeine	40	mg/ml	for	15	minutes.	
A	
B	
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	 	Figure	S4.	Cytotoxicity	of	ruxolitinib	was	ruled	out	by	LDH	assay.	
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5.2 Increased group 2 innate lymphoid cells in peripheral 
blood of adults with mastocytosis.
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Abstract
Background: Systemic mastocytosis is a hematological disease in which ab-
errant mast cells accumulate due to gain-of-function mutations in the KIT 
receptor. Group 2 innate lymphoid cells (ILC2s) are effector cells of type 2 
immune responses that also express KIT and co-localize with mast cells at 
barrier tissue sites. In mouse models, mast cell-ILC2 crosstalk can drive local 
inflammation. However, a possible role for ILC2s in the pathophysiology of 
mastocytosis remains unexplored. Here, we characterized circulating ILC2s 
in a clinically diverse cohort of mastocytosis patients. 
Methods: We included 21 adults with systemic mastocytosis and 18 healthy 
controls. Peripheral blood ILC2 abundance and phenotype were analysed by 
flow cytometry and correlated to clinical characteristics, including the pres-
ence of the D816V KIT mutation.
Results: ILC2 levels were significantly higher in D816V+ mastocytosis patients 
compared to D816V- patients or healthy controls. We observed increased 
proportions of KIT+ ILC2s among patients with mastocytosis, regardless of 
D816V status. Patients with skin involvement and itch showed the highest lev-
els of ILC2s, which was independent from atopy or serum tryptase levels. 
Allele-specific quantitative PCR showed that the vast majority of ILC2s did not 
carry the D816V mutation. 
Discussion: Our findings suggest a role for ILC2s and pathogenic ILC2-mast 
cell crosstalk in mastocytosis. We hypothesize that a high cutaneous D816V+ 
mast cell burden alters the skin microenvironment to induce chronic local 
ILC2 activation and their dissemination into the circulation. Activated ILC2s 
could contribute to skin symptoms by producing inflammatory mediators 
and by further augmenting mast cell mediator release. 
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Introduction
Mastocytosis is a rare myeloproliferative disease in which aberrant mast cells 
accumulate. Most adult patients have systemic mastocytosis, which is defined 
by the involvement of at least one extracutaneous organ, most often the bone 
marrow46. In 80-90% of patients with systemic mastocytosis, a somatic D816V 
mutation is detected in the KIT receptor tyrosine kinase. Under normal con-
ditions, KIT requires binding of its ligand, stem cell factor (SCF), to induce 
mast cell proliferation and survival4. The D816V mutation leads to constitutive 
ligand-independent activation of KIT signalling, resulting in uncontrolled mast 
cell proliferation4. Patients with systemic mastocytosis can suffer from a wide 
variety of symptoms, including anaphylaxis, osteoporosis, itching, flushing, 
dyspepsia, diarrhea, fatigue, and psychological symptoms, which can greatly 
reduce quality of life229. Many of these symptoms are presumably caused by in-
creased levels of mediators released by mast cells such as histamine, tryptase, 
eicosanoids and pro-inflammatory cytokines. However, it remains unclear 
why the type and severity of symptoms can vary so greatly between individu-
al patients. In mastocytosis patients, baseline serum tryptase and urine hista-
mine levels do not correlate with individual symptoms15, suggesting that other 
cell types might contribute to the pathophysiology of mastocytosis, possibly 
through their activation by mast cell signals.
Innate lymphoid cells (ILC) orchestrate immune responses at mucosal surfac-
es in an antigen-independent manner. ILCs can be grouped into various sub-
types depending on the inflammatory cytokines they produce, including group 
2 ILCs (ILC2s) that play a central role in type 2 immunity and in allergic inflam-
matory disease230. ILC2s and mast cells both reside at barrier sites of the human 
body, such as the skin, gut and airways. While ILC2s are largely tissue-resident, 
they can also be detected in the circulation. Interestingly, like mast cells, a sub-
population of ILC2s expresses KIT, and SCF can augment ILC2 activation231. In 
mice, mast cell-ILC2 crosstalk is important to clear helminth infections but 
also to drive local inflammation232. However, whether such crosstalk is also rel-
evant in the context of mastocytosis remains to be addressed. 
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Methods
Subjects
Adult patients who fulfilled the WHO criteria33 for indolent systemic mas-
tocytosis were recruited from the Erasmus MC Mastocytosis Center outpa-
tient clinic. Healthy controls were recruited by the Franciscus Gasthuis & 
Vlietland hospital in Rotterdam. This study was performed according to the 
latest Helsinki guidelines. All subjects provided a written informed con-
sent and all experimental procedures were approved by the Medical Ethical 
Committee of the Erasmus MC in Rotterdam, the Netherlands. 
Isolation of peripheral blood mononuclear cells and flow cytometry
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood 
by density gradient centrifugation using Ficoll-PaqueTM PLUS (GE Health-
care Life Sciences). ILC2s, ILCPs and CD4+ T cells were analysed using mul-
ticolour flow cytometry. See Supplementary Text for a detailed description. 
Real-time quantitative D816V mutation detection PCR
Genomic DNA was isolated from sorted ILC2 and ILCP fractions. The pres-
ence of KIT D816V mutant alleles was evaluated using a previously de-
scribed233 routine diagnostics real-time quantitative PCR assay. See Sup-
plementary Text for additional details.
Tryptase/IgE measurements and immunophenotyping of neoplastic mast 
cells in bone marrow
Serum tryptase and IgE levels were measured by fluoroenzymeimmu-
noassay (FEIA) on a Phadia250 system (Thermo Fisher Scientific) using the 
ImmunoCAP Tryptase and Total IgE assays according to the manufacturer’s 
instructions. Flow cytometry immunophenotyping of mast cells from bone 
marrow aspirate is described in the Supplementary Text.
Statistical analysis
Depending on the type of variables, we used nonparametric Mann-Whitney 
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U tests, chi square tests and Spearman correlation analyses to determine 
statistical significance. IBM SPSS Statistics (25) and Prism Graphpad soft-
ware (8.0.2) were used for statistical analyses.
Results and discussion
Twenty-one patients with indolent systemic mastocytosis and 18 healthy con-
trols were included in our study. Sixteen had a detectable D816V KIT mutation 
in bone marrow samples. Patient characteristics are summarized in Table 
1. The percentage of ILC2s was significantly increased in peripheral blood 
of mastocytosis patients compared to healthy controls, but only in patients 
carrying the D816V mutation (Fig.1A-B). Although the abundance of circu-
lating KIT+ ILC precursors (ILCPs) was similar across all groups (Fig.1C), a 
larger proportion of the circulating ILC2 compartment was KIT+ in mastocy-
tosis patients, irrespective of D816V status (Fig.1D, Supplementary Fig.1A). 
Chemokine (CCR4, CCR6) and co-stimulatory (ICOS) receptor expression on 
ILC2s was similar between groups (Supplementary Fig.1B). D816V+ patients 
showed significantly higher serum tryptase levels (p=0.004) and a trend to-
wards higher neoplastic bone marrow mast cell burden (p=0.136) compared 
to D816V- patients (Table 1). However, we did not detect a significant correla-
tion between blood ILC2 levels and bone marrow neoplastic mast cell burden 
(Spearman’s ρ=-0.21, p=0.435) or serum tryptase levels (Spearman’s ρ=-0.073, 
p=0.752) (Supplementary Fig.2A-B).
While total CD4+ T cell levels did not differ, proportions of CRTH2+ T helper-2 
(Th2) cells, the functional counterparts of ILC2s belonging to the adaptive 
immune system230, were also significantly increased in peripheral blood of 
mastocytosis patients compared to healthy controls (Fig.1E, Supplementary 
Fig.3A-B). However, we found no significant correlation between the levels of 
CRTH2+ Th2 cells and ILC2s (Spearman’s ρ=0.13, p=0.58). 
We next explored associations between circulating ILC2 populations and 
clinical symptoms in mastocytosis patients. Patients with maculopapular cu-
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taneous mastocytosis (MPCM) showed elevated levels of ILC2s as compared 
to healthy controls and patients without MPCM (Fig.2A). This is in line with 
the high D816V prevalence (88.2%) in the MPCM+ group and only a single 
D816V+ patient without MPCM. Additional analysis using clinical data from 
our complete cohort of 263 adults with mastocytosis confirmed increased 
skin involvement in D816V+ patients as compared to D816V- patients: 73% 
versus 42%, respectively (p=0.002, chi-square test). Compared to healthy con-
trols, D816V+ patients who reported itch had higher levels of ILC2s,  irrespec-
tive of their KIT expression status (Fig.2B, Supplementary Fig.4A-B). 
138
CHAPTER 5
Table 1. Baseline characteristics of patients and controls.
	
	
	
	 Healthy	
controls	
(N=18)	
Mastocytosis	
patients	
(N=21)	
D816V+	
patients	
(N=16)	
D816V-	
Patients	
(N=5)	
P-value	
(D816V+	vs	
D816V-)	
Sex	(male/female)	 7/11	 10/11	 7/9	 3/2	 ns	
Age	(years)	 37.6	(10.4)*#	 53.0	(15.4)	 55.2	(13.8)	 46	(5.3)	 ns	
Serum	tryptase	(µg/L)	 N.A.	 51.3	(72.2)	 62.9	(78.7)	
	
11.8	(34.6)	 0.004	
Neoplastic	MC	burden	
BM	(%)	¶	
N.A.	 0.12	(0.13)	 0.14	(0.10)	 0.04	(0.03)	 ns	
Total	IgE	(U/ml)	 N.A.	 26	(31)	 29	(33)	 13	(15)	 ns	
Maculopapular	
cutaneous	
mastocytosis	(%)	
N.A.	 81.0%	 93.8%	 40%	 0.008	
Itch	(%)	 N.A.	 66.6%	 68.8%	 60%	 ns	
Atopy	(%)	**	 33.3%	 19.0%	 31.25%	 0%	 ns	
Anaphylaxis	(%)	 N.A.	 23.8%	 25%	 20%	 ns	
Flushing	(%)	 N.A.	 42.9%	 43.8%	 40%	 ns	
Osteoporosis	(%)	 N.A.	 42.9%	 50%	
	
20%	 ns	
Diarrhoea	(%)	 N.A.	 38.1%	 43.8%	 20%	 ns	
N.A.,	not	applicable	;	ns,	not	significant	;	MC,	mast	cell	;	BM,	bone	marrow.		
*	Continuous	variables	shown	as:	mean	(standard	deviation)	
**	Atopy	in	mastocytosis	patients	was	defined	by	clinical	symptoms	of	asthma,	rhinoconjunctivitis,	and/or	
proven	sensitization	to	pollen	or	house	dust	mite	by	skin	prick	test	or	specific	IgE	measurement.	For	
healthy	controls,	atopy	was	defined	as	a	history	of	allergic	rhinoconjunctivitis	and/or	food	allergy.	
#	Controls	were	significantly	younger	than	mastocytosis	patients	(p=0.001)	
¶	Neoplastic	mast	cell	burden	in	the	bone	marrow	was	defined	by	aberrant	expression	of	CD2	and/or	CD25	
as	measured	by	flow	cytometry.		
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Figure 1. ILC2s are increased in peripheral blood of D816V+ mastocytosis pa-
tients. (A) Flow cytometry gating strategy for ILC precursors (ILCP), KIT+ ILC2s and 
KIT- ILC2s. (B) Proportions of total ILC2s (left) and of KIT+ ILC2s (right) in peripheral 
blood of healthy controls (HC), D816V negative (D816V-) and D816V positive (D816V+) 
mastocytosis patients. (C) Proportions of ILCPs in peripheral blood of HC, D816V- and 
D816V+ patients. (D) KIT+ ILC2 proportions of total ILC2s in peripheral blood of HC 
and mastocytosis (MC) patients. D816V- patients are indicated by yellow symbols; 
D816V+ patients by red symbols. (E) Proportions of CRTH2+CD4+ T cells in periph-
eral blood of HC and MC patients. D816V- patients are indicated by yellow symbols; 
D816V+ patients by red symbols. Data are shown as symbols for individual patients/
controls, together with bar graphs for mean values +SEM. Comparisons between 
groups were evaluated using a Mann-Whitney U test; p<0.05 was considered statisti-
cally significant.
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Figure 2. ILC2 levels and phenotype correlate with skin symptoms and atopy. (A) To-
tal (left) and KIT+ (right) ILC2 proportions in all mastocytosis patients with or without 
maculopapular cutaneous mastocytosis (MPCM). (B) Total (left) and KIT+ (right) ILC2 
proportions in D816V+ mastocytosis patients with or without itch. (C) Total ILC2 pro-
portions in D816V+ mastocytosis patients (MC) and healthy control (HC) subjects with 
or without atopy. (D) Scatter plot showing an absence of correlation between total IgE 
levels (U/mL) and ILC2 abundance (Spearman’s ρ=0.007, p=0.98). Data are shown as 
symbols for individual patients/controls, with bar graphs in panels A-C showing mean 
values +SEM. Comparisons between groups were evaluated using a Mann-Whitney U 
test; p<0.05 was considered statistically significant.
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Of note, D816V+ patients with or without atopy showed similar levels of ILC2s 
and we found no significant correlation between serum IgE levels and ILC2 
abundance (Spearman’s ρ=0.007, p=0.98) (Fig.2C-D). Furthermore, ILC2 
abundance and KIT expression were not associated with anaphylaxis, diar-
rhoea, osteoporosis or flushing, and we found no significant correlations 
with D816V allelic burden in peripheral blood (p>0.05). CRTH2+ Th2 cell levels 
were not specifically increased in patients with the D816V mutation, MPCM 
or itch (p>0.05), emphasizing the specificity of the association between ILC2s 
and D816V+ mastocytosis with skin involvement.
To assess whether the altered ILC2 compartment in mastocytosis patients is 
linked to the occurrence of the D816V KIT mutation in the ILC lineage, we 
performed allele-specific quantitative PCR on isolated genomic DNA from 
ILC2s and ILCPs. Despite a ~1-2% mutant allele detection sensitivity (see Sup-
plementary Text), we could not detect D816V allelic DNA in ILC2s or ILCPs 
(Supplementary Fig.5A-B), indicating that the D816V mutation is absent or 
very rare in circulating ILCs. 
Here we describe, to the best of our knowledge, the first explorative investi-
gation into the abundance and phenotype of ILC2s in patients with mastocy-
tosis. We found that patients with the activating D816V KIT mutation in mast 
cells showed elevated frequencies of circulating ILC2s compared to healthy 
controls or D816V- patients. The increased circulating ILC2 levels in D816V+ 
patients were linked to the presence of MPCM and itch. Together, our ob-
servations reveal positive associations between ILC2 frequencies, the D816V 
mutation and specifically skin symptoms. 
Since we could not detect the D816V mutation in peripheral blood ILCs, the 
increased ILC2 abundance in the circulation of mastocytosis patients with 
cutaneous symptoms is likely a consequence of excessive mast cell activity 
in the bone marrow or skin rather than a cell-intrinsic ILC2 defect. Howev-
er, increased bone marrow output of ILC2s appears an unlikely scenario, as 
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circulating ILC2 levels did not correlate with bone marrow mast cell burden 
or serum tryptase levels. Hence, we postulate that constitutive mediator re-
lease by D816V+ skin mast cells, including inflammatory molecules such as 
IL-1β, TGFβand IL-33-activating proteases (e.g. chymase and tryptase)8, could 
activate skin-resident ILC2s and create a favourable microenvironment for 
recruiting circulating ILC2s (Fig.3). Moreover, mast cell-derived prostaglan-
din D2 has been previously shown to stimulate ILC2 migration via CRTH2 234. 
Furthermore, soluble SCF levels are higher in lesional skin of mastocytosis 
patients235, potentially increasing the local SCF availability for KIT+ ILC2s. 
Chronic ILC2 activation could in turn contribute to a cutaneous cytokine mi-
lieu that promotes inflammation, mast cell mediator release and skin symp-
toms - similar to mechanisms suggested for atopic dermatitis31. Prolonged 
stimulation of tissue ILC2s can trigger their systemic dissemination236, which 
can explain the increased ILC2 presence in the circulation in D816V+ mas-
tocytosis. Interestingly, KIT+ ILC2s express the skin-homing chemokine re-
ceptor CCR10231,237, implying that this ILC2 subset is capable of efficiently mi-
grating towards the skin (Fig.3). In line with enhanced skin migration of KIT+ 
ILC2s in mastocytosis, we observed that patients with frequent itch showed 
a reduced relative proportion of KIT+ cells within their circulating ILC2 com-
partment compared to patients without itch.
In summary, we conclude that circulating ILC2s are elevated in D816V+ mas-
tocytosis and are associated with the presence of MPCM and itch, providing a 
strong rationale for performing in-depth studies into the role of ILC2s in the 
pathophysiology of mastocytosis. 
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Figure 3. Proposed model for pathological ILC2-mast cell interplay in the skin of 
D816V+ mastocytosis. Constitutive mediator release by D816V+ skin mast cells, includ-
ing inflammatory molecules such as IL-1β, TGFβ and IL-33-activating proteases (e.g. 
chymase and tryptase) activate skin-resident ILC2s and create a favourable microen-
vironment for recruiting circulating ILC2s (i.e. via CCR10). Elevated soluble SCF levels 
further augment KIT+ ILC2 activation. Chronic ILC2 activation in turn contributes to 
an inflammatory cutaneous cytokine milieu (e.g. via production of IL-9) that further 
promotes mast cell activity and skin symptoms but also triggers ILC2 dissemination 
into the circulation. Solid arrows denote activation via indicated signaling molecules; 
dashed arrow indicate cleavage of IL-33 into mature active IL-33; striped arrows depict 
cellular migration. 
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Supplementary data belonging to:
Increased group 2 innate lymphoid cells in peripheral blood 
of adults with mastocytosis.
Methods
Flowcytometry analysis and fluorescence assisted cell sorting
PBMCs were subjected to extracellular staining with antibodies for 60 min-
utes at 4°C, and for 15 minutes at 4°C with LIVE/DEAD™ Fixable Green Dead 
Cell Stain Kit (Thermofisher). Stainings were performed with five to ten 
million PBMCs in order to obtain sufficient number of ILCs. The follow-
ing antibodies to human proteins were used (including manufacturer, di-
lutions used and clone numbers). From BioLegend: Peridinin chlorophyll 
protein–cyanine 5.5 (PerCP-Cy5.5)-conjugated anti-CCR4 (1:40, L291H4), 
Briliant violet (BV)421-conjugated anti-CD117 (1:20, 104D2), Fluoresce-
in isothiocyanate (FITC)-conjugated anti-CD94 (1:20, DX22), Alexa Fluor 
(AF)700-conjugated anti-NKp46 (1:20,9E2). From Thermofischer: Allophy-
cocyanin (APC)-conjugated anti-CD127 (1:20, eBioRDR5), FITC-conjugated 
anti-CD3 (1:100, UCHT1), anti-CD14 (1:200, 61D3), PE-indotricarbocyanine 
(Cy)7-conjugated Streptavidin (1:1000). From Miltenyi Biotec: Biotinylat-
ed anti-CRTH2 (1:50, BM16). From Beckman Dickinson: FITC-conjugated 
anti-CD19 (1:300, HIB19), anti-CD16 (1:400, 3G8), anti-TCRgd (1:20, B1), 
Phycoerythrin (PE)-conjugated anti-CCR6 (1:20, 11A9), BV650-conjugat-
ed anti-ICOS (1:20, DX29), BV605-conjugated anti-CD56 (1:50, NCAM16.2), 
BV785-conjugated anti-CD4 (1:30, SK3). For flowcytometry analysis, data 
were acquired on an LSR II or a FACSymphony flow cytometer using FACS 
Diva software 6.1 (BD Biosciences) and analyzed using FlowJo 10 (BD Bio-
sciences). We sorted ~2000 ILC2s (Lineage-CD127+CRTH2+) or ILCPs (Line-
age-CD127+CD117+CRTH2-) in 1.5 ml eppendorf tubes rinsed with 10% fetal 
calf serum for real-time quantitative D816V mutation detection PCR using a 
FACSAria (BD Biosciences).
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Real-time quantitative D816V mutation detection PCR
Genomic DNA was isolated from sorted ILC2 and ILCP fractions (with a 
FACSAria, see above) using the DNeasy Blood & Tissue Kit (Qiagen) according 
to the manufacturer’s instructions. The presence of KIT D816V mutant alleles 
was evaluated using a previously described233 (Electronic routine diagnostics 
real-time quantitative PCR assay that uses wild-type and mutation-specific 
primer/probe sets. The D816V mutation was deemed undetectable if cycle 
threshold (CT) values were >38. DNA from HMC1.2 cells were used as a con-
trol for the D816V mutant allele and DNA from peripheral blood buffy coats 
as control for the wild type allele. The quantitative range of the assay was 
controlled for by including a standardized serial dilution of HMC1.2 or pe-
ripheral blood buffy coat genomic DNA in the same run. Accurate detection 
of both alleles was observed down to the 0.01% dilution (as indicated by the 
positive control bars in Supplementary Fig.5).
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Tryptase and IgE measurements
Serum tryptase was measured by FEIA technology using the Phadia250 sys-
tem (Thermo Fisher Scientific, Uppsala, Sweden) according to the manufac-
turer’s instructions. Total serum IgE (U/mL) was also measured by fluoroen-
zymeimmunoassay (FEIA) on the Phadia 250 system using the ImmunoCAPTM 
Total IgE test (Thermo Fisher Scientific, Uppsala, Sweden), according to man-
ufacturer’s instructions.
Immunophenotyping of neoplastic mast cells in bone marrow
Flow cytometry immunophenotyping of mast cells from bone marrow aspi-
rate is performed routinely in our lab for diagnostic purposes, and precise 
methods have been previously described in great detail 238. Briefly, bone mar-
row aspirate is collected in heparin tubes and processed within 24 hours. 
Erythrocytes are lysed using ammonium chloride after which leucocytes are 
washed with PBS/BSA and resuspended at 6x10^7 cells/mL. Fifty µL of this 
suspension is stained (10 minutes at room temperature) using the following 
antibodies: CD117-PE (104D2), CD45-PerCP (2D1), CD25-APC (2A3), CD117-PE-
Cy7 (104D2; custom conjugated), CD34-APC-Cy7 (8G12; custom conjugated) 
(all from BD Biosciences); CD2-FITC (T11), CD2-PE (T11), CD33-PE (My9) (all 
from Beckman Coulter); and CD117-APC (104D2; Dako Cytomation, Glostrup, 
Denmark). Subsequently, cells are washed with PBS/BSA and resuspended in 
FACSFlow Solution (BD Biosciences). Data are acquired using a FACSCalibur 
or FACS Canto B. Of note, 1x10^6 cells are recorded per tube. Data are ana-
lyzed using FACS Diva software. Mast cells are gated based on strong CD117 
expression and subsequent gating is performed in the six-colour analysis us-
ing CD33 positivity and CD34 negativity. Neoplastic mast cells are CD2 and/
or CD25 positive.  
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Immunophenotyping	of	neoplastic	mast	cells	in	bone	marrow	
Flow	cytometry	immunophenotyping	of	mast	cells	from	bone	marrow	aspirate	is	performed	routinely	in	
our	lab	for	diagnostic	purposes,	and	precise	methods	have	been	previously	described	in	great	detail	238.	
Briefly,	bone	marrow	aspirate	is	collected	in	heparin	tubes	and	processed	within	24	hours.	Erythrocytes	
are	lysed	using	ammonium	chloride	after	which	leucocytes	are	washed	with	PBS/BSA	and	resuspended	
at	6x10^7	cells/mL.	Fifty	µL	of	 this	 suspension	 is	 stained	 (10	minutes	at	 room	temperature)	using	 the	
following	 antibodies:	 CD117-PE	 (104D2),	 CD45-PerCP	 (2D1),	 CD25-APC	 (2A3),	 CD117-PE-Cy7	 (104D2;	
custom	 conjugated),	 CD34-APC-Cy7	 (8G12;	 custom	 conjugated)	 (all	 from	 BD	 Biosciences);	 CD2-FITC	
(T11),	 CD2-PE	 (T11),	 CD33-PE	 (My9)	 (all	 from	 Beckman	 Coulter);	 and	 CD117-APC	 (104D2;	 Dako	
Cytomation,	 Glostrup,	 Denmark).	 Subsequently,	 cells	 are	 washed	 with	 PBS/BSA	 and	 resuspended	 in	
FACSFlow	Solution	 (BD	Biosciences).	Data	are	acquired	using	a	FACSCalibur	or	FACS	Canto	B.	Of	note,	
1x10^6	cells	are	 recorded	per	 tube.	Data	are	analyzed	using	FACS	Diva	software.	Mast	cells	are	gated	
based	on	strong	CD117	expression	and	subsequent	gating	 is	performed	in	the	six-colour	analysis	using	
CD33	positivity	and	CD34	negativity.	Neoplastic	mast	cells	are	CD2	and/or	CD25	positive.			
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	 	 Supplementary	 Figure	 1.	 Flowcytometry	 analysis	 of	 ILC2s	 in	peripheral	 blood	 of	 mastocytosis	 patients.	 (A)	 Proportions	 of	
KIT+	 ILC2s	 in	 peripheral	 blood	 of	 healthy	 controls	 (HC),	 D816V-	
and	D816V+	patients.	(B)	Proportions	of	CCR4+,	CCR6+	and	ICOS+	
ILC2s	 in	 peripheral	 blood	 of	 healthy	 controls	 (HC),	 D816V-	 and	
D816V+	 mastocytosis	 patients.	 Data	 are	 shown	 as	 symbols	 for	
individual	 patients/controls,	 together	with	 bar	 graphs	 for	mean	
values	+SEM.	Comparisons	between	groups	were	evaluated	using	
a	 Mann-Whitney	 U	 test;	 p<0.05	 was	 considered	 statistically	
significant.	
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Supplementary Figure 2. Peripheral blood ILC2s levels do not correlate with bone 
marrow mast cell burden or serum tryptase levels. Scatter plots showing an absence 
of correlation between ILC2 abundance and neoplastic bone marrow mast cell burden 
(panel A; spearman ρ=0.21, p=0.435) or serum tryptase levels (panel B; spearman ρ=-
0.073, p=0.752). Data are shown as symbols for individual patients/controls.
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Supplementary	Figure	3.	Flowcytometry	analysis	of	CD4+	T	cells	
in	 peripheral	 blood	 of	 mastocytosis	 patients.	 (A)	 	 Flow	
cytometry	gating	strategy	for	total	CD4+	and	CRTH2+CD4+	T	cells.	
(B)	 Proportions	 of	 CD4+	 T	 cells	 in	 peripheral	 blood	 of	 healthy	
controls	 (HC),	D816V-	 and	 D816V+	mastocytosis	 patients.	Data	
are	shown	as	 symbols	 for	 individual	patients/controls,	 together	
with	 bar	 graphs	 for	mean	 values	 +SEM.	 Comparisons	 between	
groups	 were	 evaluated	 using	 a	 Mann-Whitney	 U	 test;	 p<0.05	
was	considered	statistically	significant.	
	
Supplementary	Figure	4.	Associations	
between	 itch	 and	 circulating	 ILC2	
levels	 in	 mastocytosis	 patients.	 (A)	
Total	 (left)	 and	 KIT+	 (right)	 ILC2	
proportions	 in	 healthy	 controls	 (HC)	
all	 mastocytosis	 patients	 with	 or	
without	frequent	itch.	(B)	KIT+	and	KIT-	
ILC2	 levels	 in	HC	and	all	mastocytosis	
patients	 with	 or	 without	 frequent	
itch.	 D816V	 mutation	 status	 is	
indicated	 for	 each	 individual	 patient	
(blue:	 D816V+,	 yellow:	 D816V-).	 Data	
are	 shown	 as	 symbols	 for	 individual	
patients/controls,	 together	 with	 bar	
graphs	 for	 mean	 values	 +SEM.	
Comparisons	 between	 groups	 were	
evaluated	 using	 a	 Mann-Whitney	 U	
test;	 p<0.05	 was	 considered	
statistically	significant.	
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Supplementary Figure 5. Failure to detect D816V allelic DNA in genomic DNA iso-
lated from circulating ILC2s or ILCPs. Shown are cycle threshold (Ct) values from 
diagnostic quantitative PCR assays for the wildtype and D816V KIT alleles on genomic 
DNA isolated from ~2000 sorted ILCPs (A) and ILC2s (B) of six mastocytosis patients 
with detectable D816V KIT alleles in bone marrow samples. Serially diluted DNA from 
HMC1.2 cells was used as a positive control for the D816V mutant allele; DNA from 
peripheral blood buffy coats was used as control for the wild type allele. Internal con-
trols (‘pos. ctrl’) for both PCR assays (10% and 0.01% dilutions) are indicated in the fig-
ure. The D816V mutation was deemed undetectable (‘ND’) if Ct values were >38. Com-
bining the number of input cells, the succesfull amplification of the 0.01% dilution 
control and the ~8 Ct remaining detection range, this experimental setup translates to 
a ~1%-2% mutant allele detection sensitivity.
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6.1 Discussion and future perspectives
Mastocytosis is an elusive disease that has many faces. Consequently, devel-
opments and progress in all aspects of clinical care are evolving rather slowly. 
In almost every introduction of a paper about  mastocytosis, it is stated that 
it is a rare disease. The prevalence of indolent systemic mastocytosis (ISM) 
was estimated to be 13:100,000 in The Netherlands in 2013 which is actually 
not that low 38. Although different definitions are used internationally, the 
official definition of a rare disease in the European Union is a prevalence of < 
5:10,000 239. Of note, the estimated prevalence of 13:100,000 only encompass-
es ISM and the total prevalence of all subtypes of mastocytosis among all ages 
must be higher. Although still a rare disease, its rarity cannot be used as an 
reason to base the clinical care largely on expert opinion. In 2019, 52 publi-
cations have been added to the Pubmed database that listed the major Mesh 
term ‘mastocytosis’, were written in English and involved human subjects. 
Only fifteen of these (28.8%) were original studies, the rest were case reports, 
non-systematic reviews or expert opinion papers. In this thesis, we have tried 
to find scientific grounds for certain aspects of the common care for masto-
cytosis. Still, many uncertainties concerning the pathophysiology as well as 
clinical aspects  remain.
Pathophysiological considerations: more than a mast cell disease
Mastocytosis is characterized by an increased amount of phenotypically ab-
errant mast cells. It seems logical to attribute most symptoms and complica-
tions of this disease to the consequences of increased mast cell mediators, 
and mast cell invasion of organs. However, mast cells are in constant inter-
action with their direct environment 3,26. It could therefore by expected that 
other parts of the immune system and/or adjacent non-immune cells are in-
fluenced in case of mastocytosis. Since ILC2s are important in type 2 immu-
nity, are present in the same sites as mast cells, and can express KIT in their 
mature form 230,231, we considered this an interesting cell type to investigate in 
mastocytosis. We indeed found that the relative number of ILC2s in periph-
eral blood was increased in those patients with ISM that harbor the D816V 
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mutation in KIT (Chapter 5). Since our study was a first exploratory attempt, 
we could merely hypothesize on the pathophysiological mechanisms behind 
the demonstrated increase in ILC2s. Given the association of ILC2 abundance 
with skin involvement and D816V mutation, it appears that the neoplastic 
mast cell population in the skin induces changes in ILC2 homeostasis. Mast 
cells can produce many substances that activate ILC2s and have been demon-
strated to be essential to enable ILC2 activation in helminth infection 232. Vice 
versa, ILC2 activation leads to skin inflammation, providing activating signals 
to mast cells 31. However, the increase in ILC2s is more likely to be a result of 
changes due to mastocytosis than a cause of mastocytosis-related symptoms, 
since the number of ILC2s did not correlate with other symptoms than skin 
involvement in our study. 
A remarkable additional finding in the study in chapter 5.2 was the significant 
association between the D816V mutation and skin involvement in patients 
with SM: 93.8% of D816V+ patients had MPCM versus 40% of D816V- patients. 
This association has not been published before as a specific finding but might 
provide insight in the pathophysiology of mastocytosis. Hypothetically, 
D816V+ mast cells are more likely to migrate to the skin than D816V- mast 
cells. Another explanation might lie in the fact that D816V+ mast cells do not 
need SCF to survive, leading to increased availability of SCF to other dermal 
cells. SCF is naturally present in the skin, where it is produced by keratino-
cytes and fibroblasts 240. It was already demonstrated in the 90’s that the levels 
of cell-free SCF are increased in the skin of patients with mastocytosis 241. 
Consequently, the proliferation and/or activation of dermal cells that express 
KIT could  be enhanced in mastocytosis, altogether leading to a clinical pic-
ture of MPCM. Next to ILC2s, melanocytes also express KIT 242. In one study 
in mice, increased availability of keratinocyte-derived SCF led to epidermal 
melanocytosis 243. Thereby, melanocytes might be responsible for the hyper-
pigmentation that is seen in MPCM 244. Interestingly, the prevalence of malig-
nant melanoma appears to be increased among patients with systemic masto-
cytosis. One Danish study in fact found a hazard ratio of 7.5 compared with 
154
CHAPTER 6
the general population 179. The demonstrated increase in both KIT-bearing 
cell types ILC2s and melanocytes suggests that the altered skin environment 
in (D816V+) mastocytosis has functional consequences for various other cell 
types than only mast cells. These, so far  hypothetical, mechanisms provide a 
rationale for research of more cell types than only mast cells in mastocytosis.
Diagnosis
As with every rare disease, an important issue is the lack of awareness among 
physicians who do not encounter patients with mastocytosis regularly. This 
led to a significant delay in diagnosis of over 8 years when calculated in 2015 
(Chapter 2) 102,103. Unfortunately, the mean time to diagnosis from the 63 pa-
tients in our database who have been diagnosed with mastocytosis between 
January 1st 2016 and July 1st 2020 is still 9.2 years (standard deviation 9.2). This 
underlines the task still ahead of us to better inform patients and physicians 
about mastocytosis. Due to the delay in diagnosis, patients suffer from debili-
tating symptoms which are potentially avoidable, and they are refrained from 
preventive measures against anaphylaxis and osteoporosis. 
The diagnostic work-up also requires a certain level of expertise. Serum 
tryptase levels are often used as a screening tool. Yet we have demonstrated 
in this thesis that serum tryptase levels are not sufficiently reliable to rule out 
systemic mastocytosis in all adults (Chapter 3.1) 245. This can be confusing 
since the WHO set a cut-off for the serum tryptase level of 20 μg/L as a minor 
criterion for the diagnosis of SM 33. This cut-off value is seemingly arbitrary, 
and was never supported by published research. Another paper on this topic 
also questioned the reliability of a cut-off level of 20 μg/L, although they did 
not find any systemic mastocytosis in patients with a serum tryptase level <10 
μg/L 15. However, this might represent inclusion bias since this was a retro-
spective analysis as well. Removal of the minor criterion of a serum tryptase 
level >20 μg/L could probably increase the detection SM. A prospective study 
would be necessary to define a more reliable cut-off value for bone marrow 
biopsy, although other parameters such as mastocytosis in the skin, anaphy-
laxis and osteoporosis should be taken into account in the diagnostic process. 
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The development of a sensitive RQ-PCR for D816V mutated KIT in peripher-
al blood has helped to screen more effectively for SM, especially in patients 
with Hymenoptera related anaphylaxis, although this assay does not reach a 
sensitivity of 100% 246. The exact indications for bone marrow examination 
for SM remain a topic of discussion. Several algorithms and scoring systems 
have been developed over time to aid physicians in this clinical decision, but 
these algorithms were never validated by other researchers than the groups 
that developed the tools 90,247. Furthermore, the assessment of the material 
acquired by bone marrow biopsy requires special expertise. This was demon-
strated by the mastocytosis expertise network in Spain: The researchers 
performed a new bone marrow examination and compared the results to a 
prior bone marrow examination in the referral center and found an agree-
ment of only 34% for KIT mutation analysis, 68% for cytomorphology, 75% 
for immunophenotyping and 80% for histopathology 248. Another retrospec-
tive analysis from a German expertise center revealed misdiagnoses in 36% 
of 140 included patients with advanced systemic mastocytosis 249. These data 
are probably representative for the situation in other Western countries and 
stress the importance of specialized laboratory facilities in order to avoid re-
peat bone marrow examinations for our patients. 
When a person is diagnosed with SM, it is important to correctly counsel 
them on their prognosis. The risk of anaphylaxis is a major cause of anxie-
ty for patients 52. This is not surprising since the lifetime prevalence of ana-
phylaxis among patients with SM is 30-49% 47,48,103. However, it is difficult to 
determine who is at risk and who can be reassured. Several clinical charac-
teristics have been demonstrated to be associated with an increased risk for 
anaphylaxis, such as the absence of skin mastocytosis, male sex, presence 
of atopy, and an increased total IgE level 77 50. Interestingly, there is no linear 
association between serum tryptase level and the risk on anaphylaxis: the 
risk is the highest for patients with a moderately increased serum tryptase 
level 50,158. Measurement of specific IgE to Hymenoptera venom is also less 
sensitive in patients with mastocytosis, who often have no detectable or low 
levels of specific IgE despite experiencing severe anaphylactic reactions 55. 
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Since anaphylaxis is a potentially life threatening condition, it is unsafe to 
completely rely on these characteristics when informing an individual pa-
tient or determining whom to prescribe adrenalin auto-injectors. Our own 
efforts to use the basophil activation test (BAT) to assess one’s risk on Hy-
menoptera venom related anaphylaxis proved unsuccessful (Chapter 3.2) 250. 
This implies that Hymenoptera venom induced mast cell activation does not 
happen via IgE in mastocytosis, but for instance through direct binding of 
venom components to the MRGPRX2 receptor. There have been no publica-
tions on the role of MRGPRX2 in Hymenoptera venom-related anaphylaxis at 
the time of writing. Furthermore, the low sensitivity of the BAT in our study 
might have been due to technical reasons. Urra et al. recently demonstrated 
that the identification of basophils by IgE instead of CCR3 (chemokine CC 
receptor type 3) led to a much higher sensitivity 251. Another weakness of our 
study on Hymenoptera venom related anaphylaxis is that component analysis 
of wasp venom was not performed, although this has become common prac-
tice in the years after our BAT study. This was based on a study in Groningen 
that showed that the sensitivity of sIgE diagnostics among patients with mas-
tocytosis can be enhanced by the measurement of sIgE against components 
of wasp venom55. Moreover, the same study showed that lower cut-off levels 
should be used for sIgE against wasp venom in patients with mastocytosis 
specifically 55. However, it is still unknown whether the presence of sIgE can 
predict Hymenoptera venom-related anaphylaxis in the future for patients 
who have not yet experienced anaphylaxis before. This might be a topic that 
can never be reliably answered, since many factors probably play a role in 
Hymenoptera venom-related anaphylaxis in mastocytosis, and this can hard-
ly be simulated in an in vitro test system.
Organization of care and quality of life
Many aspects of the clinical care for patients with mastocytosis are based 
on expert opinion. There is a lack of evidence-based guidelines on a na-
tional as well as international level. In fact, only one official guideline 
was published in the U.S.A. in 2018, which mainly focuses on the diag-
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nosis of mastocytosis and the treatment of advanced systemic masto-
cytosis 67. It is unclear how patients with different subtypes of mastocy-
tosis should be followed up after the diagnosis was made. Too frequent 
hospital visits will lead to higher medical costs, and might increase the 
burden of disease on patients. On the contrary, insufficient clinical guid-
ance puts the patient at risk for untreated symptoms and complications. 
It has been demonstrated in this thesis as well as in other papers that the 
chance of progression of disease from indolent to advanced systemic masto-
cytosis is negligible 86,252, although a recent study in the ECNM database re-
vealed that 4.9% of ISM patients showed progression to a more advanced 
subtype according to WHO criteria 253. The regular measurement of serum 
tryptase level is probably sufficient to screen for progression of disease in 
patients with ISM, since this correlated well to the mast cell load 106. In line 
with this, a rise in the serum tryptase level was indicative of an increase in 
liver and/or spleen size as shown in Chapter 3.3 of this thesis 252. The D816V 
allele burden in peripheral blood can also be used for follow-up 44 but is a 
more expensive assay. 
Another important reason for follow-up of patients with ISM is the risk of 
osteoporosis. In our own cohort, 54% of patients had a decreased bone min-
eral density, of whom 48% was male (Chapter 2.1) 103. However, it might not 
be necessary to perform regular bone mineral density measurements for ev-
ery patient. For a patient who does not have osteoporosis at diagnosis, the 
chance of developing osteoporosis in the following years is not increased 254. 
Of course, risk factors for osteoporosis such as vitamin D deficiency, meno-
pause and other endocrinological factors should be taken into account when 
establishing an individual’s risk of osteoporosis. 
As outlined previously, ISM has an excellent prognosis and does not influ-
ence one’s life expectancy 39,40,255. However, the health related quality of life 
of patients can be significantly influenced. As demonstrated in Chapter 2.2 of 
this thesis, patients with mastocytosis had a similar perception of their own 
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health to patients with cancer 229. The prevalence of psychological symptoms, 
such as depressive mood and anxiety, was also significantly increased com-
pared with a healthy norm group, but lower than in patients with chronic pain 
229. This supports the hypothesis that the increased prevalence of depression 
and anxiety in patients with mastocytosis can at least partially be attributed 
to having a chronic disease with debilitating symptoms, rather than solely 
the specific effect of mast cell mediators to the brain. As shown in the results 
of a patient survey by Jennings et al., the unpredictability of symptoms is a 
major cause of stress for patients 52. Furthermore, the presence of fatigue can 
also have a negative influence on one’s psychological functioning and overall 
health-related quality of life. In a small study of 28 patients with SM, a VAS of 
53 mm was reported for fatigue compared with 6 mm in healthy controls 63. 
However, the range in VAS for fatigue in the mastocytosis group was wide: 15-
91 mm63, illustrating the large variation in symptoms and burden of disease.
Another possible explanation for the increased presence of (subjective) psy-
chological symptoms could be that mast cell mediators such as histamine 
directly influence brain metabolism. There are two histamine receptors 
present in the brain: H1R and H3R. Activation of H1R through the binding of 
histamine helps the body to be active, and leads to increased wakefulness, in-
creased body temperature, cardiac rate, and decreased appetite. Activation of 
H3R, which is the main present histamine receptor in the brain, has opposite 
effects and leads to increased sleepiness. Although this has not yet been stud-
ied in patients with mastocytosis, high levels of histamine could theoretically 
influence their mood and quality of sleep through these receptors. Of note, 
insomnia was one of the domains in the SCL-90 for which our cohort scored 
significantly higher than healthy controls. 
Another relevant neuropeptide is serotonin. Human mast cells produce lit-
tle to none serotonin but there is evidence that they can express a receptor 
for serotonin 256. This neurotransmitter has been linked extensively to psy-
chiatric disorders, mainly depression. Previous research indeed showed an 
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impaired serotonin metabolism in patients with mastocytosis: two different 
groups showed that patients with mastocytosis had significantly lower lev-
els of tryptophan and its metabolite serotonin than healthy controls 92,257,258. 
Interestingly, there was an association between the level of serotonin and 
psychiatric symptoms but also fatigue, flushing and diarrhea 257. The associ-
ation between low levels of tryptophan and gastrointestinal symptoms was 
confirmed in another study 259. We also found a correlation between the SCL-
90 score and fatigue and diarrhea (Chapter 2.2), which therefore might be 
explained by  lower levels of serotonin. The decreased levels of serotonin are 
hypothesized to result from increased conversion of tryptophan into an in-
active metabolite kynurenin by the enzyme indoleamine 2,3-dioyxygenase 
(IDO). The activity of IDO is stimulated by inflammatory cytokines, mainly 
interferon-ƴ, interleukin 6 (IL-6), and tumor necrosis factor alpha (TNF-α) 259. 
These data implicate a possible role for serotonin reuptake inhibitors in the 
treatment of patients with SM with mood disturbance, but also flushing and 
gastrointestinal symptoms. Further research is necessary to investigate this 
hypothesis.
Previous studies showed a much higher rate of psychological problems than 
our cohort. In a French study, 64% of patients with ISM had symptoms of 
depression, and 38.6% had some degree of cognitive impairment 65,66. A simi-
lar prevalence of self-reported depression was found in a Dutch and another 
French cohort 53,91. We could not confirm the presence of cognitive dysfunc-
tion in our own cohort, as results of a Cognitive Failure Questionnaire were 
comparable to the healthy norm group  (data not published). This might be 
due to the used questionnaire and the study population: the French cohort 
in which a high rate of cognitive impairment was reported also had high de-
grees of depression and cognitive dysfunction is a symptom of depression. 
Furthermore, since mastocytosis has such a heterogeneous clinical picture, 
different study cohorts can vary significantly. The reproducibility of such 
studies is further endangered by the often small study cohorts. This stresses 
the importance of the confirmation of all findings in other cohorts and col-
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laboration between expertise centers to form larger and more representative 
study populations. 
Medical procedures and mastocytosis
An important topic for patients with mastocytosis is the risk of iatrogenic 
anaphylaxis due to medication  and invasive procedures. Theoretically, mast 
cells can be activated by a wide range of triggers including small molecule 
drugs, physical triggers such as temperature changes, friction and stress. All 
these factors are present in invasive medical procedures and therefore, it was 
historically advised to avoid a large list of drugs including most analgesics 
and radiologic contrast media. These advises are still given to date, leading to 
unnecessary anxiety in both patients and physicians. Consequently, patients 
with mastocytosis are sometimes subjected to medieval-style procedures 
without analgesics because of this fear for anaphylaxis, or on the other hand 
overtreated with prophylactic drugs to avoid anaphylaxis. They are often ad-
vised to avoid NSAIDs, although this is largely based on theoretical grounds. 
We performed the first prospective study to investigate the risk on NSAID hy-
persensitivity in patients with mastocytosis (Chapter 4) and found that only 1 
out of 50 participants had an objective hypersensitivity reaction to acetylsal-
icylic acid (ASA), consisting of an urticarial rash that subsided after adminis-
tration of an oral antihistamine 93 Albeit less reliable, an additional retrospec-
tive analysis of the entire cohort of the mastocytosis center was performed, 
showing a prevalence of 4.1% of self-reported NSAID hypersensitivity reac-
tions. Three out of these 8 patients had anaphylaxis related to an NSAID and 
needed treatment in an emergency department. Interestingly, 2/8 patients 
later underwent an NSAID challenge that was negative. It is well know that 
NSAIDs can aggravate an anaphylactic reaction by acting as a cofactor. There 
are several possible mechanisms whereby NSAIDs can enhance a reaction 
caused by mast cell activation. Firstly, they cause increased permeability of 
gut mucosa, thereby improving allergen availability of mucosal mast cells 
and antigen presenting cells. Secondly, basophils were proven to be more re-
active to allergens in the presence of ASA 260,261. Similar experiments have not 
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been published with mast cells yet, probably because it is technically more 
challenging to obtain live mast cells from a human individual. However, one 
interesting study using murine mast cells showed a dose-dependent dual ef-
fect of ASA on mast cells 262. At high doses, ASA inhibited all mast cell activity, 
whereas at an intermediary dose the COX2 expression was increased 262. Thus 
patients with mastocytosis who have experienced anaphylaxis, especially (re-
current) iatrogenic anaphylaxis, should still be warned that NSAIDs can wors-
en mast cell activation. Also, patients with classic risk factors for NSAID hy-
persensitivity such as asthma or angioedema should avoid COX-1 inhibitors. 
However, the majority of patients with mastocytosis can safely use NSAIDs. 
Next to NSAIDs, invasive medical procedures form another cause of anxiety 
and uncertainty for patients with mastocytosis. In Chapter 4, a study is pre-
sented in which the evidence for iatrogenic anaphylaxis is reviewed 211. Not 
surprisingly, there are very few comprehensive studies on this subject. The 
available evidence largely comes from cohort studies that enlist self-report-
ed reactions, and case reports. From one large retrospective Spanish cohort, 
the risk on anaphylaxis associated with general anesthesia was 5.4% with-
out premedication and 0.4% with premedication 139. Although this is higher 
than in the general population, it should be no reason to avoid anesthesia. 
The evidence for the type and doses of premedication is also lacking, and 
recommendations are based on guidelines for radiocontrast allergy. For pa-
tients with mastocytosis, the risk on anaphylaxis due to radiocontrast media 
appeared to be low, and premedication is only advised in patients with pre-
vious reactions to radiocontrast media or to other drugs. Again, mechanistic 
evidence is lacking. One study from the 90’s investigated the effects of three 
kinds of iodine containing contrast media on basophils and mast cells and 
mainly found that basophils and lung mast cells were activated by the con-
trast media but skin and gut mast cells were not 263. To date, other contrast 
media are used with a lower osmality which should theoretically be less likely 
to activate basophils or mast cells. However, there are currently no studies 
published to corroborate this theory. Based on the current knowledge and 
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experience, radiologic contrast media can safely be administered to patients 
with mastocytosis without additional measures, except of course those indi-
viduals who have a documented radiologic contrast media allergy.
Searching new targets for therapy
Once the diagnosis of mastocytosis is made, the treating physician can en-
counter the next problem: The lack of effective therapeutic options that have 
been adequately researched. This is also the case in patients with masto-
cytosis. Until recently, studies were mainly focused on advanced systemic 
mastocytosis because of its adverse survival chances. The majority of these 
studies investigated  tyrosine kinase inhibitors (TKI) that target KIT to cause 
apoptosis of mast cells. For years, the only KIT inhitibitor that was available 
was imatinib, which is not effective for cells with the common D816V muta-
tion. In 2018, midostaurin was registered, which also inhibits mutated KIT 
activity 75. Midostaurin effectively reduces the mast cell load and has great-
ly enhanced the survival of patients with advanced systemic mastocytosis. 
Another TKI directed at KIT, avapritinib, showed very promising results in a 
phase I trials among patients with advanced systemic mastocytosis with 56% 
reaching complete or partial response 264. Avapritinib appears to be more spe-
cific to D816V mutated KIT which hopefully leads to fewer side effects than 
midostaurin 265. These TKI provide no cure for mastocytosis, and when it is 
interrupted, the mast cells will start proliferating again. Moreover, neoplastic 
mast cells can become resistant to TKI. Lastly, the TKI mentioned have con-
siderable side effects, mainly intractable nausea, but also myelosuppression 
and discoloration of hair 75.
For indolent systemic mastocytosis, there are currently no registered drugs 
available. As stated previously, indolent systemic mastocytosis does not influ-
ence one’s life expectancy, but its symptoms can cause a significant burden 
on the quality of life of affected individuals. It would therefore be useful to 
broaden the array of pharmacological options for patients with benign vari-
ants of mastocytosis. Next to well-known mediators such as histamine, eicos-
anoids and tryptase, mast cells produce many cytokines that are associated 
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with constitutional symptoms in mastocytosis 7,64,196,197. It could  theoretically 
be more effective to find one drug that inhibits the release of all these media-
tors than to combine several drugs that block the actions of these mediators 
on other cells. One small trial of midostaurin for indolent systemic mastocy-
tosis showed a moderate effect on symptoms, although this was a non-con-
trolled trial, and nausea again was a common side effect  71. The multi-TKI 
masitinib was found to diminish mast cell mediator-related symptoms such 
as fatigue and pruritus in only 8-25% of patients, respectively 70. A phase II tri-
al with avapritinib for indolent systemic mastocytosis is currently running at 
the time of writing, and preliminary data show promising effects. Long term 
results are obviously lacking for all TKI for mastocytosis. Interestingly, the 
symptoms of systemic mastocytosis greatly overlap with another hematolog-
ical disease termed Myeloproliferative Neoplasms (MPN). This represents a 
spectrum of three conditions in which either too many erythrocytes or plate-
lets are being produced, or fibrosis of the bone marrow occurs. In patients 
with MPN, increased levels of several cytokines such as IL-6 and TNF-α are 
found to correlate with clinical symptoms 266. The TKI ruxolitinib, an inhibi-
tor of JAK1 and JAK2, has been proven very effective to reduce the symptom 
burden of MPN patients in clinical trials 224,225 and is now registered for the 
treatment of MPN. Interestingly, ruxolitinib also reduced symptoms such as 
itch and fatigue in two reported patients with systemic mastocytosis 203,204. 
For these reasons, ruxolitinib or other JAK-STAT inhibitors might be effec-
tive for highly symptomatic patients with systemic mastocytosis, but also in 
other mast cell related conditions such as mast cell activation syndrome and 
chronic spontaneous urticaria. We decided to perform an in vitro study to 
investigate the exact effects of ruxolitinib on mast cell activity (chapter 5) 267. 
Ruxolitinib appeared to effectively inhibit cytokine production as induced by 
substance P and the nonspecific pan-activator calcium ionophore (A23187) 
without causing mast cell apoptosis. However, high concentrations were nec-
essary to achieve statistically significant reduction of degranulation induced 
by substance P or codeine. It is known that TKI (partly) lose their specifici-
ty in high concentrations and it can be questioned whether ruxolitinib still 
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only inhibits JAK1 and JAK2 activity in such high concentrations 221. Efforts 
to prove STAT5 phosphorylation were unsuccessful due to technical difficul-
ties, but incubation of mast cells with the specific STAT5 inhibitor pimozide 
achieved similar effects on mast cell activation, suggesting a role for STAT5 in 
cytokine production by mast cells, and to a lesser extent also degranulation. 
As with most research, this study generated more questions than answers. 
Firstly, codeine and substance P were used to induce mast cell degranulation 
and cytokine production. These were chosen because we were interested in 
non-IgE mediated mast cell activation, as well as the fact that substance P is 
an important autologous mediator for pain and itch and plays a role in chronic 
spontaneous urticaria 268. Both codeine and substance P are ligands to G-pro-
tein coupled receptors (GPCR) such as the MRGPRX2 and neurokinin 1 receptor 
13,59,153. One of the most important intracellular proteins that act downstream 
of GPCRs is considered to be phosphoinositide 3-kinase (PI3K) and not the 
JAK-STAT pathway. The fact that ruxolitinib and pimozide did exert an effect 
on mast cell activation suggests that JAK-STAT must also be involved down-
stream of GPCR. Indeed, there is some evidence of crosstalk between PI3K 
and STAT5 in neoplastic mast cells and other myeloid malignancies: activated 
STAT5 enhances the catalytic domains p85 and p110 of PI3K and enhances the 
transcription of Akt 218,219. As expected, when STAT5 metabolism is inhibited, 
the PI3K/Akt pathway is also less effective 20. Lastly, it has been shown that the 
PI3K-Akt cascade is important for IgE mediated mast cell degranulation 269. 
Secondly, it must be noted that STAT5 is constitutively active in neoplastic 
mast cells and that the JAK-STAT metabolism therefore might differ from 
wild-type mast cells. Theoretically, the JAK activity is  decreased by negative 
feedback loops when STAT5 is continually active. Another possible concern 
is the fact that in other in vitro studies, KIT activation via SCF has shown to 
inhibit MRGPRX2-induced mast cell degranulation 270. This implies that in-
terference with proteins that execute KIT’s signals intracellularly (i.e. STAT5) 
could create an opposite effect on mast cell activation on the longer term, if 
no cytotoxic effect on mast cells is exerted.
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Overall, loose bits and pieces of knowledge are present, but data that eluci-
date the exact roles and interaction of JAK2, STAT5, PI3K and Akt downstream 
of MRGPRX2 activation are still lacking. Figure 1 depicts a very schematic 
model of the presumed interaction between the MRGPRX2 receptor and the 
JAK-STAT pathway as we know now. But before we can confidently expose 
patients with mastocytosis to JAK-STAT inhibitors, it is important to elucidate 
the exact functionality and interaction of JAK-STAT and PI3K-Akt, as well as 
other intracellular routes, downstream of the MRGPRX2 receptor.  
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Figure 1
Figure 1. Schematic overview of cooperating receptors. Upon binding of its ligand 
SCF, the KIT receptor (A) becomes activated and induces phosphorylation of JAK2 
(B), which in turns induces phosphorylation of STAT5. Secondly, STAT5 translocates 
into the cell nucleus to act as a transcription factor (C). STAT5 can probably also en-
hance the signaling pathway that arises from activation of the MRGPRX2 receptor via 
stimulating the catalytic domains of PI3K (D) and enhancing transcription of Akt (E) 
ultimately leading to degranulation and the production of pro-inflammatory media-
tors (F). Through unknown mechanisms, KIT activation provides negative feedback 
to MRGPRX2 (G). Figure adapted from master thesis A.C. van Stigt. 
Conclusion
In this thesis, several myths on mastocytosis were hopefully turned into more 
factual knowledge. 
It can be concluded that the baseline serum tryptase level is not sufficient-
ly sensitive to screen for the presence of systemic mastocytosis, especially 
in adult patients with mastocytosis in the skin or Hymenoptera venom-re-
lated anaphylaxis. However, serum tryptase is a reliable marker for disease 
progression in patients with proven systemic mastocytosis. Despite its good 
prognosis, indolent systemic mastocytosis puts a significant burden on the 
quality of life of patients. The increased prevalence of psychological symp-
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toms is probably caused by a combination of the bothersome symptoms and 
direct effects of mast cell mediators to the brain cells. 
Anaphylaxis is an important influence on the quality of life of patients. How-
ever, the risk on iatrogenic anaphylaxis is lower than often expected, and 
NSAIDs and radiologic contrast media can safely be administered to most 
patients with mastocytosis, hopefully relieving some of the anxiety in many 
mastocytosis patients. It is still unclear how to predict an individual’s risk on 
anaphylaxis, especially Hymenoptera-induced anaphylaxis. 
There are also many questions to be answered about the pathophysiological 
mastocytosis. Ideally, phenotyping of the neoplastic mast cell clone of an in-
dividual would lead to a tailored therapeutic approach. For this purpose, in 
vitro techniques and methods to isolate viable mast cells from the human body 
should be improved. These translational research methods are probably more 
representative than in vitro experiments with single cell type cultures. Fur-
thermore, little is known about the effects that neoplastic mast cells exert on 
the rest of the immune system and the local milieu in skin, bone marrow or 
mucosa. Clarification of those effects could provide better understanding of 
mastocytosis as a whole and hopefully help to treat patients more accurately.
Research of a rare condition is only possible by cooperating (inter)national-
ly, since research in small cohorts has important limitations, especially with 
such a heterogeneous disease. It would also be of great value to share find-
ings beyond the small community of mast cell researchers, since mast cells 
are most probably important players in other conditions such as fibrosis, au-
to-immune diseases and cardiovascular disease. 
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7.1 Summary
Due to the heterogeneous nature of mastocytosis, several questions and di-
lemmas arise in the daily clinical care for patients. A large part of the current 
practice is based on expert opinion. The aim of this thesis was to elucidate 
some of these myths and other clinical questions. 
In chapter 1, an introduction is given on mast cell biology and the definitions, 
pathophysiology and clinical aspects of mastocytosis. 
Chapter 2 starts with a description of the cohort of 136 adult patients with sys-
temic mastocytosis as defined by the WHO. This paper described the variety 
of clinical symptoms among different subtypes of systemic mastocytosis and 
provided some interesting findings that led to follow-up research questions. 
The average delay from the onset of symptoms to diagnosis was 8.1 years. 
This can be explained by a lack of unawareness for mastocytosis among both 
physicians and patients. Mastocytosis was recognized earlier in patients with 
flushing or anaphylaxis than in patients with MPCM or osteoporosis. Fur-
thermore, a difference was detected in clinical phenotype between patients 
with indolent systemic mastocytosis with or without skin involvement. Those 
without skin involvement were more often male, and anaphylaxis and oste-
oporosis were more prevalent in these patients. Of note is that 23.5% of the 
total cohort had a serum tryptase level <20 μg/L at the time of diagnosis. It 
can thus be questioned whether this level is the right cut-off as a minor crite-
rium in the WHO criteria. We have elaborated on that question in chapter 3.1 . 
Furthermore, chapter 2 contains a cross-sectional cohort study in which 
neuropsychiatric morbidity in mastocytosis was investigated by obtaining a 
screening questionnaire on psychological symptoms (SCL-90) and the SF-36. 
Although previous studies had already reported a high prevalence of neu-
ropsychiatric symptoms such as fatigue, depression and cognitive dysfunc-
tion in mastocytosis, no-one had yet compared the psychological burden of 
patients with mastocytosis to patients with other chronic diseases. Our study 
showed that patients with mastocytosis indeed have more neuropsychiatric 
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symptoms than healthy controls, but less than patients with chronic pain. 
Strikingly, patients with mastocytosis had a similarly unfavorable perception 
of their general health to cancer patients. We concluded that the burden of 
disease is high in patients with mastocytosis. The increased prevalence of 
psychological symptoms is probably a consequence of both the impact of 
physical discomfort as well as the direct effects of mast cell mediators to the 
brain. It is recommended to evaluate the psychosocial situation of every pa-
tient with mastocytosis and to offer adequate counselling if necessary. 
In chapter 3, several dilemmas in diagnostics are studied. First, we specifi-
cally investigated the value of serum tryptase as a screening tool for the pres-
ence of systemic mastocytosis. As expected from the previous findings from 
the cohort study in chapter 2, 28.3% of the 198 patients who were included 
had a serum tryptase level below the WHO cut-off of 20 μg/L and 10.1% had a 
serum tryptase level of < 11.4 μg/L which is the international cut-off value for 
the normal range. Despite the probable biases that apply to this retrospective 
study, it can be concluded that especially in patients with adult-onset MPCM 
or Hymenoptera venom-related anaphylaxis, a serum tryptase level < 11.4 is 
not sufficiently reliable to rule out systemic mastocytosis.  
In chapter 3.2, we tried to find a method to identify those patients with mas-
tocytosis who are at risk for Hymenoptera-related anaphylaxis by means of a 
basophil activation test (BAT). Unfortunately, the BAT was positive in merely 
one patient of the total cohort of 29, whereas 78% of patients with Hymenop-
tera-related anaphylaxis had a positive intradermal test and 67% had detect-
able specific IgE in serum. The BAT therefore was not of additional value to 
predict Hymenoptera-related anaphylaxis.
A third question that arose from daily practice was whether routinely per-
formed abdominal ultrasonography was useful in the follow-up of patients 
with indolent systemic mastocytosis. Until 2017, ultrasonography of the abdo-
men was routinely performed every one to three years to screen for hepatos-
plenomegaly as a sign of progression of disease. In this study, 88 patients were 
included and the median follow-up time was 11.2 years. Nine patients with 
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indolent systemic mastocytosis developed new hepatosplenomegaly, but no-
one developed advanced systemic mastocytosis. The increase in liver- and/or 
spleen size was positively correlated with an increase in serum tryptase level. 
We thus concluded that routine abdominal radiographic testing is not recom-
mended in patients with indolent systemic mastocytosis and that the absolute 
risk of progression to advanced subtypes is neglibible. Clinical examination 
and serum tryptase are sufficient to screen for (the unlikely) progression of 
indolent to advanced systemic mastocytosis. 
Chapter 4 describes two studies on drug-related reactions in mastocytosis. 
This is a major issue in the daily practice of a mastocytosis clinic and a rea-
son for anxiety in many patients. First, we reviewed the available evidence 
for iatrogenic anaphylaxis in mastocytosis and found that most recommen-
dations are based on case reports, unsupported hypotheses, or in vitro data. 
The actual risk on iatrogenic anaphylaxis appears to be low in both adults 
and children with mastocytosis. A moderately increased risk on anaphylaxis 
of 5.4% was demonstrated for major surgery with general anesthesia. This 
risk could be decreased to 0.4% by administering adequate pre-medication. 
Local anesthesia appeared safe. We formulated practical recommendations 
for perioperative management of both children and adults with mastocyto-
sis, but with the restriction of a lack of reliable clinical evidence. 
Chapter 4.2 describes a study in which the prevalence and severity of NSAID 
hypersensitivity was investigated. Fifty adults with all subtypes of masto-
cytosis underwent a randomized, placebo-controlled, double-blind provo-
cation test with acetylsalicylic acid. Contrary to popular belief, the rate of 
hypersensitivity reactions was low. Only one patient experienced an urticar-
ial rash several hours after completion of the provocation test. Three other 
patients had subjective symptoms, which could theoretically be attributed 
to mast cell activation but which were very mild. It therefore appeared that 
NSAIDs can be safely administered to most patients with mastocytosis. In a 
retrospective study of our entire outpatient cohort with mastocytosis, risk 
factors for the presence of NSAID hypersensitivity were identified. Extra 
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caution was advised in patients who have experienced previous hypersensi-
tivity reactions to any kind of drug, and patients with traditional risk factors 
for NSAID intolerance such as asthma or nasal polyposis. 
In chapter 5, translational studies are described that are aimed at gaining 
more insight in the pathophysiological mechanisms of mastocytosis. In chat-
er 5.1, a new possible therapeutic strategy is explored in vitro. Ruxolitinib is 
a JAK1/2 inhibitor that is used in classical myeloproliferative neoplasms. In 
these patients, it is very effective against itch and constitutional symptoms. 
Moreover, two case reports of the use of ruxolitinib in systemic mastocy-
tosis confirmed the effects on itch, fatigue and gastrointestinal symptoms. 
Based on these results, we hypothesized that ruxolitinib would inhibit mast 
cell degranulation and cytokine production. We studied this in vitro using 
two different mast cell lines which were stimulated with substance P and 
codeine. Ruxolitinib indeed effectively inhibited mast cell degranulation and 
cytokine production, although relatively high doses were needed to signif-
icantly reduce mast cell degranulation. Inhibition of STAT5 with another 
compound, pimozide, was also effective to inhibit cytokine production, but 
only weakly inhibited mast cell degranulation. The JAK-STAT pathway thus 
appears more important for cytokine production than for degranulation in 
mast cells. 
Chapter 5.2 contains a study in which the percentage of group 2 innate lym-
phoid cells (ILC2) are investigated in peripheral blood of patients with indo-
lent systemic mastocytosis. This study shows that ILC2s are more abundant 
in patients with systemic mastocytosis that harbor the D816V KIT mutation. 
Patients with systemic mastocytosis but without the D816V mutation did not 
have significantly different ILC2 percentages compared with healthy con-
trols. Given the association between the presence of skin mastocytosis and 
ILC2 abundance, we hypothesize that the increased numbers of aberrant 
mast cells in the skin might provide signals that enhance ILC2 migration 
and proliferation. Of course, more in-depth research is necessary to find a 
mechanistic explanation for the findings in this study. 
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Chapter 6 elaborates on the findings described above as well as possible 
strengths and weaknesses of this thesis. Furthermore, the implications for 
the daily practice and future research are discussed. 
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7.2 Samenvatting
De heterogene aard van mastocytose leidt tot diverse vragen en dilemma’s 
omtrent de klinische zorg in de dagelijkse praktijk. Een groot deel van de hui-
dige zorg is gebaseerd op ‘expert opinie’. Het doel van dit proefschrift was om 
enkele van deze mythes te ontrafelen. 
Hoofdstuk 1 omvat een introductie over mestcel biologie en de definities, 
pathofysiologie en klinische aspecten van mastocytose. 
Hoofdstuk 2 start met een beschrijving van een cohort van 136 volwassen 
met systemische mastocytose, zoals gedefinieerd door de WHO. Dit artikel 
beschrijft de variatie van klinische symptomen tussen de verschillende 
subtypes van systemische mastocytose en enkele interessante aanvullende 
bevindingen. Het duurde gemiddeld 8,1 jaar vanaf het begin van symptom-
en totdat de diagnose systemische mastocytose officieel gesteld werd. Dit is 
grotendeels te verklaren door de onbekendheid van het ziektebeeld bij zowel 
artsen als patiënten. Mastocytose werd eerder gediagnosticeerd bij mensen 
met flushing of anafylaxie dan met MPCM of osteoporose. Verder werd er een 
verschil in klinische fenotype gevonden tussen patiënten met indolente sys-
temische mastocytose met en zonder huid betrokkenheid. Patiënten zonder 
huid betrokkenheid waren vaker man en anafylaxie en osteoporose kwamen 
vaker voor in deze groep. Van belang is op te merken dat 23,5% van het totale 
cohort een serum tryptase waarde <20 μg/L had op het moment van diagnose. 
Dit is de huidige afkapwaarde als mineur criterium in de WHO criteria, maar 
gebaseerd op deze bevindingen kan de vraag gesteld worden of dit de juiste 
afkapwaarde is. In hoofdstuk 3.1 wordt verder ingegaan op deze vraag. 
Vervolgens bevat hoofdstuk 2 een studie waarin de neuropsychiatrische mor-
biditeit van 50 volwassenen met mastocytose werd onderzocht door middel 
van een screenende vragenlijst over psychologische symptomen (de SCL-90) 
en de SF-36. Eerder studies toonden reeds een hoge prevalentie aan van neu-
ropsychiatrische symptomen zoals vermoeidheid, depressie en cognitieve 
dysfunctie. Echter werd in geen enkele eerdere studie de groep met mastocy-
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tose vergeleken met patiënten met andere chronische aandoeningen. Onze 
studie toonde aan dat patiënten inderdaad meer neuropsychiatrische symp-
tomen hebben dan gezonde controles, maar minder dan patiënten met chro-
nische pijn. Opvallend genoeg was de perceptie van de algemene gezondheid 
onder de patiënten met mastocytose gelijk aan die van de patiënten met 
kanker. Alhoewel onze studie geen pathofysiologische mechanismen heeft 
onderzocht, lijkt de toename van psychologische symptomen waarschijnlijk 
het gevolg van zowel de impact van fysieke klachten als de directe effecten 
van mestcel mediatoren op het brein. Het wordt aanbevolen om de psycho-
sociale situatie van elke patiënt met mastocytose te evalueren en zo nodig 
begeleiding te bieden.  
  
In hoofdstuk 3 worden diverse dilemma’s omtrent diagnostiek bestudeerd. 
Hoofdstuk 3.1 beschrijft een retrospectief onderzoek naar de waarde van 
het serum tryptase als screenend instrument voor aanwezigheid van syste-
mische mastocytose. Zoals verwacht naar aanleiding van de bevindingen uit 
de cohort studie in hoofdstuk 2.1, had 28,3% van de 198 patiënten in deze 
vervolg studie een serum tryptase onder de WHO afkapwaarde van 20 μg/L 
en 10,1% had een serum tryptase gehalte < 11.4 μg/L welke de internationale 
normaalwaarde is. Uiteraard kent een retrospectieve studie een groot risico 
op inclusie bias en is dit niet de beste methode voor het onderzoeken van 
een screenend instrument. Echter kan wel geconcludeerd worden dat het se-
rum tryptase onvoldoende betrouwbaar is voor het screenen op systemische 
mastocytose bij patiënten met MPCM die na de puberteit zijn ontstaan of Hy-
menoptera gerelateerde anafylaxie. 
In hoofdstuk 3.2 werd onderzocht of de basofiel activatie test (BAT) een goede 
screenende assay is voor het voorspellen van Hymenoptera gerelateerde 
anafylaxie bij mensen met mastocytose. De BAT was echter positief in slechts 
één patiënt van de totale groep van 29, terwijl zeven van de negen patiënten 
met Hymenoptera gerelateerde anafylaxie wel een positieve huidtest hadden 
en zes van de negen hadden detecteerbaar specifiek IgE tegen wespengif. De 
BAT bleek dus een onbetrouwbare test voor het identificeren van diegenen 
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die risico lopen op Hymenoptera gerelateerde anafylaxie. 
In hoofdstuk 3.3 wordt de waarde van routinematig verrichte echografie van 
de buik voor het detecteren van progressie van indolente naar agressievere 
vormen van systemische mastocytose onderzocht. Tot 2017 werd in het Eras-
mus MC bij deze patiënten standaard elke één tot drie jaar een echo abdomen 
verricht, maar de vraag rees of dit zinvol was. Er werden 88 patiënten met sys-
temische mastocytose geïncludeerd en de mediane follow-up duur was 11,2 
jaar. Negen van de patiënten ontwikkelde nieuwe hepato- en/of splenomega-
lie, maar niemand ontwikkelde agressieve mastocytose of een bijkomende 
hematologische neoplasie. Het serum tryptase was gecorreleerd met een toe-
name van lever- en/of milt grootte. Het risico op progressie van indolente 
systemische mastocytose op zichzelf bleek verwaarloosbaar. Derhalve con-
cludeerden wij dat jaarlijks lichamelijk onderzoek en serum tryptase gehalte 
voldoende zijn voor het screenen naar progressie van ziekte bij mensen met 
indolente systemische mastocytose. 
Hoofdstuk 4 omvat twee studies naar medicijn gerelateerde overgevoelighe-
idsreacties bij mastocytose. Dit is een belangrijke kwestie in de dagelijkse 
praktijk van een mastocytose kliniek en een reden voor onzekerheid bij pa-
tiënten. Hoofdstuk 4.1 is een review naar het bewijs voor iatrogene anafylax-
ie bij mastocytose. Hieruit blijkt dat de meeste aanbevelingen voor gebruik 
van medicatie, met name pijnstillers en anesthetica, voortkomen uit casus 
beschrijvingen, ongefundeerde theoretische hypotheses of in vitro data. Het 
feitelijke risico op iatrogene anafylaxie blijkt zowel bij kinderen als volwas-
senen met mastocytose laag te zijn. Voor algehele narcose is het risico wel 
bewezen hoger dan in de algemene bevolking, namelijk 5,4% in één grote 
studie. Dit risico kon verlaagd worden naar 0,4% door toedienen van pre-
medicatie. In ons review formuleerden wij aanbevelingen voor perioperatief 
management van mensen met mastocytose, alhoewel opnieuw gebaseerd op 
beperkt wetenschappelijk bewijs. 
In hoofdstuk 4.2 wordt het risico op NSAID gerelateerde hypersensitiviteit 
onderzocht. Vijftig volwassenen met mastocytose ondergingen een dubbel-
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blinde, placebo-gecontroleerde provocatie met acetylsalicylzuur. In tegen-
stelling tot wat meestal gedacht wordt, was het aantal patiënten met een pos-
itieve provocatie laag: Slecht één patiënt ontwikkelde een urticariële uitslag 
enkele uren na afronding van de provocatie en drie anderen hadden subjec-
tieve symptomen die mogelijk toe te schrijven zijn aan mestcel activatie. Alle 
reacties waren mild van aard. Hieruit kan geconcludeerd worden dat NSAID’s 
veilig kunnen worden voorgeschreven aan de meeste mensen met mastocy-
tose. In een retrospectieve analyse van het gehele Erasmus MC cohort van 
volwassenen met mastocytose werden vervolgens een aantal risicofactoren 
voor NSAID hypersensitiviteit geïdentificeerd. Extra voorzichtigheid wordt 
aanbevolen bij mensen die eerder overgevoeligheidsreacties hebben gehad 
op andere medicamenten en patiënten met de traditionele risicofactoren 
voor NSAID hypersensitiviteit zoals astma en neuspoliepen. 
In hoofdstuk 5 worden twee translationele studies beschreven. In hoofdstuk 
5.1 werd een mogelijke nieuwe medicamenteuze behandeling voor mastocy-
tose onderzocht in vitro. Ruxolitinib is een JAK1/2 remmer die is geregistreerd 
voor behandeling van myeloproliferatieve neoplasmata. In deze patiënten 
werkt ruxolitinib erg goed tegen o.a. jeuk en constitutionele symptomen. 
Bovendien zijn er twee casus beschrijvingen gepubliceerd waarin ruxolitinib 
werd gebruikt voor de behandeling van systemische mastocytose en waarin 
het gunstige effect op jeuk, vermoeidheid en gastro-intestinale symptomen 
werd bevestigd. Gebaseerd op deze gegevens vermoedden wij dat remming 
van de JAK-STAT route effectief kon zijn voor het remmen van mestcel de-
granulatie en cytokine productie. Dit werd bestudeerd in twee verschillende 
mestcel lijnen die werden gestimuleerd met substance P en codeïne. Incu-
batie van de mestcellen met ruxolitinib remde inderdaad de mestcel degran-
ulatie en cytokine productie, alhoewel relatief hoge doses nodig waren voor 
het bereiken van een statistisch significant effect. Remming van STAT5 met 
pimozide leidde ook tot afname van cytokine productie maar had geen signifi-
cant effect op de mestcel degranulatie. De JAK-STAT route is derhalve mogeli-
jk belangrijker voor de cytokine productie van voor mestcel degranulatie, al-
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hoewel vervolg studies nodig zijn voor het beter interpreteren van deze data. 
In hoofdstuk 5.2 werd het gehalte “group 2 innate lymphoid cells” (afgekort 
ILC2s) in perifeer bloed van patiënten met indolente systemische mastocy-
tose onderzocht. Dit onderzoek toonde aan dat ILC2s verhoogd aanwezig zijn 
in bloed van patiënten met mastocytose die de D816V KIT mutatie hebben. 
Het ILC2 percentage van patiënten met mastocytose maar zonder D816V 
mutatie was niet significant verschillend van gezonde controle personen. 
Aangezien er ook een associatie gevonden werd tussen het ILC2 percentage 
en aanwezigheid van huid mastocytose, veronderstellen wij dat het toege-
nomen aantal afwijkende mestcellen in de huid van deze patiënten signalen 
verspreiden die leiden tot toegenomen migratie en proliferatie van ILC2s. 
Vervolg onderzoek is noodzakelijk om de precieze interactie tussen (afwi-
jkende) mestcellen en ILC2s verder te onderzoeken. 
In hoofdstuk 6 wordt verder ingegaan op de betekenis en beperkingen van 
bovenstaande onderzoeken  en de mogelijke implicaties voor zowel de klin-
ische praktijk als toekomstig onderzoek. 
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8.3 Abbreviations
A23187 Calcium ionophore
AdvSM Advanced systemic mastocytosis: common denominator
  for all aggressive subtypes
ALAT Alanine aminotransferase
ASA Acetylsalicylic acid
ASAT Aspartate aminotransferase
ASM Agressive systemic mastocytosis
BAT Basophil activation test
BM  Bone marrow
CCR3 Chemokine CC receptor type 3
CM  Cutaneous mastocytosis
ECNM European Competence Network for Mastocytosis
ESR Erythrocyte sedimentation rate
FcεR1 IgE receptor type 1
GPCR G-protein coupled receptor
H1R Histamine 1 receptor
H3R Histamine 3 receptor
HMC1 Human mast cell 1 (cell line)
HVA Hymenoptera venom-related anaphylaxis
IDT Intradermal test
IgE  Immunoglobulin E
IL-6 Interleukin 6
ILC2 Group 2 innate lymphoid cells
ILCP Innate lymphoid precursor
IQR Interquartile range
ISM Indolent systemic mastocytosis
ISM s- ISM without skin involvement
ISM s+ ISM with skin involvement
JAK1 Janus kinase 1 
JAK2 Janus kinase 2 
LAD2 Laboratory of allergic diseases type 2 (cell line)
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MC  Mast cell
MCL Mast cell leukemia
MCP-1  Monocyte chemoattractant protein 1
MIS Mastocytosis in the skin
MPCM Maculopapular cutaneous mastocytosis
  (formerly known as urticaria pigmentosa)
MRGPRX2 Mas-related G-protein coupled receptor 2 
NSAID Non-steroidal anti-inflammatory drug
PBMC Peripheral blood mononuclear cells
PCR Polymerase chain reaction
PI3K Phosphoinositide 3-kinase 
RQ-PCR Real time quantitative polymerase chain reaction
SCF Stem cell factor
SCL-90 Symptom checklist 90
SD  Standard deviation
SF-36 36-item short form survey
sIgE Specific IgE to one (component of an) allergen
SM  Systemic mastocytosis
SM-AHN Systemic mastocytosis with associated hematological neoplasm
SSM Smouldering systemic mastocytosis
STAT5 Signal transducer and activator of transcription 5
Th2 Type 2 T helper cell
TKI Tyrosine kinase inhibitor
TNFα Tumor necrosis factor alpha
VAS Visual analogue scale
WHO World health organization
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Research	presentation	MPN	working	group	 2017	 0,5	
EAACI,	Munich	(1	presentation)	 2018	 0,5	
														Patient	educational	meetings	for	mastocytosis,		
														Erasmus	MC	(3x)	
2016	-	2020	 2	
National	symposium	Myeloproliferative	Neoplasms	 2018	 0,5	
NVVA	conference	 2019	 0,5	
Science	day	Erasmus	Internal	Medicine	(poster)	 2019	 0,5	
Regionale	refereeravond	Allergologie	&	Immunologie,	
Rotterdam	(2x)	
2019	 1	
EMBRN,	Uppsala	(poster	presentation)	 2019	 0,5	
European	Hematology	Association,	Amsterdam	 2019	 1	
Symposium	patient	society	for	MPN	NL	 2019	 0,5	
Research	meeting	Laboratory	of	Medical	Immunology	
Erasmus	MC	
2020	 0,5	
Research	meeting	Department	of	Psychology	&	psychiatry	 2020	 0,5	
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Erasmus	MC	
	 	 	
(Inter)national	conferences	attended	 	 	
NIV	conference	Maastricht	 2015,	2016	 2	
Component	Resolved	Diagnostics	in	Allergology	 2015	 0,3	
NVVA	conferences	(x5)	 2016	-	2019	 2	
Rotterdam	Internal	Medicine	day	symposium	(x2)	 2016,	2017	 2	
National	symposium	Allergy	&	Clinical	Immunology,	
Rotterdam	(x4)	
2015	-	2019		
	
1,2	
Symposium	Mast	cells	And	Urticaria,	Paris	 2015	 1,0	
Opening	symposium	Mastocytosis	Centre,	Groningen	 2016	 0,3	
Science	days	Erasmus	Internal	Medicine	(x2)	 2017,	2019	 2	
EMBRN,	Prague	 2017	 1	
EAACI,	Helsinki	 2017	 1	
EAACI,	München	 2018	 1	
European	Competence	Network	Mastocytosis	conference,	
Paris	
2017	 1	
European	Competence	Network	Mastocytosis	conference,	
Salerno	
2018	 1	
National	Conference	on	Mastocytosis,	Groningen	 2019	 0,3	
EMBRN,	Uppsala	 2019	 1	
EAACI,	London	digital	version	 2020	 0,3	
	 	 	
Other	 	 	
Peer-reviewing	for	journals	 	 	
Internal	Medicine	Journal		 2016	 0,3	
Clinical	&	Experimental	Allergy		 2016	 0,3	
Calcified	Tissue	International		 2016	 0,3	
Journal	of	Allergy	&	Clinical	Immunology	(2	manuscripts)	 2017	 0,6	
Clinical	Pharmacology:	Advances	and	Applications		 2019	 0,3	
Acta	Haematologica	 2020	 0,3	
Respiratory	Research		 2020	 0,3	
	 	 	
Teaching	 	 	
Clinical	Reasoning	classes	for	Bachelor	students	 2015	-	2017	 2	
Supervision	of	clinical	interns	in	internal	medicine	 2015	-	2018	 2	
Coaching	of	medical	bachelor	students	 2016	-	2019	 1	
Supervision	of	yearly	systematic	review	project	for	Bachelor	
students	
2018	-	2020	 1	
Supervision	of	students	in	scientific	projects	 	 	
Mark	Rietveld	 2015	 1	
Louk	de	Mol	 2016	 1	
Sophie	van	der	Vet	 2017	 1	
Marie	Roos	Vermeiren	 2018	-	2019	 1	
Jan	Sakoltchik	 2018	-	…	 1	
Astrid	van	Stigt	 2018	-	2019	 1	
Liselotte	Jeletich	&	Bas	Munting	 2019	-	…	 1	
Lecturing	 	 	
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Dermatology	residents	 2017	 0,3	
Lecturing	of	medical	Bachelor	and	Master	students	on	
various	occasions	and	subjects	
2016	-	…	 2	
Immunology	lecturing	for	residents	on	various	occasions	 2018	-	…	 0,5	
Lecture	on	mastocytosis	for	laboratory	staff	 2018	 0,3	
Allergology	lecturing	Master	students	5x	per	year	 2018	-	…	 2	
Acute	Medicine	residents	 2020	 0,3	
	 	 	
Total	ECTS	 	 67,3	
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broncheoalveolar lavage. 
  M.A.W. Hermans, A. Broijl, P.L.A. van Daele 
  Journal of Medical Case Reports
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for 28-day Mortality of
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